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Abstract
Chronic kidney disease (CKD) is a major public health problem with significant clinical,
societal and psychosocial burdens. Nutrition has been an integral part of medical
management in patients with CKD for more than a century; its importance has shifted
away from the pre-dialysis stages since the 1970s due to technological advances in
renal replacement therapy (RRT), namely dialysis and transplantation. However,
nutrition abnormalities can emerge before or during dialysis and continue to be
associated with poor outcomes. This suggests a need to revisit nutrition management
in end stage kidney disease (ESKD) to gain a broader insight into its effects on clinical
outcomes.

The aim of this thesis was to examine the relationships between nutritional factors and
clinical outcomes in people with ESKD, addressing the question, “Is nutrition
management good enough only when it starts at or near dialysis initiation?”
This thesis was built on a “research in practice” framework. A series of studies was
conducted using retrospective data on clinical cohorts attending the renal unit at the St.
George Hospital, Sydney.

Study I examined the available data from all attending patients at the initiation of
dialysis from 2000 to 2010. This study examined the association between nutritional
parameters at the initiation of dialysis and mortality in the clinical cohort (2000-2010, n
=167). The hypothesis was that poor nutrition at the start of dialysis predicted high
mortality risk. The mean glomerular filtration rate (GFR) at the start of dialysis was
8.0±2.7 mL/min/1.73m2; about half (52.1%) of the patients were rated as malnourished
or scored B or C using subjective serum albumin (s-albumin) and malnutrition (SGA
score B or C) independently predicted mortality over the 10 year study period (P
<0.0001, P <0.0001, P =0.01 and P =0.02 respectively). Overweight and obesity
defined as body mass index (BMI) 26 kg/m2 did not show any advantage on survival
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(P =0.73). The combination of malnutrition and overweight/or obesity (SGA B and C +
BMI ≥26 kg/m2) was global assessment (SGA). Older age (>65 years), presence of
peripheral vascular disease, reduced associated with a three-fold increase in mortality
risk with adj. HR 2.96, 95% CI: 1.12–7.33, P =0.02 compared to being well nourished
with a BMI <26 kg/m2 (referent). Being well nourished (SGA = A) was found to be
associated with lower mortality risk irrespective of the levels of s-albumin and BMI.
Thus, malnutrition at the start of dialysis was found to be an independent predictor of
mortality. In addition, no statistical difference in survival was observed between the
early and late start groups, which commenced dialysis with a GFR equal and above, or
less than, 7 mL/min/1.73m2. Therefore, the results supported the recommendations in
the literature that with careful clinical management of ESKD, including nutritional
inputs, dialysis can be started at lower levels of GFR. This has tremendous healthcare
cost implications.

A multidisciplinary pre-dialysis assessment clinic was established in 2002 following the
preliminary analysis of data on the clinical cohort after two years. Study II of the thesis
focused on the cohort attending the pre-dialysis clinic. This study was conducted in two
parts.

Study IIa was a cross-sectional study of the nutritional characteristics of patients first
attending the new multidisciplinary pre-dialysis assessment clinic during the period
2002 to 2008 (n =210). The hypothesis was that a high prevalence of nutritional
abnormalities was present before starting dialysis. The mean GFR was 17.3±6.5
mL/min/1.73m2 with 40.5% of patients rated as malnourished (SGA score B or C).
Energy and protein intakes correlated positively with GFR, being r =0.17, P <0.01 and r
=0.29, P <0.0001 respectively. Intakes of energy, protein and other micronutrients were
sub-optimal in a large number of patients. This was attributed to reduced renal function,
symptoms burden (51.0%), self-imposed inappropriate dietary regimen (17.1%) and
possibly also poor eating habits. Thus, the patients who mainly presented to the clinic
ix

in CKD stages 4 to 5 had a high prevalence of abnormal nutrition parameters before
dialysis was required.

In Study IIb, the reference data collection period was extended for a further 4 years to
enable analyses on baseline data for a ten year period (April 2002 to March 2012,
n=501). In the preliminary clinic evaluation eighteen months after it started, patients
had low GFR on presentation and the prevalence of malnutrition was high. We
hypothesized as the clinic became more established, earlier referral with higher levels
of GFR would occur over time and better nutritional status in the first clinic assessment
would be achieved. For ease of comparison, the data were divided into two halves, or
two 5-year periods, comparing patients referred between April, 2002 and March 2007
(period 1) to those referred between April 2007 and March 2012 (period 2). GFR was
16.7±6.7 vs. 22.1±9.1 mL/min/1.73m2, P <0.0001 in periods 1 and 2 respectively, so
patients were enrolled in the clinic earlier in the second half of the study period. The
prevalence of obesity (32.0% vs. 44.7%, P <0.01) and diabetes (33.0% vs. 51.4%, P
<0.0001) increased significantly over time – parallel to the obesity and diabetes
epidemics in the general population while the malnutrition rate remained high at 39.7%
vs. 42.0% (P =0.62) despite no significant increase in prevalence. Thus the prevalence
of malnutrition remained high despite earlier referral for nutrition intervention.

In conclusion, nutrition abnormalities merged during the decline of kidney function
before the initiation of dialysis. Nutritional factors, along with older age (>65 years),
and co-morbidities at the initiation of dialysis independently predict mortality. To answer
the question “Is nutrition management good enough only when it starts at or near
dialysis initiation?” the answer is NO. Through research in practice, the results of this
thesis suggested structured nutrition management should be implemented well before
dialysis is required and even before the pre-dialysis stage to improve health outcomes
in patients with ESKD.
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Chapter 1 Nutrition Management in Chronic Kidney Disease
1.1

Introduction

Chronic kidney disease (CKD) has become a public health problem worldwide,1-3
including Australia,4-6 and imposes tremendous clinical, societal and psychosocial
burdens. Nutrition has been an integral part of medical treatment of people with end
stage kidney disease (ESKD) for more than a century, 7-10 in particular, to alleviate
symptoms, to control complications and to retard disease progression. Since the
1970s, technological advances in renal replacement therapy (RRT), namely dialysis
and transplantation, have shifted the emphasis and resources to manage people on
RRT. Thus the role of nutrition therapy in the prevention and management in nondialysis or pre-dialysis stages seemingly receives less significant attention. Nutrition
abnormalities emerge during the decline of kidney function even before reaching
dialysis,11, 12 and poor nutrition status at the start of dialysis is known to associate with
undesirable outcomes.13-15 Furthermore, there is a growing body of evidence
suggesting not all ESKD patients benefit from dialysis, especially elderly patients and
patients with a high number of co-morbidities.16-18 Therefore, there is a need to revisit
and gain a broader insight into the role of nutrition management in the non-dialysis
stages and its effects on outcomes after initiation of dialysis. This information is needed
to formulate management strategies and health care planning to improve clinical
outcomes of these patients irrespective of the management pathway chosen: dialysis
or conservative (no-RRT). This first chapter summarises the available evidence
regarding the nutritional management of adult patients with ESKD, specifically in
relation to pre-dialysis factors affecting post-dialysis outcomes. The literature search
includes background and rationale for formulating the research design of studies in this
thesis, up to and including the final planning stage in June 2007.
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1.2

Overview of medical management of kidney disease

1.2.1 Stages of chronic kidney disease and nutrition

The three basic functions of the kidney are excretion, regulation and hormonal
balance.19, 20 As kidney function declines, these functions become impaired and lead to
a stage of uraemia. Uraemia is a word derived from two ancient Greek words ouron
(urine) and haima (blood) to describe the presence of increased amounts of urea and
other nitrogenous end products of protein and amino acid metabolism in blood.21,

22

Examples of protein waste products are guanidines, acids, ammonia, phosphates, uric
acid, oxalate, phenols, aromatic and aliphatic amines and middle molecules. Table 1
summarises the main functions of the kidney and the consequences of impaired
function.

Table 1-1 Primary functions of the kidney and consequences of impaired
function
Renal function
Excretory

Regulation

Endocrine
(hormonal
balance)

Normal
Metabolic waste products, especially
protein waste (e.g., creatinine, urea,
ammonia, uric acid), other metabolites
and toxins
• Acid-base balance
• Homoeostasis
• Fluid and electrolytes balance
• Blood pressure (nitric oxide, reninangiotensin system)
• Metabolism (glucose and lipids)
• Parathyroid hormone (PTH), vitamin D,
calcium and phosphate metabolism
• Erythropoietin/haemoglobin synthesis
• Degradation of hormones, e.g., insulin,
glucagon, PTH

Impaired
Accumulation:
uraemia
build-up of fluid, electrolytes,
metabolites, toxins
 Uncontrolled:
• acidosis
• hypertension
• glucose and lipid abnormalities
 hormonal imbalance:
• osteodystrophy
• anaemia
• glucose intolerance

As kidney function deteriorates, the build-up of uraemic toxins and deranged
metabolism exert detrimental effects on the body. Dialysis, a life-sustaining therapy is
required to substitute the function of the diseased kidney to control these
complications. Eligible patients who meet the stringent criteria may go on a waitlist for
kidney transplantation, which helps to regain kidney function.
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In order to achieve a standardised language and protocols to guide best practice, the
clinical practice guidelines Kidney Disease Outcomes Quality Initiatives, National
Kidney Foundation (NKF K/DOQI™)23,

24

and Kidney Disease: Improving Global

Outcomes (KDIGO)25 classify CKD into five stages based on the glomerular filtration
rate (GFR), a measure of kidney function. According to KDOQI guidelines, CKD is
defined as “either kidney damage or GFR <60 mL/min/1.73m 2 for more than 3 months,
and kidney damage is defined as pathologic abnormalities or markers of damage,
including abnormalities in blood or urine tests or imaging studies”.23 Table 1-2
summarises the classification and treatment goals for the five stages of CKD.

Table 1-2 Stages of CKD and clinical action plan
Stage
1

2
3
4
5

GFR
Description
Treatment goal
(mL/min/1.73m2)
≥90
Renal damage with Diagnosis, treatment of comorbid conditions, slowing
normal or  GFR
progression, cardiovascular
disease risk reduction
60–89
Renal damage with Estimate progression
mild  GFR
30–59
Evaluate
and
treat
Moderate  GFR
complications
15–29
Preparation
for
renal
Severe  GFR
replacement therapy
<15 (+ dialysis)
Renal failure
Renal replacement therapy
(dialysis) if uraemia present
TM

Adapted from K/DOQI : Definition and classification of stages of CKD; Guideline 2: Evaluation
23, 24
and Treatment.
GFR= Glomerular filtration rate

Once the GFR falls below 30 mL/min/1.73m2 or stage 4 CKD, patients enter the predialysis phase; tertiary care by the nephrologist and the multidisciplinary renal team is
recommended23, 24, 26 to prepare for the future dialysis program in stage 5 or when GFR
falls below 15 mL/min/1.73m2.

1.2.2 Risk factors for CKD progression and mortality

Treatments in CKD focus on prevention, risk reduction of developing CKD, or, once
CKD is developed, to reduce progression rate and the risk of developing complications

3

associated with traditional risk factors (Table1-3) and non-traditional risk factors (Table
1-4).23, 27, 28

Traditional risk factors are risk factors that have been defined and validated in
prospective studies in the general population. Non-traditional risk factors are those that
occur as a consequence of impaired renal function. Their prevalence and severity
increase as kidney function declines. Tables 1-3 and 1-4 list the risk factors for the
development of CKD, the factors affecting progression and mortality once CKD is
developed. Patients with CKD are at increased risk of developing cardiovascular (CV)
disease and CKD is now regarded as an independent risk factor for CV disease.28 CV
disease is prevalent in CKD patients, varies between 25–50% depending on stages
and may account for 50% of all mortality.29 It manifests from early stages of renal
insufficiency and CV events occur even before dialysis is required. Therefore, to
reduce the risk of, and treat, CV disease are as vital as managing kidney failure itself.
CKD and CV disease share many common risk factors; therefore the risk factors for
cardiovascular disease and its relationship with CKD are also listed in Tables 1-3 and
1-4. It is beyond the scope of this literature review to discuss all individual risk factors in
detail; information collated is based on a number of significant publications, clinical
practice guidelines and reviews,1, 27, 30-34 with a focus on nutrition and related factors.
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Table 1-3 Risk factors (traditional) for chronic kidney disease and cardiovascular disease
Risk factors

development of

progression

+
+

unconfirmed
unconfirmed

Cardiovascular
disease
(development of)
+
+

+

+

Not established

Not established

Singh et al.37

+

unconfirmed

n/a

+

Sarnak et al.29

+

+

+

+

Dyslipidaemia –  LDL cholesterol

unconfirmed

unconfirmed

+

+

Dyslipidaemia –  HDL cholesterol
Dyslipidaemia –  triglycerides
Family history of heart disease
Family history of kidney disease
Gender (male)
History of acute kidney injury (AKI)
Hypertension
Kidney/urinary tract stones
Menopause

unconfirmed
unconfirmed
Not established
+
+
+
+
unconfirmed
Not established

unconfirmed
unconfirmed
Not established
+
+
+
+
unconfirmed
Not established

+
+
+
Not established
+
Not established
+
Not established
+

+
+
unconfirmed
unconfirmed
unconfirmed
Not established
+
Not established
Not established

UK Prospective Diabetes Study (UKPDS),38 Diabetes
Control and Complications Trial (DCCT),39 Australian
Diabetes, Obesity, and Lifestyle Study (AusDiab),40
Klein et al.,41 Grundy et al.42
Werner et al.,43 Atherosclerosis Risk in Communities
(ARIC) Study.44  LDL cholesterol is risk factor for CV
disease, but association with future loss of eGFR
remains unresolved
Toth,45 Vaziri46
Vaziri46
Pohjola-Sintonen47

Increased in age
Ethnicity (Australian aboriginal/
African American)
Exposure to nephrotoxic drugs /
chemicals
Cardiovascular disease/ left
ventricular hypertrophy
Diabetes mellitus (glycaemic
control)

Chronic kidney disease

Mortality
+
+

Comments
(Information based on clinical practice guidelines
and reviews1, 27, 30-35 and selected references)
Sarnak et al.29
Hoy36

Eriksen et al.48
Basile49
Haroun et al.50
Clayman et al.,51 Gillen et al.52
Kannel et al.53
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Table 1-3 continued
Metabolic syndrome (MetS)

+

unconfirmed

+

unconfirmed

Nephron mass (low), e.g., low birth
weight, nephrectomy
Obesity
Physical inactivity
Proteinuria/Albuminuria
Psychosocial stress/ disadvantages
Smoking
Urinary tract infection
Urinary tract obstruction

+

+

Not established

Not established

+
+
+
+
+
+
+

+
unconfirmed
+
unconfirmed
+
+
+

+
+
+
+
+
Not established
Not established

+
Not established
+
Not established
+
Not established
Not established

Kurella et al.,54 Hu et al.,55 Qiao et al.56 Absolute CV
risk of MetS does not appear higher than those of
individual components
Luyckx et al.,57 Hoy et al.58
Fox et al.,59 Hubert et al.,60 Hsu et al.61
Hallan et al.62
Sarnak et al.29
Hallan et al.,62 Haroun et al.50

“+” denotes positive effect; LDL = low density lipoprotein; HDL = high density lipoprotein; UK = United Kingdom
n/a= not applicable
Not established = relationship is unknown and is unlikely to present
Unconfirmed = relationship is suspected and awaits further studies for evidence
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Table 1-4 Risk factors (non-traditional) for CKD progression and mortality
Risk factors

CKD
progression

 s-albumin
Anaemia
Bone mineral disorders/  calcium x
phosphate products
Cardiovascular disease
CKD,  GFR/ stage CKD
Dyslipidaemia –  LDL cholesterol, 
HDL cholesterol and  triglycerides
Electrolyte imbalance
Family history of CKD
 Homocysteine
Inflammation/ infection
Malnutrition/ protein and energy
wasting (PEW)
Oxidative stress
Proteinuria/ albuminuria
 Renin-angiotensin system activity
Thrombogenic factors
Uraemic toxicity

Mortality

unconfirmed

Cardiovascular
disease
Risk factors
altered by CKD
unconfirmed

+
+

+
+

+
+

+

n/a

+

n/a

+

+

unconfirmed

+

+

+
+
unconfirmed
+
unconfirmed

+
Not established
unconfirmed
+
+

unconfirmed
unconfirmed
unconfirmed
unconfirmed
unconfirmed

unconfirmed
+
+
unconfirmed
+

+
+
+
+
Not established

unconfirmed
unconfirmed
unconfirmed
unconfirmed
unconfirmed

+

Comments
(Information based on clinical practice guidelines and reviews,1, 27,
30-34 and selected references)
Low base line albumin appear to associate with faster rate of GFR
decline in diabetic patients
Deicher et al.63
Schwarz et al.,64 Tomiyama et al.,65 and Voormolen et al.66
Coresh et al.67 Cardiovascular morbidity and mortality increase once
eGFR is below 60 mL/min
Sarnak et al.,29 Tonelli et al.,68 Fried et al.69 Faster rate of progression
associated with  baseline kidney function
As listed in Table 1-3a, Massy et al.70
Weir et al.71
Samuelsson et al.,72 Finocchiaro et al.73
Stenvinkel et al.74
Through effects of inflammation, atherosclerosis and oxidative
stress74, 75
Modlinger et al.76
Jafar et al.77
Remuzzi et al.78
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Table 1-4 continued
 Uric acid

unconfirmed

unconfirmed

+

 Vitamin D

unconfirmed

unconfirmed

unconfirmed

Volume overload (fluid)

unconfirmed

+

unconfirmed

Johnson et al.,79 Suliman et al.80 Uric acid level associated with
calcium/phosphate metabolism, dyslipidaemia, inflammation.
Independent effects on progression and mortality unconfirmed
Mehrotra.81 Vitamin D insufficiency and deficiency evident and
associated with bone mineral disorder, albuminuria, CV disease in this
population. However, relationship with CKD progression unconfirmed

“+” = positive effect, CKD = chronic kidney disease; LDL = low density lipoprotein; HDL = high density lipoprotein; s-albumin = serum albumin
n/a= not applicable
Not established = relationship is unknown and is unlikely to present
Unconfirmed = relationship is suspected and awaits further studies for evidence
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Many of these modifiable risk factors are nutrition-related, namely: hypertension (HT);
dyslipidaemia; diabetes mellitus (DM, glycaemic control); metabolic syndrome; obesity;
anaemia; bone mineral disorders (BMD), including serum calcium x phosphate
products; CV disease; inflammation; malnutrition / protein and energy wasting (PEW);
oxidative stress; proteinuria; increased uric acid; low vitamin D level; and fluid volume
overload. Due to the complex metabolic derangements in kidney failure, the efficacy of
nutrition intervention alone and/or as adjunct therapy to pharmacological management
has been inconclusive and requires further controlled trials. The studies of effects of
nutrition interventions on individual nutrient or food component modification, such as
protein and sodium, will be further explored in this review.

1.2.3 Medical management of non-dialysis CKD: an overview

Medical management of non-dialysis CKD focuses on prevention, risk identification,
ongoing monitoring and treatment to slow down the rate of decline of renal function.
These treatments are predominantly by pharmacological agents. Due to the kidneys’
key roles in energy and nutrient metabolism, nutrition and exercise interventions are
inseparable parts of management of CKD. The main treatment objectives are to
manage the known modifiable risk factors discussed in the previous section. Priority
interventions23, 33, 82, 83 that are known to be effective in slowing the disease progression
are (1) to control blood pressure using angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists or blockers (ARB), which have proven
renoprotective effects and calcium channel blockade, and (2) to achieve optimal
glycaemic control in patients with diabetes. Observational studies indicated the
association of abnormal clinical parameters and kidney disease progression (Table 14). However, further intervention studies are required to examine the reno- protective
effects of modifying these factors e.g. lipid-lowering therapy and dietary protein
restriction. The Study of Heart and Renal Protection (SHARP)

84

commenced in

9

2003 aimed to answer if cholesterol-lowering therapy using a combination of

simvastatin and the cholesterol-absorption inhibitor ezetimide could reduce
cardiovascular events and survival. Unfortunately, dietary monitoring and
modifications were not included in the study.

In consistent results on disease

progression were found in various low protein diets studies which will be
discussed in detail in section 1.4.1. Other important interventions are to prevent or
manage CV disease and other uraemic-related complications, such as fluid and
electrolytes imbalance, acid-base balance, anaemia and bone disease management.
The rate of decline of GFR may not be regular; it is also important to prevent and
correct any factors that may lead to acute decline in renal function, including volume
depletion, obstruction of urinary tract, intravenous radiographic contrast, use of certain
medications such as nonsteroidal anti-inflammatory agents (NSAIDs), antihypertensive
medications, antimicrobial agents and immunosuppressants.23,

83

In clinical practice,

dietitians are required to understand the medications commonly used in this population
and their effects on nutrition management; examples are the drug-nutrient interaction of
phosphate binders and iron or potential hyperkalaemic effects associated with the use
of ACE-I and ARB. A list of commonly used medications is presented in Appendix A.

1.3

Causes and consequence of nutrition abnormality in ESKD: an overview

1.3.1 Introduction

By CKD stage 3 to 4, significant biochemical and haematological derangements and
nutritional abnormalities may exhibit with various levels of severity. These
abnormalities become more severe as GFR deteriorates;12, 85 as patients get closer to
stage 5, RRT or a conservative care pathway for management of ESRD is considered.
Although clinical and nutritional status of many patients may improve after dialysis
starts,86-88 dialysis does not completely replace the function of the kidney or correct all
the metabolic abnormalities associated with uraemia; patients remain in a state of

10

chronic uraemia. The dialysis process itself also introduces a new set of problems,
altering nutrition requirements due to nutrient losses into dialysate, protein degradation
and catabolic effects of dialysis.89,

90

Therefore nutritional status continues to be

compromised. Factors causing nutrition abnormalities and consequences are
summarised in Table 1-5. All these factors are interrelated to alter energy, protein and
nutrient requirements, either increased or decreased due to the decreased clearance
or altered metabolism.
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Table 1-5 Factors causing nutrition abnormalities and consequences in ESKD
Impaired
function and
other causes
Impaired
excretion/
accumulation

Regulation/
Uncontrolled
homeostasis
Hormonal
imbalance

Dialytic factors
(for patients on
dialysis
program)

Miscellaneous
clinical factors

Age and life
cycle-related
factors

Psychosocial

Factors
Uraemia
Build-up of fluid, electrolytes,
metabolites, toxins
 Urine output

Acidosis
Hypertension
Glucose and lipid abnormalities
 Fibroblast growth factor 23 (FGF-23)
Insulin resistance
Osteodystrophy
Anaemia
Glucose intolerance
Leptin
Biocompatibility
Nutrient losses
 Energy expenditure
Inadequate dialysis
Frequent blood sampling and losses
Peritoneal dialysis-related abdominal
distension, fullness and constipation
Co-morbidities
Medication
Frequent hospitalisation
Inflammation
Obesity
Older age (> 65 years)
Osteoporosis
Sarcopenia
Poor dentition
 Physical inactivity
 Functional capacity
 Independency
 Memory
Depression
Loss of income
Poor food preparation skill

Nutritional abnormality
 Symptom (e.g., nausea, poor appetite,
gastrointestinal symptoms taste change)
leading to  dietary intake
 Potassium
 Phosphorous
 Uric acid
Fluid restriction
Augmentation of proteinuria
 Protein degradation
 Serum lipids
 Glucose
 Protein wasting
Increased iron, vitamin B12 and folate
requirements
Altered vitamin D/ calcium/ phosphate
requirements
 Catabolism
Protein degradation
 Dietary intake
 Protein wasting
 Glucose load,  triglycerides
 GI symptom,  appetite

Drug-nutrient interaction, altered nutrient
availability and metabolism
 Nutrition requirements
 Dietary intake
Altered vitamin D/ calcium/ phosphate
requirements
 Ability to obtain/ prepare foods

 Dietary intake
 Quality of life (QOL)s
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1.3.2 Overview of malnutrition in ESKD
Malnutrition is associated with detrimental consequences in patients with ESKD. In
general terms, malnutrition is defined as “the condition that develops when the body
does not get the right amount of the vitamins, minerals, and other nutrients it needs to
maintain healthy tissues and organ function”.22 It can be under-nutrition or overnutrition. Under-nutrition is “a consequence of consuming too few essential nutrients or
using or excreting them more rapidly than they can be replaced; whereas over-nutrition
is usually a result of “eating too much, eating too many of the wrong things, not
exercising enough or taking too many vitamins or other dietary replacements”. 22 In
patients with ESKD, uraemic malnutrition generally refers to patients with kidney
disease, who have suboptimal nutritional status characterised by reduced body weight,
depleted fat stores, loss of somatic protein (muscle mass) and low levels of visceral
proteins such as s-albumin, pre-albumin and transferrin.75 Various nutrition parameters
have been examined in longitudinal studies as markers of malnutrition or undernutrition and predicted poor outcomes; these including a nitrogen index less than
80%,91 depleted total body potassium,92

low s- albumin,15,

93, 94

reduced energy intake (<25kcal/kg/d),15 reduced appetite,95-97
assessment (SGA)

13, 14, 98, 99

reduced MAMC,15
subjective global

and related composite score such as malnutrition

inflammation complex syndrome (MICS).100 Prevalence of malnutrition is high in
patients with ESKD, it has been reported to be approximately 28% to 40% in stages 4
to 5 non-dialysis patients
dialysis),13,

99

85, 98

; 39% to 55% in incident dialysis patients (at the start of

and 20% to 76% in prevalent or established dialysis patients.101,

102

Malnutrition is associated with morbidity and mortality,90, 91, 98, 103-105 hospitalisation13, 98,
106

and poor quality of life (QOL).107, 108

The cause of uraemic malnutrition or PEW is multifactorial, 109, 110 and is a consequence
of metabolic and hormonal derangements in kidney failure (Table 1-5, Figure 1-1). The
main factors are reduced spontaneous energy and protein intake11 due poor appetite111
and taste aversion to foods caused by uraemic toxicity, altered energy expenditure
13

(EE),112,

113

dietary restriction, inflammation,95 catabolism,114 metabolic acidosis,115,

116

altered hormone response,117 altered gastrointestinal function118 and dialytic factors (in
dialysis patients).119,

120

These problems are also compounded by osteoporosis and

sarcopenia which are commonly found in the aging population with or without CKD.

Figure 1-1 Mechanism associated with the development of uraemic malnutrition
in ESKD

 Kidney Function
(GFR)

Cardiovascular
disease /
atherosclerosis

Build up of
uraemic toxins

Altered energy
and nutrient
metabolism

Uraemic
Symptoms

Altered metabolism,
haemostats and
hormonal imbalance

Acidosis

Chronic
inflammation

+ve

 Appetite/
anorexia
-ve
Inadequate
dietary intake

Altered resting
energy
expenditure

Proteolysis /
protein
degradation

-ve
Muscle wasting

 Physical
activity

Insulin
resistance

 Anabolism

Uraemic Malnutrition

Abbreviation: “+ve”= positive, “-ve”= negative
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It is well accepted that there are two types of malnutrition: Type I is defined as “true”
malnutrition related to uraemia per se, such as inadequate intake of energy and
protein, physical inactivity and inadequate dialysis (in patients on dialysis). Type II
malnutrition is caused by inflammation which leads to malnutrition and cardiovascular
disease and is also known as malnutrition, inflammation and atherosclerosis (MIA)
syndrome.74,

75

It is characterised by elevated inflammatory markers (e.g. CRP) and

pro-inflammatory cytokines (e.g. interleukin-1 and tumour necrosis factor-); these are
known to inhibit appetite and increase protein catabolism, leading to protein energy
wasting (PEW). Table 1-6 summarises the features of type I and II malnutrition

Table 1-6 Features of type I and type II malnutrition
Clinical and nutritional Parameters
S-albumin
Co-morbidity
Presence of inflammation,
e.g.  C reactive protein (CRP)
Dietary protein and energy intake
Resting energy expenditure
Oxidative stress
Protein catabolism
Improved by dialysis and nutritional
support

Malnutrition
Type I
Normal to moderate 
Uncommon
No

Normal

Normal
Yes

Type II

Common
Yes

Normal to 



Probably not unless underlying
clinical cause is managed

75

Adapted from Stenvinkel et. al.

Type I and Type II malnutrition may co-exist, continue to overlap, and change
magnitude during the course of decline of kidney function and use of RRT. As shown in
Figure I-1, all contributing factors are interrelated and in a vicious circle compounding
the effects of each other. Therefore, treating the cause of inflammation and ensuring
adequate protein and energy intake (EI) to manage PEW are of equal importance. The
consequences of malnutrition on clinical outcome and survival will be discussed further
in section 1.3.4.
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1.3.3 Overview of overweight and obesity in ESKD

While under-nutrition is known to associate with poor outcomes, on the other hand, the
overweight and obesity paradox has created much debate in the renal community on
its effect on outcome and survival. A body mass index (BMI) level between 25.0 to 29.9
is categorised as overweight and a BMI ≥30.0 is categorised as obese. 121 The
factors122, 123 leading to the development of overweight and obesity are excess caloric
intake, physical inactivity, insulin resistance, genetics, epigenetics, comorbidity and
medications that alter metabolism, such as steroids.

In the general population, overweight and obesity are associated with the development
of a number of chronic and clinical conditions, such as HT, dyslipidaemia, DM, CV
disease,

cerebral

vascular

disease

(CVD)

and

some

types

of

cancer.60, 124, 125 The “J-curve” relationship is observed between mortality risk and the
range of BMI levels, in that underweight and being obese are associated with higher
mortality risk.126, 127 However, high BMIs or obesity appear to exert protective effects in
the dialysis population;105,

128, 129

this is known as “reverse epidemiology”.130-132 The

“reverse epidemiology” phenomenon in ESKD is not well-understood but may reflect
that highest risk individuals with earlier stages of CKD die from cardiovascular disease
without progressing to CKD stage 5. However, other researchers reported the “J-curve”
relationship between BMI and survival was evident in the Australian ESKD
population.133 Overweight and obesity have different impacts on clinical outcomes
depending on CKD stages and treatment. Such effects on the dialysis (haemodialysis
[HD] or peritoneal dialysis [PD]) and transplantation populations are very different to
those patients not yet on dialysis and are beyond the scope of this thesis to discuss
these mechanisms. In general, there is a lack of detailed published studies for the nondialysis CKD population to describe the association between BMI and mortality, and
the evidence of “reverse epidemiology” has been inconclusive.134 In the Framingham

16

Heart Study, obesity showed an increased risk in the development of CKD,135 probably
mediated through other risk factors such as CV disease, HT, DM, insulin resistance,
metabolic syndrome, inflammation, prothrombotic state, a cluster of metabolic risk
factors collectively called atherosclerotic cardiovascular disease (ASCVD).122 In a
number of cohorts, obesity has been identified as an independent predictor for CKD. 59,
61, 136

Patients with high waist-to-hip ratios or central adiposity appear to have the

highest risk of developing CKD.137 Obesity is not just a risk factor for CKD, but also
accelerates progression as it enhances hyperfiltration and hyperperfusion, irrespective
of the presence of HT, and magnifies the effects of HT on albuminuria to increase
kidney injury.138 Other obesity-related metabolic disorders that magnify CKD
development and progression are IgA nephropathy,139 diabetic nephropathy, stone
disease (urate nephropathy)140, 141 and obesity-related glomerulopathy (ORG), a form of
focal segmental glomerulosclerosis (FSGS).138, 142

Wasting can occur in overweight or obese CKD patients or patients could gain fat
stores and lose muscle mass. In a retrospective analysis that included approximately
70,028 incident HD patients,143 high BMI (defined as ≥25 kg/m2) had lower hazard of
death (HR, 95% CI: 0.85, 0.83–0.87; P <0.001) compared to those who had a BMI <25
kg/m2. However, the protective effect of high BMI was limited to those patients with
normal or high muscle mass as measured by urinary creatinine (UCr) >25th percentile
of the study population, that was 0.55 g/d. Whereas patients with high BMI with inferred
low muscle mass, defined as UCr <0.55 g/d, had increased mortality risk (HR, 95% CI:
1.14, 1.10–1.18; P <0.001). In a prospective cohort of patients who were assessed
close to or just after the initiation of dialysis, PEW was found to be a predictor of
mortality in both obese and non-obese sarcopenia patients.144 These studies
suggested the importance of body composition rather than BMI alone to predict
mortalities.
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In addition to malnutrition and obesity, other consequences of nutritional abnormalities
listed in Table 1-5, such as osteodystrophy due to altered vitamin D, calcium and
phosphate requirements, are all important contributing factors to poor clinical
outcomes.

1.3.4 Nutritional factors affecting outcomes and survival in patients with ESKD
Many nutrition abnormalities emerge during the decline of kidney function12, 74 and are
present at the start of dialysis.145, 146 Longitudinal survival studies (Table 1-7) identified
a number of nutritional and related factors at the commencement of dialysis associated
with poor outcomes of ESKD patients. The significant factors affecting outcome
included: older age (> 65years); presence of co-morbidities, such as cardiovascular
disease and DM; low kidney function, measured by serum creatinine clearance (CrCl)
or GFR; and nutritional factors, such as low BMI, reduced serum albumin (s-albumin),
reduced EI, reduced muscle mass, history of weight loss, reduced hand grip strength
and malnutrition scored using the subjective global assessment (SGA). SGA is a
diagnostic tool for malnutrition based on the clinician’s subjective judgement on
medical and physical assessment of a patient.147-150 The role of SGA in nutritional
assessment in CKD will be discussed in Section 1.5.2.

These studies indicated high prevalence of malnutrition (42–55%) and presence of
nutrition abnormalities at the start of dialysis. However, the interpretation of the
relationship between malnutrition and renal function varied depending on a number of
factors, including patient selection criteria and history of pre-dialysis nephrology care.
Most importantly, despite nutrition status usually improving after dialysis started,86,

87

the extent of improvement during the first year of treatment depended on the nutritional
status at the time of initiation of dialysis; therefore baseline nutritional parameters
predicted the value at the end of one year study period.87 Thus, it comes into view that
pre-dialysis nutritional status has influence over clinical outcomes after initiation of
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dialysis. Like nutritional status, the closely related QOL factor107, 108 is another important
outcome measure in dialysis patients. High prevalence of anaemia (56%),
hypoalbuminaemia (52%) and depressive symptoms and poor physical function score
measured by Short Form Health Survey (SF-36) were observed in a study of 422
incident HD patients.151 While the importance of timely pre-dialysis care to improve
clinical outcomes requires further investigation, patient-centred outcome measures
such as QOL should also be considered.
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Table 1-7 Nutritional and related factors at commencement of dialysis and outcomes
Author/ study
Country
*Year
CANUSA Study13
US
1996

Patient number, age (yr) Dialysis
Outcome
and study duration
(GFR at start of measures
dialysis,
mL/min/1.73m2)
n =680
PD
Mortality
age: 54.3 (18–82)
(n/a)
study: 40 mth
f/u: 24 mth
Technique failure
Hospitalisation

Rocco106
US
1996
Barrett152
Canada
1997
Chung99
Korea
2000

n =1752
age: 57.4±15
study: 36 mth
f/u: n/a
n =820
age:58.3±15.4
study: till end of April 1995
f/u: 6 mth (all patients)
n =91
age: 53 (22–76)
study: 52 mth
f/u: 24 mth

Significant factors and outcomes
SGA – malnutrition (%), Relevant non-affecting factors
(mortality risk of relevant nutritional factors displayed if appropriate)
 Age, CV Disease,  CrC,  KT/V, DM (on insulin);
 s-alb – per 1g/L , RR (95% CI): 0.94 (0.90–0.97)
 % LBM (1%-lower % associated with 3%  in the RR of death)
Malnutrition by SGA score (55.4%), for 1 unit  improvement RR (95% CI): 0.75
(0.66–0.85)
 s-alb – per 1g/L , RR (95% CI): 0.95 (0.92–0.95)
CCr – for 5L/wk/1.73m2,  RR (95% CI): 0.95 (0.9 1–0.99)
 CCr ecoefficient multiplicative factor indicating relative time hospitalised compared
to alternative within variable. ecoefficient for s-alb =0.95, ecoefficient for 1 unit
improvement of SGA score =0.82
 Age,  physical activity, DM primary cause of ESKD, Caucasian, PVD, absence
of HT, angina, smoking, CCF,  s-alb (multiple regression analysis, for  of 1.0
g/dL, r =0.23, P <0.0001)

HD
(n/a)

Hospital days/yr

HD & PD

Mortality

OR (95% CI):  age, 60–70 yr: 2.4 (1.1–5.2) and ≥70 5.0 (2.4–10.5);
Presence of cardiac symptoms: OR (95% CI): 3.2 (1.6–6.7), malnutrition-MD
assessed (18.7%): 2.5 (1.5–4.2); s-alb: 2.5 g/dL, 2.2 (1.1–4.4). P values n/a

PD
(n/a)

Mortality

 Age, malnutrition by SGA score (45.0%) RR (95% CI): 2.38 (1.17–5.35),
P <0.015
 FFM – for each kg, RR (95% CI): 0.92 (0.84–1.00), P <0.046
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Table1-7 continued
Stenvinkel14
Sweden
2002

n =206
age: 52.0±12.8
Study: n/a
f/u: 37±2.0 mth

HD and
(7.0±1.0)

Beddhu143
USA
2003

n =70,028
age: ~ 65±14.0
study: 48 mth
f/u: not reported

HD
(n/a)

Mortality
(all-cause
cardiac)

Chung153
Korea
2003

n =153
age: 53.3±12.3
study:84 mth
f/u: 20.8±15.2 (1.0–6.8) mth

PD
(n/a)

Mortality

Combined CMD and malnutrition by SGA (48.5%) within CMD group. Adj. HR
(95% CI): 9.0 (2.14–32.24), P =0.006;
Malnutrition by SGA =41.8% in total sample;
Malnutrition alone adj. HR, 95% CI: 2.72, 0.17–20.64 (NS)

Wang154
US
2003

n =393
age: 55.5±15.0
study: 120 mth
f/u: median 13.4 (range 0.1–
104.8) mth
n =377
age: 64.0 (17–89)
study:180 mth
f/u: 36 mth

PD
(n/a)

Peritonitis rate

Male gender
 s-alb (Univariate analysis, for 1 g/L , RR (95% CI): 0.79 (0.65–0.95), P =0.015

HD
(n/a)

Mortality

n =149
age: 55.2±17.2 (19–90)
study: n/a
f/u: 12 mth

HD
Hospitalisation
(9.02±5.8, range
0.70–35.8)

adj. HR (95% CI):
 low initial body weight (BMI per 1 kg/m2 increment) 0.96 (0.94–0.98),
P <0.0001;
diabetic nephropathy 1.3 (1.14–1.65), P <0.0001;
weight loss within 12 mth of dialysis initiation 2.16 (1.83–2.55), P <0.0001
Mean length of hospital stay per yr of highest vs. lowest quartiles of studied
parameters: s-alb 3.83±5.68 vs. 8.96±9.96 day/yr, P =0.006; creatinine
4.72±11.57 vs. 12.43±15.15 day/yr, P =0.017
CrCl or residual renal function (NS)

Wiesholzer155
Austria
2003
Pupim156
USA
2004

PD Mortality

Age, gender, DM, CVD,  HGS, CRP Malnutrition by SGA score (39.0%), adj.
HR (95% CI): 1.78 (1.31–2.49), P <0.001
 s-alb per g/L  – unadjusted HR (95% CI): 0.95 (0.91–0.98), P <0.01. adj. HR
NS.  LBM (male) per kg , adj. HR (95% CI): 0.95 (0.89–1.00), P =0.06
BMI,  LBM (female)
 BMI (>30 kg/m2) with  muscle mass (defined as Cr <25th percentile), all-cause
and mortality adj. HR (95% CI): 1.14 (1.10–1.18), P <0.001 and cardiovascular death
adj. HR (95% CI): 1.19 (1.13–1.26), P <0.001
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Table 1-7 continued
Johansen157
n =418,055
USA
age:
56.7±12.8
2004
64.3±16.9
study: 78 mth
f/u:24 mth (median)
133
McDonald
n =9,679
Australia
age: 47–70
2004
study: 121 mth
f/u: n/a
Chandna158
n =318
UK
age: ~ 59.3±14.9
2005
study: ~ 10 yr
f/u:36 mth
Beddhu159
n =5059
USA
age=64±14yr
2005
study: 3 yr
f/u:1 to 3 yr
Araujo15
Brazil
2006

n =344
age 18–90
study: 120 mth
f/u: n/a

HD and PD
to (n/a)

Mortality

High BMI, adiposity and fat mass

PD
(n/a)

Mortality

HD and PD
(n/a)

Mortality

Obesity or BMI >30 kg/m2:
adj. HR (95% CI) for mortality 1.36 (1.14–1.54), P <0.05 and technique failure 1.17
(1.07–1.26), P <0.01
BMI <20 or >30 kg/m2 J-curve relationship existed in fractional polynomial analysis
nPCR levels <0.8 g/kg/d at initiation of dialysis predicted:
future low nPCR levels at 3 mth and 1 yr P <0.001, and 3 yr P <0.01;
mortality – adj. HR(95% CI): 1.51 (1.08–2.10), P <0.015
Also refer to Table 1-7 regarding the pre-dialysis data
Total protein intake (TPI) using highest quartile as referent (60.2 g/d): those in the
lowest quartile (32.4 g/d) had adj. HR (95% CI): 1.18 (1.05–1.33),
P <0.001;
Dietary protein intake (DPI) defined as TPI per kg of weight using 1.2 g/kg/d as
referent, DPI <0.8 g/kg/d had adj. HR (95% CI): 0.85 (0.73–0.99), P =0.04
Adj. HR (95% CI) for mortality:
age (>60 yr): 1.87 (1.22–2.87), P =0.004
 s-alb: 1.59 (1.02–2.46), P =0.04; DM: 1.93 (1.23–3.04), P =0.004
 MAMC: 0.97 (0.96–0.99), P =0.008
 energy intake (>25 kcal/kg/d): 0.96 (0.92–0.99), P =0.03
Gender, KT/V, BMI, TSF

HD and PD
Mortality
(CrCl:
ranged
from 7.8±6.2 to
12.2±6.2 over 4
quartiles)
HD
Mortality
(n/a)

Abbreviation: UK = united Kingdom;  = increased;  =decreased; yr = year; f/u = follow up; mth = month; HD = haemodialysis; PD = peritoneal dialysis;
CV = cardiovascular ; CrCl = creatinine clearance; RR = relative risk; OR = Odds ratio; HR = hazard ratio; adj. HR = adjusted hazard ratio;
CI = confidence interval; NS = non-significant (statistically); KT/V = dialysis constant x time/ volume of distribution (urea kinetic study); DM = diabetes mellitus;
s-alb = serum albumin; BMI = body mass index; LBM = lean body mass; FFM = fat-free mass; MAMC = mid-arm muscle circumference; TSF = triceps
skinfold; SGA = subjective global assessment; nPCR = normalised protein catabolic rate; CMD = co-morbid disease
Expression of figures: n±SD – standard deviation; n(n1-n2) – range
* ordered by year
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The relationship between levels of kidney function at the time of starting dialysis and
nutritional status has seldom been investigated. In a cross-sectional retrospective
analysis of 134 incident dialysis patients,146 the “late start” group (GFR <10
mL/min/1.73m2) when compared with the “early start” group (GFR >10 mL/min/1.73m2),
had significantly lower levels of s-albumin (36.6±5.0 vs. 39.3±4.8 g/L, P =0.02), a lower
nitrogen index (%) as measured by the in vitro neutron activation analysis reflecting
body protein store (88±13 vs. 106±9, P <0.0001) and a higher proportion of
malnourished patients defined by nitrogen index <85.0% (46/108 vs. 0/46, P <0.0001).
Late referral to nephrologists, defined as <3 months prior to dialysis initiation, was
significantly higher in the late start group too (P <0.04). It appeared that patients who
started dialysis at lower GFR levels were more likely to be malnourished. Nutrition
intervention in the pre-dialysis stage was not reported in this study. While the result of
this study suggested dialysis should be started early, in contrast, in the Netherlands
Cooperative Study on the Adequacy of Dialysis (NECOSAD)145 with 114 incident
dialysis patients, the baseline data indicated that even at a mean commencing GFR of
6.2 mL/min/1.73m2, nutritional status was well-maintained, with 69.0% of patients
meeting the normalised protein nitrogen appearance (nPNA) norm of 0.8 g/kg/d; 67.0%
of patients had an s-albumin level in the normal range and 71.0% were rated as normal
nutrition (SGA score A) at the third month of assessment. In addition, 90.0% of the
studied patients received pre-ESKD management defined as care in a nephrology
outpatient clinic for at least a month (median 19, range 1.4–256 months). However, the
history of nutrition intervention was not mentioned. Two of the survival studies13, 14 (also
see Table 1-6) reported baseline renal function and prevalence of malnutrition, but
again there was no mention of the history of nutrition intervention. In the Swedish
study,14 the mean GFR at the start of dialysis was 7.0±1.0 mL/min/1.73m2 and 42.2% of
patients were classified as malnourished. Patients who agreed to participate in the
study were assessed within 4 weeks before dialysis started and were less than 70
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years of age. In the Canada-USA (CANUSA) Peritoneal Dialysis Study,13 55.4% of
patients were classified as malnourished and the baseline renal CrCl was 38.8
L/week/1.73m2. Strict exclusion criteria were applied to patients who consented to
participate in the study, such as patients who were unlikely to survive for at least
6 months or who had active systematic inflammatory disease. These studies provided
substantial evidence to support that nutrition abnormality and related factors present at
the start of dialysis were associated with poor outcomes. These suggest timely nutrition
intervention in the pre-dialysis stage may be crucial to improve outcomes. The nutrition
status of the non-consented patients was either not known or possibly worse due to
unplanned dialysis.

1.3.5 Nutritional intake and abnormalities in non-dialysis CKD stages 4 to 5

As observed in cross-sectional and prospective longitudinal studies (Table1-8),
nutritional intakes decrease and nutritional status deteriorates as renal function
decreases through stages 4 to 5 CKD, before reaching dialysis. Positive correlations
exist between energy, protein and some nutrient intake and GFR.11,

12, 160

However,

these relationships do not appear linear, levelling off after the initial declines and
remaining low.161 In advanced CKD, the reduced nutrition intake was thought to be the
biological adaptation of uraemia caused by neurological changes that led to a gradual
alteration of the sense of taste.162 Despite correlated declines in energy, protein and
nutrient intakes with GFR, dietary intakes are also likely to be influenced by cultural or
regional eating habits and food patterns161 and diet-reporting behaviour.163 In a
longitudinal study with 1,282 subjects,158 the authors observed a dramatic and
significant reduction of protein intake measured by normalised protein catabolic rate
(nPCR) late in the course of progressive CKD when CrCl fell below 15 mL/min,
approximately 3 months preceding initiation of dialysis.
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Table 1-8 Energy and protein intakes in non-dialyse CKD stages 4 to 5
Author/
Country
*Year

study

Patient number
and age (year)

Renal function
CrCl/ GFR
(mL/min/1.73m2)

Study type
[Stratification
factor if applied]
Pollock160
Australia
1997

Intake
Energy
(kcal/kg/d)
Method

Protein (DPI)
(g/kg/d)
Method

Nutrition parameters
BMI
(kg/m2)

s-alb
(g/L)

n =766
age:61.8±1.1
(range 7–88)

36.1±2.1

n/a

0.89±0.02
UUN

24.2±0.3

41.7±0.3

Relationship between GFR and:
DPI: r =0.50; P <0.0001
BMI: r =0.23; P <0.0001
s-alb: r =0.14; P <0.0001
(inverse correlations with age, chol, TG
and BSL)

n =484
age:63±15

28.2±16.1

29.0±7.4
7 day recall

1.02±0.20
7 day recall

25.8±4.3

n/a

n =27
age:57±17

18.0±5.0

23.6±7.8
24hr recall

1.04±0.24
24hr recall

23.8±3.8

44.0±5.0

Relationship between GFR and protein,
lipids and glycides r =0.025, 0.30, and
0.29 respectively
CKD patients have lower intake of
energy, proteins, lipids and
carbohydrates compared to population
average except higher total lipid and
M/UFA intake
Relationship between:
Energy intake and BMI: r =0.84;
P <0.05)
s-alb and CRP: r =0.91; P <0.01
(also see Table 1-8)

Cross-sectional
Lusvarghi161
Italy
1998
Cross-sectional

Carvalho164
Brazil
2004
Cross-sectional

Comment and relevant findings
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Table 1-8 continued
Fassett/LORD
Study163
Australia
2007

n =113
age: 60±15

40.3±19.4

21.5±7.8
F-diary

0.9±0.3
F-diary

28.6±6.0

40.2±4.5

All:
n =1,785
age: 51.2±12.9
n =540
age: 51.0±12.4
n =355
age: 51.2±13.6
n =204
age: 51.3±13.2
All:
n =201
age: 63±13
SGA A:
n =128
age: 61±15
SGA B
n =62
age: 66±10
SGA C
n =11
age: 67±9

All: 39.8±21.1

29.4±9.31
F-diary

1.00±0.25 UUN
1.05±0.34 F-diary

27.6±4.1 (M)
26.6±5.4 (F)

40.6±3.9 (M)
39.9±3.4 (F)

>37 group

31.0±9.30

21–37 group

29.2±10.0

<21 group

26.4±6.90

n/a

n/a

1.06±0.30
1.13±0.35
0.97±0.22
1.05±0.34
0.88±0.19
0.90±0.27
Mean figure for all
patient: n/a UUN

28.1±4.1 (M)
26.8±5.6 (F)
27.4±4.3 (M)
26.8±5.6 (F)
26.4±3.7 (M)
26.1±5.3 (F)
n/a

41.0±3.9 (M)
40.6±3.2 (F)
40.3±3.8 (M)
39.6±3.4 (F)
39.9±4.0 (M)
38.8±3.7 (F)
n/a

14.6±5.1

n/a

1.04±0.32

29.2±5.8

38.2±4.0

12.3±4.1

n/a

0.88±0.22

27.7±5.3

36.0±6.0

10.5±4.5

n/a

0.76±0.22

22.6±4.0

34.1±4.0

Cross-sectional
Kopple, MDRD12
USA
2000
Cross-sectional
[GFR]
Caravaca85
Spain
2001
Cross-sectional
[SGA]

Underreporting observed in 70.8% of
patients with Goldberg cut-off of
EI/RMR <1.27. They were more likely
to be female and younger, and have a
 BMI and  serum creatinine. Mean
energy, calcium, zinc and dietary fibre
intakes were all less than
recommended
Statistically significant difference of
various parameters occurred between
GFR >37 vs. 21–37 mL/min groups,
21–37 vs. <21 mL/min groups, P <0.05.
(also see Table 1-8)

Protein intake (PNA) correlated with
renal function (measured by Kt/V urea),
r =0.53, P <0.0001 best fit in quadratic
regression curve; or renal function
measured by CrCl-Cu, r =0.53, P
<0.0001 in linear regression line.
PNA was significantly higher in SGA A
vs. SGA B or C groups, P <0.05
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Table 1-8 continued
Duenhas165
Brazil
2003
Cross-sectional
[GFR]

Ikizler11
USA
1995
Longitudinal
Chandna158
UK
2005
Longitudinal

All:
n =487
age: 53.4±15.0
n =126
age: 54.0±13.8
n =119
age: 52.8±15.7
n =127
age: 52.4±16.8
n =115
age: 54.2±13.7
All:
n =90
age: 53±15
f/u: 16.8±11.8
mth

All
(mean GFR n/a)

24.9±8.2

0.98±0.32 F-diary
0.95±0.36 PNA

25.6±4.6

38.0±6.7

>43 group

25.9±9.2

27.1±4.7

38.0±7.2

30–43

25.5±8.3

25.0±4.4

38.0±6.3

20–29

24.4±7.2

25.3±4.9

38.0±7.2

<20

23.5±7.9

25.0±4.2

38.0±5.8

All: 35.1±26.1
>50
50–25
24–10
<10

n/a
n/a
n/a
n/a
n/a

1.04±0.42
1.15±0.34
0.99±0.37
0.96±0.29
0.91±0.29
0.93±0.29
0.88±0.33
0.84±0.29
0.82±0.28 UUN
1.01±0.21
0.85±0.23
0.70±0.17
0.54±0.16

n/a
n/a
n/a
n/a
n/a

38.0±0.5
n/a
n/a
n/a
n/a

All:
n =1,282
age: 55.8±15.5
f/u: 84 mth

All: mean-n/a
>50
25–50
10–25
<10

n/a
n/a
n/a
n/a
n/a

n/a
1.17±0.31 UUN
1.04±0.27
0.93±0.21
0.74±0.18

n/a
n/a
n/a
n/a
n/a

n/a
n/a
n/a
n/a
n/a

Energy intake higher GFR >43 vs. <20
mL/min groups, P <0.05. Protein intake
(PNA) significantly lower in GFR <43
groups vs. >43 mL/min group, P <0.05
(also see Table 1-8).
CrCl correlated positively with PNA (r
=0.30, P <0.01), energy intake (r =0.17,
P <0.01) and protein intake
(r =0.21, P <0.01)

 DPI as  CrCl (r =0.46, P <0.0001).
Reduction became more noticeable
when CrCl fell below 25 mL/ml; when
CrCl fell below 10 mL/min, protein
intake below minimal requirement of
0.6g/kg/d
Protein intake (nPCR) significantly
different among CrCl groups
(P <0.001). 2-phase exponential
association between nPCR and CrCl
observed. Gentle decline of nPCR in
mild and moderate renal failure ended
in dramatic decline when CrCl reached
15 mL/min

Abbreviation: n/a = not available or not measured; CrCl = creatinine clearance; GFR = glomerular filtration rate; UUN = urinary urea nitrogen; F-diary = food
diary; s-alb = serum albumin; PNA = protein equivalent of nitrogen appearance; chol = cholesterol; TG = triglyceride; BSL = blood sugar level;
M/UFA = monounsaturated fatty acid; CRP = C reactive protein; EI/RMR = energy intake: resting metabolic rate ratio; vs. = versus; SGA = subjective global
assessment; Htc = haematocrit; Ccr-Cu = urea clearance; nPCR = normalised protein catabolic rate
Expression of figures: n±SD – standard deviation; n(n1-n2) – range
* ordered by year
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The prevalence of malnutrition measured by SGA ranged from 28–44% in the CKD
stages 3 to 5 non-dialysis population, and was associated with poor body composition,
vascular abnormality, hospitalisation and mortality (Table 1-9). Strong associations also
existed between reduced renal function, nutritional abnormalities, reduced intake and
malnutrition. In a longitudinal study over a 12-month period, malnutrition at baseline
was associated with mortality, composite end-point of death or dialysis and acute
hospitalisation.98

Furthermore, the relationship between the detrimental effects of

uraemic symptoms and renal function (measured by CrCl) was not linear and escalated
once CrCl fell below 13 mL/min.85 All these observations have significant clinical and
economic implications for renal services.

In summary, the results of these studies indicated that as renal function declines,
dietary energy and protein intakes, nutritional status reflected by nutritional markers
such as anthropometrical (body compositions), and biochemical and histological
measures all deteriorated. Sub-optimal nutrition intake and status could be detected
when GFR dropped below 40 mL/min/1.73m2. Interestingly, symptoms burden in
relation to protein and energy intakes, intake of other nutrients, food components,
dietary patterns and food habits were seldom examined. To date, only two studies are
known to have examined the dietary intake and nutritional status in the Australian
ESKD population,160, 163 both of which represented samples of much “younger” patients
(60±15 and 61.8±1.1 years) with higher levels of GFR (40.3±19.4 and 36.1±2.1
mL/min) than those referred for pre-dialysis management (GFR <30 mL/min) in our
setting (Appendix B). Therefore, further study is required in this population in the local
setting.
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Table 1-9 Relationships between nutritional and related factors in non-dialysis CKD stages 4 to 5
Author/
Country
*Year

study Patient number Study type
and age (yr)

Renal function
Significant factors associating with reduced renal function
(CrCl/
GFR Malnutrition (%)
mL/min/1.73m2)
Relevant non-affecting factors

Stenvinkel74
Sweden
1999

n =109
age: 52±1

Case with age- 7.0±1.0
matched healthy
control (n =22)

Kopple, MDRD12
USA
2000

n =1,785
age: 51.2±12.9

Cross-sectional

Lawson98
Australia
2001
Caravaca85
Spain
2001

SGA (malnutrition =44%) in univariate analysis,  s-vitamin E,  CRP, CKD patients:
 mean carotid intima-media area (18.3±0.6 vs. 13.2±0.7 mm2, P <0.0001) and
 prevalence of carotid plaques (72.0% vs. 32.0%, P =0.001) indicative of rapidly developing
atherosclerosis. Related to malnutrition, inflammation, oxidative stress, genetic components

39.8±21.1

 GFR correlated with  sum of skinfolds/ body fat and  transferrin in male;  transferrin
and s-alb in female
Decline of GFR may contribute to decline in many nutritional measures related to reduced
protein and energy intakes
n =50
Prospective case SGA A (n =36): SGA (malnutrition =28%)
age: 69.1 (95% control with 12 28.5±12.5
Significantly  mortality (21% vs. 3%, P =0.04), composite end-point of death or dialysis
CI: 62.9–75.4)
mth f/u
SGA B or C (n =14): (50.0% vs. 11.0%, P =0.02) and  likelihood of acute hospitalisation (78.0% vs. 23.0%,
20.7±10.9
P =0.001) in malnourished group
n =201
Cross-sectional
Mean value n/a
SGA (malnutrition =36%) and uraemia score
age: 63±13
Determinants of malnutrition with OR (95% CI) and P value were
14.6±5.1 in SGA =  co-morbidity: 10.29 (4.73–22.37), P <0.0001
A group and below
 Ccr-cu: 0.96 (0.98–0.94), P =0.0015
 Htc: 0.91 (0.85–0.98), P =0.014
Ccr (r =0.38, P <0.0001) and Ccr-Cu (r =0.42, P <0.0001) correlated with uraemia score in
cubic curves. Ascending inflection of uraemia score occurred when GFR <13 mL/min/1.73m2,
indicating non-linear relationship between effects of uraemia and GFR
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Table 1-9 continued
Duenhas165
n =487
Brazil
age: 53.4±15.0
2003
Cupisti166
Italy
2004
Carvalho164
Brazil
2004

Cross-sectional

<43

CrCl correlated directly and significantly with MAMC (r =0.20, P <0.01). In multiple regression
analyses, CrCl, energy and protein intakes independent predictors of BMI (P <0.01) and
MAMC (P <0.05)

n =70
age: 52±1

Cross-sectional

<15

SGA (malnutrition =28.6%)

n =27
age: 57±17

Cross-sectional

18.0±5.0

Fat stores (TSF) depleted in 60% of patients
Not CRP nor s-alb

Abbreviation: n/a = not available or not measured; CrCl = creatinine clearance; GFR = glomerular filtration rate; UUN =urinary urea nitrogen; F-diary = food
diary; s-alb = serum albumin; PNA = protein equivalent of nitrogen appearance; chol = cholesterol; TG = triglyceride; BSL = blood sugar level;
M/UFA = monounsaturated fatty acid; CRP = C reactive protein; EI/REE = energy intake: resting energy expenditure ratio; vs. = versus; SGA = subjective
global assessment; Htc = haematocrit; Ccr-Cu = urea clearance; f/u = follow-up
Expression of figures: n±SD – standard deviation; n(n1-n2) - range
* ordered by year
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1.3.6 Other nutrition-related factors and outcomes in non-dialysis CKD stages
4 to 5

As CKD progresses, the magnitude of other nutritional abnormalities and related
factors also increases. These include:


anaemia,167-169 a risk factor for cardiovascular disease in CKD and associated with
Malnutrition Inflammation and Atherosclerosis (MIA) syndrome



the “J-shaped” relationship between systolic blood pressure and occurrence of
stroke, seen in a clinical cohort with a median follow-up time of 111 months170



sodium or salt intake, which has been considered a potential modifiable risk factor
for the progression of CKD. A reduced sodium intake, together with pharmacologic
intervention using ACE-I and ARB, are recommended to control blood
pressure71, 171



BMD, including the management of calcium, phosphorous and vitamin D to reduce
vascular calcification and prevent hip fracture especially in the elderly172-174



uric acid level, which is prevalent in CKD and associated with CKD progression,175
has a “J-shaped” relationship with all-cause mortality and is associated with
dyslipidaemia, calcium/phosphate metabolism and inflammation.80

1.4

Nutrition intervention studies in non-dialysis CKD stages 4 to 5

1.4.1 Protein-restricted diets in non-dialysis CKD stages 4 to 5
Patients with kidney failure are in a state of “protein intolerance” or protein waste
“intoxication”. The recommended daily intake (RDI) for adults in the general population
is approximately 0.75 g/kg/d (0.75 g/kg/d for women and 0.84 g/kg/d for men);176 this
level assumes a coefficient of variation of 12.0% of the estimated average requirement
(EAR) of 0.6 g/kg ideal body weight (IBW)/d.176, 177 Clinically stable non-dialysed CKD
patients have similar requirements and nitrogen balance studies have shown subjects
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could achieve neutral nitrogen balance with ~0.6 g/kg IBW/d when energy ≥25
kcal/kg/d was ingested. However, with 30–35 kcal/kg/d, it was more likely to reduce net
urea generation, and maintain neutral or positive nitrogen balance and body mass.
Therefore, 30–35 kcal/kg/d is recommended in clinical practice guidelines for these
patients.178 Other pioneer case reports and clinical studies revealed similar results that
different levels of low protein intake (0.4–0.6 g/kg/d) required 35–50 kcal/kg/d to
maintain nitrogen balance and control uraemia.179 The classic “Giovannetti diet” was
used to prolong life of terminal ESKD patients provided ~18 g/d of protein,
predominantly with foods containing essential amino acids, such as eggs, plus a large
quality of non-protein high energy foods to optimise nitrogen balance but limit the buildup of uraemic toxins.180, 181

In addition to the rise in serum nitrogenous waste levels, foods that are rich in protein
are also rich in sodium, purine/uric acid and phosphates that contribute to uraemic
complications. Nevertheless, the use of dietary protein restriction as part of CKD
treatment has been controversial, despite being used anecdotally for more than a
century. The arguments in the literature for182-185 and against186-188 the use of a proteinrestricted diet are summarised in Table 1-10. It is beyond the scope of the current
review to discuss each of the experimental studies in detail. A number of systematic
reviews,189,

190

meta-analyses191,

192

and randomised control trials (RCTs)193-196

supported the benefit of dietary protein restriction in CKD. The details of seven recent
RCTs are presented in Table 1-11.
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Table 1-10 Summary of the rationale for or against the use of a low protein diet
For

Against

Level of protein intake
 0.6 g/kg/d (+ adequate energy)
 Optimal level and duration of intake have not
been defined
 0.3 g/kg/d + ketoacids (+ adequate energy)
Efficacy
Improve signs & symptoms (and reduce on-set of):  Benefits demonstrated in experimental models
  peripheral neuropathy
but not in clinical trials
  insulin resistance
  red blood cell lipid peroxidation
  osteodystropathy
  albuminuria
  proteinuria
Progression rate
Inconsistent findings due to:
 Benefits demonstrated in experimental models
 short study duration
but lacking in clinical evidence
 inclusion of early and non-progressing CKD  No significant slowing of progression
patients
 inclusion of non-adherent patients
 unregulated use of ACE-I
 undefined treatment targets and mechanism,
e.g., blood pressure, phosphorous
Once optimal compliance is achieved, the diet can
slow progression rate
Renoprotective effects
May help:
 No additional benefit above the reninangiotensin system blockade, blood pressure
  albuminuria
reduction and statin
  proteinuria
 reduce total sodium, uric acid and phosphate
intake
Safety/adverse effects
Supervised diet management:
 May induce or further exacerbate malnutrition
 preserve nutrition status
  albumin
 maintain body weight and protein stores
 does not jeopardise survival after initiation of
dialysis
Meta-analysis
 Meta-analysis supports the efficacy of a  Publication bias favouring studies with positive
protein-restricted diet in slowing progression
results
Compliance
 Good compliance noted in a number of  Compliance is generally poor
intervention studies
 Can be measured by urinary nitrogen
appearance and dietary assessment
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Table 1-11 Controlled trials with protein modification in non-dialysis CKD stages 4 to 5
Patient number, age (yr),
renal function (GFR or CrCl
in mL/min/1.73m2 or
otherwise specified) and
study duration
197,
198
Rosman
n =228
The
age: 47.8 (15–73)
Netherlands
CrCl: 10–60
1984/ f/u study f/u =>24 mth
1989
further f/u: 48 mth
Author/
Study
Country
*Year

Ihle194
Australia
1989

n =64
age: 37 (19–69)
CrCl: 14.4
f/u: 18 mth

Williams199
UK
1991

n =95
age: 45±2
CrCl:23–28
f/u: 19±3 mth

Intervention (sample size)

Outcome measures

Significant findings

C: Group A1 (n =44) or A2 (n =30):
free diet, but if s-urea >25 mmol/L
to  protein intake. Remark: A1
and A2 groups had mean 55g/d
and 70 g/d protein intake
I: Group B (n =35): CrCl 31–60, Pro
0.6 g/kg/d
Group C (n =40): CrCl 10–30, Pro
0.4 g/kg/d
C: regular diet (~0.75–1.0 g/kg/d)
(n =33)
I: 0.4 g/kg/d Pro, PO4 <700 mg/d
(isocaloric:35–40 kcal/d) (n =31)

 Change of renal
function using reciprocal
creatinine 1/[cr]

 Conclusion by 1984 (24 mth f/u): regression analysis
indicated  in 1/[cr] was 3–5 times lower in protein
restricted groups than in control groups
 Conclusion by 1989 (48 mth f/u): limited benefit
except in patients with glomerular disease

 Development of ESKD
defined by development
of symptoms
necessitating dialysis or
serum [Cr] >1300
µmol/L
 Nutritional parameters
 Renal function
 Nutrition indexes

 9/33 vs. 2/31 of C vs. I group developed ESKD
(P <0.01). Significant fall of CrCl in C compared with I
group
 No difference in nutrition indexes and nutritional
status maintained

C: no Pro or PO4 controlled diet
(n =32)
I1: Pro 0.6 g/kg/d, PO4 800 mg (n =33)
I2: P04 800mg + binder (n =30)
All with energy: 30 kcal/kg/d

 No difference in change of renal function and nutrition
indexes
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Table 1-11 continued
Locatelli200
Italy
1991

n =456
age: 48.5 (18–65)
Cr: 133–619 umol/L
f/u: 24 mth

D’amico195
Italy
1994

n =128
age:~54.0±12.7
CrCl: 15–17
f/u: 27.1±21.8 mth

Klahr/MDRD193
Kopple/MDRD201
USA
1994/1997
(Data of
omitted)

VLPD

Levy202
2nd analysis and
follow-up study
1996

n =585
age: 38.6±8.9
GFR: 51.3±14.4
f/u: 26 mth

C: regular diet (1.0 g/kg/d) (n =230)
I: 0.6 g/kg/d (isocaloric:35–40 kcal/d)
and 30 kcal/kg/d
Stratified into three groups according
to severity of renal insufficiency or
serum Cr (µmol/L) level:
Group A: 133–221 (n =216)
Group B: 222–442 (n =187)
Group C: 443–619 (n =53)
C: controlled protein (1.0 g/kg IBW/d)
(n =65)
I: low protein (0.6 g/kg IBW/d) (n =63)
Energy: 30–35 kcal/kg IBW/d and
controlled for sodium, phosphorous
and lipids
C: usual diet (1.3 g/kg/d) + PO4
16–20 mg/kg IBW/d (n =294)
I: 0.58 g/kg/d + PO4 5–10 mg/kg
IBW/d (n =291)
Energy: not specified (>25 kcal/kg
IBW/d)

Reaching
end-point:  Borderline advantage of study diet to reach end point
doubling of the baseline
(P =0.06), but insignificant effects on slowing disease
plasma creatinine or need
progression rate
for dialysis
 Nutritional status and blood pressure maintained

End-point:
CrCl

halving

the C (40%) vs. I (28%) reached end-point during study
period (P =0.038)
Significant independent factors: baseline CrCl
(Coefficient =–0.7874, P =0.02) and proteinuria
(Coefficient =+1.0033, P =0.000)
Nutritional status maintained in study group

 Decline in GFR rate
 End-point occurrence of
ESKD or death

 Non-linear fall of GFR in I group showing slower
decline rate 4 months after commencement of
intervention. Overall, marginal benefit of 1.1
mL/min/year  in GFR (NS)
 No difference in occurrence of end-point
 I:  albumin,  transferrin,  body weight and % fat
and arm muscle area in relation to  energy intake
nd
2 analysis: longer time to renal failure. A 0.2 g/kg/d
lower achieved total protein intake associated with
1.15 mL/min/yr slower mean decline in GFR
(P =0.011)
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Table 1-11 continued
Meloni 196
n =89
Italy
age: 62.2±13.4
2004
GFR: 46.8±5.8
(results of non- f/u: 12 mth
diabetic
presented)

C: free protein diet (level of intake not
stated) (n =45)
I: low pro diet (0.6 g/kg/d) (n =44)
Energy: not specified or instruction
not mentioned

 Renal function
 Nutritional status

 I: slower decrease in renal function. Mean  in GFR
of C vs. I group 6.05±1.23 vs. 3.47±0.26
mL/min/1.73m2 (P <0.001)
 At end of study, energy intake of C vs. I group
2,290±360 vs. 1830±205 kcal/d. Weight loss/
reduced obesity index observed in I group (P <0.05)
 No decrease in s-albumin or pre-albumin, no other
signs of malnutrition

Abbreviation: MDRD = Modification of Diet in Renal Disease study; RCT = randomised control trial; C = control group; I = intervention group; GFR =
glomerular filtration rate; CrCl = creatinine clearance; mth = month; Cr = creatinine; Pro = protein; PO4 = Phosphorous; ESKD = end stage kidney disease
Expression of figures: n±SD – standard deviation; n(n1-n2) - range
* ordered by year
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To date, the Modification of Diet in Renal Disease (MDRD) study has the most rigorous
study design among all RCTs to examine the efficacy of a low protein diet on the rate
of decline of renal function.193 At the end of the 2.2 year follow-up (range 0–3.7), the
low protein diet group compared to the usual diet group resulted in a small absolute
benefit of 1.1 mL/min/year decrease in GFR. In this study, the low protein diet and the
control groups were instructed to consume 0.58 vs. 1.30 g/kg IBW/d of protein
respectively; but by the end of the study period, the estimated intake was 0.70 vs. 1.10
g/kg IBW/d. The estimated EI was lower in the low protein group and showed an
increase in albumin but a reduced arm muscle mass. Overall, the nutritional status did
not deteriorate. In the secondary analysis and follow up of the MDRD study, 202 each
0.2 g/kg/d lower protein intake was associated with a 1.15 mL/min/year slower mean
decline in GFR (P =0.011), and the estimated proportion of patients reaching renal
failure or death within three years of follow-up was 30.0% vs. 51.0% for a protein intake
of 0.6 g/kg/d compared to 0.8 g/kg/d. The key factors for not achieving the distinctive
slower progression rate in the initial analyse were: a) not all types of kidney disease
progress at the same rate, for example, patients with polycystic kidney disease could
be less responsive to the diet therapy; and b) possible insufficient statistical power.
RCTs193, 203 and Cochrane systematic review204 indicated the use of a very low protein
diet (VLPD), ~0.3 g/kg/d of protein supplemented with ~ 0.3 g/kg/d essential amino acid
or Ketoacid analogues were effective in controlling uraemic symptoms, postponing
dialysis and maintaining nutritional status. Although these products are not available in
Australia, they should potentially be considered in patients with very advanced kidney
failure not planning for dialysis. Furthermore, in countries where dialysis treatment is
expensive and not readily available, this regimen should be made available to patients
with ESKD.
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The inconclusive and debatable recommendation for the levels of protein restriction
could be a result of a number of study limitations in previous research. In addition to
those described in the MDRD study, the followings factors should also be considered:


the definition of an end-point, such as the rate of fall of GFR, change of kidney
injury markers, appearance of symptoms, initiation of dialysis or death. The effect
of modifying protein intake may have effects on some, or a combination of these
parameters. If untreated, nutritional status deteriorates rapidly towards CKD stage
5 and may accelerate the initiation of dialysis



the heterogeneity of the design of the trial, for example, CKD diagnosis, stages of
CKD or GFR levels, co-morbidities, level of protein restriction, duration of
intervention, heterogeneity of baseline nutritional status (e.g., obesity and
malnutrition), and the duration of the occurrence and severity of these conditions



controlling confounding or competing factors, such as the use of ACE-I, dietary
sodium reduction for HT control or the role of hyperphosphataemia



consideration of energy prescriptions for individuals, e.g., adjustment for
underweight, normal or overweight patients



consideration of other nutrients and dietary or food components, such as fruit,
vegetables and fish, which may affect cardiovascular health



patients’ acceptance due to the willingness to follow the diet and /or the lack of a
viable dialysis program in certain countries.

Based on the current evidence, the recommended protein and energy intakes for CKD
stages 4 to 5 are 0.75 to 1.0g/kg IBW/d and 30–35 kcal/kg IBW/d respectively.205, 206

1.4.2 Other nutrition interventions in non-dialysis CKD stages 4 to 5

In addition to the protein modification studies, there are a limited number of intervention
trials on other nutritional or related factors in CKD stages 4 to 5 (Table 1-12). The most
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important has been weight reduction in decreasing proteinuria, blood pressure and
serum lipids, all modifiable risk factors for CKD progression. In a small RCT of 5
months’ duration of patients with proteinuric nephropathies, a hypocaloric diet resulted
in weight loss accompanied by reduced proteinuria.207 In another 12-month RCT, a
hypocaloric diet induced weight loss, which had a comparable effect to the antihypertensive medication Captopril on reducing proteinuria.208 In these small, shortterm studies in CKD patients, weight loss through hypocaloric dietary intervention
reduced proteinuria. However, larger, long-term studies are needed to examine these
effects on renal outcomes, including the rate of decline of renal function or time to
reach ESKD.

For patients with diabetic nephropathy, a low iron-available, polyphenol-enriched,
carbohydrate-restricted (CR-LIPE) diet209 appeared to be superior than a standard
restricted protein diet of 0.8 g/kg/d in slowing down the CKD progression rate, reaching
ESKD or death (P <0.01). The energy distribution for protein: fat: carbohydrate: alcohol
in the control diet was 25–30:30:35:5–10%; other nutrients and food components were
not stated. However these results cannot be generalised due to small sample size and
lack of monitoring of diet compliance. Other supportive studies were in CKD stages 1–3
and included one that showed that over 12 months a hypocaloric diet in obese diabetic
patients led to significant reduction in body weight (BW), blood sugar, blood pressure,
serum lipids, proteinuria and albuminuria, and improvement in GFR.210

To date, there has not been any controlled study on the effect of sodium restriction in
CKD stages 4 to 5. Retrospective analyses demonstrated the effect of low verses high
sodium intake (assessed by urinary sodium level) on slowing the decline of GFR for
patients also on a low protein diet.211 In-depth reviews71, 212-214 suggest the importance
of sodium restriction on blood pressure control and CKD progression based on shortterm experimental or physiological studies, or evidence from the non-renal population.
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Nevertheless, high sodium intake should be avoided as it attenuates the effects of most
antihypertensive drugs.

Table 1-12 Other controlled nutrition intervention in non-dialysis CKD stages 4–5
Author/
study
Country
*Year
Praga208
Switzerland
1995

Patient number,
age (yr),
parameters and
study duration
n =17
age:48.3±10
(34–70)
proteinuria: >1 g/d
duration: 12 mth

Intervention

Outcome
measures

RCT
I1: Hypocaloric diet
(1000–1400 kcal/d)
(n =9)
I2: Captopril 50–150
mg/d (no change in
diet) (n =9)

Weight
Proteinuria

Morales207
Spain
2003

n =30
age:56.5±15.2
(17–74)
BMI: >27 kg/m2
CrCl: 68.1±33.6
(25.9–151.2)
mL/min/1.73m2
duration: 5 mth
n =191 (diabetic
nephropathy)
age: 60±11
GFR: 63±30 (15–
75) mL/min/1.73m2
f/u: 47±22 mth

RCT
C: Usual diet
(n =10)
I: Hypocaloric diet
(n =20)

Facchini209
US
2003

RCT
Isocaloric
C: Standard,
protein-restricted
diet (0.8
g/kg/day) (n =91)
I: Low ironavailable,
polyphenolenriched, CHOrestricted diet
(CR-LIPE) (n
=100)

Significant findings

I1  BMI 37.1±3.3 to
32.6±3.2
Both groups:
proteinuria from
3.4±1.7 to 0.7±1.0
g/24 h
renal function stable
significant correlation
between body weight
loss and  in proteinuria
(r =0.69,
P <0.05)
Weight
I group:
Proteinuria
 weight by 4.1±3.0% (P
<0.05)
 proteinuria by
31.2±37.0%
(P <0.005) within group
and P <0.05 compared to
the C group
 Doubling
 Renal death occurred:
of serum cr
C vs. I: significant
doubling of serum Cr
 Cumulative
(P <0.01)
incidence
of ESKD
 Cumulative incidence
of ESKD or death
 All-cause
(P <0.01)
mortality

Abbreviation: CrCl = creatinine clearance; mth = month; f/u = follow-up; I = intervention group;
C = control group; cr = creatinine, CHO = carbohydrate
Expression of figures: n±SD – standard deviation; n(n1-n2) – range
* ordered by year
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1.5

Framework of nutritional management of CKD stages 4 to 5

Over the last decade, to guide best clinical practice in renal disease care, including
nutritional management, a number of evidence-based clinical practice guidelines have
been developed by a number of renal organisations. The process of guideline
development was based on rigorous review and grading of scientific evidence to
formulate the guidelines. These processes were followed by extensive consultation
with experts, clinicians and other relevant stakeholders, including consumers, before
the final dissemination of guidelines with graded recommendations. In 2006, the
Dietitians Association of Australia (DAA)
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endorsed the “Evidence-based practice

guidelines for the nutritional management of CKD”205 developed by the Australia and
New Zealand Renal Guidelines Taskforce (ANZRGT). The PhD candidate was one of
the co-authors of these guidelines. The purpose of the document was to compile and
summarise the nutrition components of the following published guidelines:
• Caring for Australasians with Renal Impairment (CARI) Guidelines83
• Kidney

Disease

Outcomes

Quality

Initiative

(K/DOQITM)

Clinical

Practice

Guidelines24, 216-220
• American Dietetic Association (ADA) Medical Nutrition Therapy Evidence-Based
Guides for Practice: Chronic Kidney Disease (non-dialysis) Medical Nutrition
Therapy Protocol221
• ADA Guidelines for Nutritional Care of Renal Patients (3rd Edition)222

• European Dialysis and Transplant Nurses Association and European Renal Care
Association (EDTNA/ERCA) Guidelines for the Nutritional Care of Adult Renal
Patients223

The DAA renal nutritional guidelines, the framework for evidence-based practice for the
nutritional management of CKD, are summarised in Table 1-13.
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The framework of nutritional management in CKD evolved from the nutrition care
process based on the concept of medical nutrition therapy (MNT). 221, 224 The four steps
of nutrition care process are to: 1) refer patients appropriately to a dietitian to carry out
the structured care process, including 2) nutrition assessment, 3) nutrition prescription
and intervention, followed by 4) implementation of these processes, including
evaluation and monitoring of outcomes.

Table 1-13 Framework for the development of evidence-based practice
guidelines for the nutritional management of CKD
Nutrition care process

Clinical questions related to
stage of care process
At what level of GFR should patients be
referred to the dietitian in order to
maximise nutritional intervention
opportunities?
Which specific measures best reflect
nutritional status or change in
nutritional status in CKD?
What are the goals of the intervention?
What is (are) the appropriate nutritional
intervention(s) to optimise nutritional
status in CKD and prevent
malnutrition?
What is the optimal method of
implementation and follow-up to ensure
nutritional status is maintained or
improved?

Criteria for referral to
dietitian
Nutrition assessment
Nutrition prescription/
intervention

Implementation and
management
205

Adapted from Ash

, Splett

225

Objectives

• Achieve and maintain

desirable weight and
adequate nutritional status
• Optimise status of
comorbidities
• Normalise or stabilise
biochemical markers
• Maintain skeletal muscle
stores and strength
• Patients to achieve
individual goals

224

and Hakel-Smith.

1.5.1 What do the guidelines say?

The guidelines for nutritional management of CKD stages 4 to 5, including dialysis, are
summarised in Table 1-14.

Despite the availability of these comprehensive evidence-based guidelines, there are
limitations and gaps in knowledge and practice strategies to meet the needs of
everyday clinical practice; in particular, in the domains of nutritional assessment,
prescription/intervention and implementation, including evaluation and monitoring. The
following sections will further explore these areas of practice in CKD stages 4 to 5.
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Table 1-14 Evidence-based practice recommendations for the nutritional management
of non-dialysis CKD stages 4 to 5
Evidence-based statements (Adapted from Ash205)
(and Level of evidence adapted from NM&MRC)226
Levels of
evidence
I

definition
evidence obtained from a systematic review of all relevant randomised controlled trials.

II
III-1

evidence obtained from at least one properly designed randomised controlled trial
evidence obtained from well-designed pseudo-randomised controlled trials (alternate
allocation or some other method).
III-2
evidence obtained from comparative studies with concurrent controls and allocation not
randomised (cohort studies), case control studies, or interrupted time series with a control
group.
III-3
evidence obtained from comparative studies with historical control, two or more singlearm studies, or interrupted time series without a parallel control group
Opinion
Consensus
Criteria for referral to dietitian
Clinical question:
At what level of GFR should patients be referred to the dietitian in order to maximise nutrition
intervention opportunities?
CKD Stage 4 – GFR 15–29 mL/min (Level III)
CKD Stage 5 – GFR <15 mL/min (Level I)
Nutrition assessment
Clinical question:
Which specific measures best reflect nutrition status or change in nutritional status in CKD?
CKD Stage 4
Evidence statement (level of evidence):
• Maintained percentage oedema-free (dry) actual body weight reflects optimal nutritional status
(Level II)
• BMI =18.5–25, reflects optimal nutritional status (Level IV)
• SGA and percentage ideal body weight (BMI) reflect change in nutritional status (Level IV)
• Total body nitrogen (TBN), dual X-ray absorptiometry (DEXA) or bioelectrical impedance (BIA)
reflect long-term nutritional adequacy (Level IV)
Nutrition assessment
CKD Stage 5
Evidence statement (level of evidence):
• Maintained percentage oedema-free (dry) actual BW reflect optimal nutritional status (Level II)
• BMI =23–26, reflects optimal nutritional status (Level II)
SGA maintained or improved reflects nutritional status (Level III-3)
Nutrition prescription/intervention
Clinical question:
What are the goals of nutrition intervention for CKD?
Evidence statement (level of evidence):
• Achieve and maintain desirable weight and adequate nutritional status (Level III-2)
• Optimise status of comorbidities, blood glucose control in diabetes and fluid and sodium control in
hypertension, phosphate control in hyperparathyroidism, lipid control and weight management
(Level III-2)
• Maintain skeletal muscle stores and strength, using SGA, total body nitrogen (TBN) and dual energy
x-ray DEXA (Opinion)
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Clinical question:
What are the prescriptions for appropriate nutrition intervention(s) to optimise nutritional status and
prevent malnutrition in CKD?
Evidence statement (level of evidence):
• Energy intake of 146 kJ/kg IBW/day (35 kcal/kg IBW/day) with a moderate protein restriction to
prevent protein energy malnutrition (Level II). For patients >60 years, energy intake of 125 kJ/kg
IBW/day is recommended (Level III-2)
• Protein intake for patients with GFR <25 mL/min/1.73m2, 0.75–1.0 g/kg IBW/day and should not be
<0.75 g/kg IBW/day; 50% should be high biological value (Level II)
Other nutrients: refer to guidelines
Implementation and management
Clinical question:
What are effective methods of implementation to achieve positive outcomes in CKD?
Evidence statement (level of evidence):
Education
• Pre-ESKD education forms an important part of management strategy to slow progression of renal
disease and may have a beneficial effect (Level II)
• Nutrition counselling should encompass appropriate protein and energy intake (Level III-2 and
Level IV)
• Nutrition counselling should include fluid, sodium and potassium intake and weight management
(Level IV and Opinion)
• Every patient should receive intensive nutrition counselling based on an individualised care plan
(Opinion)
Monitoring and evaluation
• Recommended times for initial consultation 45–60 minutes and review 20–30 minutes (Opinion)
* National Health and Medical Research Council (NM& MRC) designation of levels of
evidence226

1.5.2 Nutritional assessment

Assessment and monitoring of nutritional status are vital to prevent, diagnose and
monitor nutritional abnormalities in patients with CKD. No one single parameter can
unequivocally measure complex nutritional conditions, therefore multiples parameters
are required to interpret nutritional status. This section presents the tools commonly
considered in clinical practice to complement the information in Section 1.5.1. Often, a
combination of tools is selected depending on the resources, such as dietitian’s time
and equipment available in the respective institutions. However it is beyond the scope
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of this thesis to explore the development of these methods, including their validity and
reliability, or to discuss the sophisticated methods mostly used in research, such as
total body nitrogen for measuring protein status91 and doubly-labelled water for
measuring EE.227

Typical nutritional assessment methods commonly used in clinical practice involve
measuring anthropometry, biochemistry/laboratory measures, clinical signs and
symptoms, dietary intake, energy balance (exercise and EE, physical activity [PA]),
functional capacity and composite assessment tools such as SGA (Table 1-15). Good
bedside clinical assessment tools should be inexpensive, easy-to-perform, readily
available and good outcome predictors, and have high sensibility, validity,
reproducibility and good association with other nutrition parameters.

The most common combination of techniques used in clinical settings is to measure
BW (actual weight and oedema-free weight), height, triceps skinfold (TSF), mid-arm
muscle circumference (MAMC), waist and hip circumferences, blood results, appetite
score, presence of symptoms, dietary intake, PA and exercise, and SGA. The three
components of total EE (TEE) are resting EE (REE), thermic effect of food and physical
EE.227
Total energy expenditure (TEE) =

Resting energy expenditure (REE) + Thermic
effects of food + Physical energy expenditure

PA levels and exercise are part of the energy balance or EE equation; therefore it
should form part of the routine nutritional assessment. In addition, REE increases or
decreases as inflammatory state increases or muscle mass decreases respectively,
and these alter energy requirements.112, 113, 228
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Table 1-15 Nutritional assessment parameters commonly used in clinical practice in CKD stages 4 to 5
Remark: Information presented in this table focuses on the assessment of nutritional status. If information for the pre-dialysis CKD stage is not available,
229
relevant information for dialysis patients is presented. The major references are Blumenkrantz et.al., Pocket Guide to Nutritional assessment of the Patient
230
231
216
with CKD, Pupim and Ikizler and K/DOQI guidelines.

Parameters/method
Description
Anthropometry and body composition
Weight (kg)
Measure of body mass, must use
oedema free weight
BMI (kg/m2)12
Measure of body mass
Skinfold thickness, TSF and sum of
skinfold12
Mid-arm muscle circumference
(MAMC)12
Waist circumference (WC)232

Indirect measure of subcutaneous fat
Indirect measure of muscle mass

Indirect measure of abdominal
adiposity
Waist to hip ratio (WHR)
Indirect measure of abdominal
adiposity
Bio-impedance analysis
Indirect measure of fat mass and fat(BIA)112, 233-235
free mass (muscle mass and body
water)
Biochemistry and other blood parameters
Serum albumin236
Serum protein

Advantage

Disadvantage

Quick, simple bedside technique,
inexpensive
Quick, simple bedside technique,
inexpensive
Quick, simple bedside technique,
inexpensive
Quick, simple bedside technique,
inexpensive
Quick, simple bedside technique,
inexpensive
Quick, simple bedside technique,
inexpensive
Can be quick, simple bedside technique

Does not distinguish muscle and fat mass

Routinely measured, not affected by GFR.
Strongly associated with morbidity and
mortality

Unreliable marker of nutritional status. Level
affected by inflammation (CRP) and hydration
status. Is marker of illness rather than nutrition
deficit? Slow response to change of nutritional
status due to long half-life and large body pool

Does not distinguish muscle and fat mass
Requires skinfold calliper. Requires training. Must
consider inter- and intra-rater reliability
Requires skinfold calliper. Requires training. Must
consider inter- and intra-rater reliability
Difficult to position measuring tape in obese
patients
Difficult to position measuring tape in obese
patients
Requires BIA equipment, additional capital layout.
Measure of fat-free mass50 doesn’t distinguish
LBM from extracellular fluid
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Table 1-15 continued
Biochemistry and other blood parameters continued
Pre-albumin237
Serum protein

Cholesterol

Serum lipids

CRP 74, 236

Serum protein

Ferritin and transferrin

Serum protein

Clinical signs and symptoms
Appetite95, 96, 238

Check list, or part of SGA, or as
structured scoring method – ADAT

More rapid response than albumin to poor
protein intake or re-feeding due to shorter
half life and body pool. Not affected by
hydration status
Low level associated with poor dietary intake
Not affected by GFR. Rapid response to
acute or chronic inflammation. Strongly
associated with morbidity, mortality and MIA
Routinely measured (for anaemia
management)

Quick, simple bedside technique,
inexpensive. Correlated with dietary energy,
protein and nutrient intakes. Associated with
hospitalisation and survival
85,
239
Symptoms
Check list or structured scoring method, Quick, simple bedside technique,
or part of SGA
inexpensive. Predicts morbidity and mortality
Muscle wasting
Physical examination as part of SGA
Quick, simple bedside technique,
inexpensive
Loss of subcutaneous fat store
Physical examination as part of SGA
Quick, simple bedside technique,
inexpensive
Dietary intake (General reference of dietary assessment methodology based on Freudenheim240 and Thompson and Subar241)
Diet history or diet interview
To ask the respondent to report about
Quick, simple bedside technique,
method242-245
past diet
inexpensive. Captures quantity, quality and
food patterns (total diet). Literacy of
respondent is not required. Relatively low
respondent burden and does not affect
eating behaviour

Excretion is affected by GFR, so new reference
range is needed. Not routinely measured
Affected by high fat intake and use of lipidlowering medications
Not routinely measured
Affected by iron status, blood transfusion, infection
and inflammation
Subjective rating and may not associate with
intake accurately
Subjective rating and may not associate with
intake or nutritional status accurately
Based on visual appearance to rank severity of
depletion without objective measure
Based on visual appearance to rank severity of
depletion without objective measure
Interviewer training required. Problems with
errors of memory
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Table 1-15 continued
Dietary Intake continued
24-hour recall246

Food diary/record246

Food frequency questionnaire
(FFQ)247

Respondent asked to remember and
report all foods and beverages
consumed in preceding 24 hours or in
preceding day
Respondent to record foods and
beverages and amounts of each
consumed over one or more days as
specified

Respondent to report usual frequency
of consumption of each food from list of
foods for defined period of time. These
then used to calculate average daily
intake
Protein – urinary nitrogen
Protein catabolic rate (PCR) (g/day)
appearance248, 249
=6.25 X [UUN (g/day) + IBW weight
(kg) X 0.031] + urinary protein losses
Energy balance – exercise, energy expenditure and physical activity
REE (+ adjusted factors)227
By calculation using standard equation,
e.g., Harris-Benedict Formulas,250
adjusted for activity and injury factors
Questionnaire (physical activity)251
PASE Scale, HAP

Quick, simple bedside technique,
inexpensive. Literacy of respondent not
required. Relatively low respondent burden
and does not affect eating behaviour
Intake quantified, does not rely on
recall/memory

Low investigator cost and does not affect
eating behaviour

Intake of previous 24 hour prior to interview only,
not reflecting intake of longer duration. Problem of
errors of memory, intake often underreported
High investigator cost and respondent burden.
Respondent training and literacy required.
Respondent fatigue likely to cause inaccurate
recording or alter eating behaviour. May have bias
both in selection of sample and in measurement of
diet
Not quantifiably precise and requires populationspecific validated FFQ questionnaire. Difficult
cognitive task for respondent

Objective laboratory measure of urinary
nitrogen excretion (usually 24 hour) to
approximate dietary protein intake

Urinary urea and protein collection required.
Inaccuracy occurs in extreme body size and
during non-steady state of nitrogen balance

Quick, simple bedside technique,
inexpensive

Not specific to CKD population

Quick, simple bedside technique,
inexpensive

Indirectly correlated to nutritional status
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Table 1-15 continued
Functional capacity
Hand grip strength (HGS)252, 253
Questionnaire
Composite assessment score(s)
SGA and various versions147, 150
Others
Quality of life (QOL)255

Traditionally used for muscle function,
and indirectly, nutritional status

Requires hand grip dynamometer, additional capital
layout

SF-36 (physical function component),254
Karnofsky Index

Quick, simple bedside technique,
inexpensive. Useful continuous and
systematic assessment
Quick, simple bedside technique,
inexpensive

Composite assessment of nutritional
status based on clinician’s subjective
rating

Quick, simple bedside technique,
inexpensive. High validity, reliability and
predictability

Training and inter-rater reproducibility assessment
required

Questionnaire, e.g., SF-36254

Simple bedside technique, inexpensive

Time spent by patient to complete questionnaire

Indirectly correlated to nutritional status

Abbreviation; ADAT = Appetite and Diet Assessment Tool; REE = resting energy expenditure; SF-36 = Medical Outcomes Study Short Form 36-item
questionnaire; PASE = Physical Activity Scale for the Elderly; HAP = Human Activity Profile
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SGA is a well validated diagnostic tool for malnutrition in clinical settings,148 including
patients with ESKD.149,

150, 256

The final score of SGA is based on the clinician’s

subjective rating of a patient’s medical and physical examinations. The medical
examination section has four components, including weight and weight history over the
last 6 months and recent 2 weeks, dietary intake and change in dietary intake over the
last 6 months and 2 weeks, presence of gastrointestinal symptoms (anorexia, nausea,
diarrhoea or vomiting) and physical functioning. The physical examination components
assess the degree of muscle wasting and loss of subcutaneous fat over seven and
three anatomical positions respectively. The presence of ankle oedema in relation to
malnutrition is also considered. The strength of SGA is to consider weight history, in
particular unintentional loss of BW, and change of dietary intake over time using the
subject as his/her own reference. The nutrition status is then categorised as A = well
nourished, B = mildly to moderately malnourished and C = severely malnourished.
Categories B and C represent different degrees of malnutrition. There are a number of
modified SGA versions, which sub-divide the original 3-point scale (A, B and C) to a
4-point14 or 7-point scale,147, 149 so that each 1-point change of the scale correlates to a
change of nutritional status.256 These scales may allow longitudinal monitoring of
patients’ nutritional progress. Another modified SGA tool with a composite additive
score is the Malnutrition-Inflammation Score (MIS),100 which includes BMI, s-albumin,
CRP, pre-albumin and total iron-binding capacity. The MIS is well validated in the
ESKD population. The prognostic significance of SGA in the pre-dialysis population
was revealed in a prospective study that showed malnutrition – scored as SGA B or C
– was associated with mortality and hospitalisation rate.98

1.5.3 Nutrition prescription and intervention

The background to the clinical practice guidelines and the current literature review
detailed the rationale of dietary prescription and intervention for patients in various
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stages of CKD205,

206

(also see Section 1.5.1 and Table 1-14). Additional nutritional

considerations must be considered in the presence of other conditions and comorbidities, such as malnutrition, overweight/obesity, cardiovascular disease and
diabetes, as well as older patients and those who have psychosocial issues. Therefore,
nutrition prescription and intervention in ESKD involve multi-nutrient modifications and
are complex. In fact, many of these nutrition interventions are recommended to start
as early as CKD stages 1 to 3,222 with additional interventions as CKD progresses
(Figure 1-2).

1.5.4 Implementation, monitoring and evaluation
The success of nutritional management relies on proper implementation, namely the
delivery of structured care with monitoring and evaluation. These have analogy to
exercise training prescription, including the “mode”, “intensity”, “frequency” and
“duration”; in other words, “how to”, “how hard”, “how often” and “how long” (session
time and follow-up duration). As mentioned in Section 1.5.1, which reviewed the
guidelines and efficacy of dietary interventions, the effects of intervention can only be
evaluated with defined intervention strategies, frequency and duration of intervention.
At the time of this literature search, the benefit and efficacy of dietary interventions by a
dietitian in patients with non-dialysis CKD stages 4 to 5 was very limited. In a 6-month,
prospective, uncontrolled intervention study, dietitian intervention was associated with
maintained and improved nutritional status in CKD stage 4 to 5 patients.257

The

nutrition care plan process will be discussed further in Section 1.6, in conjunction with
multidisciplinary care.
In summary, the evidence-based guidelines, together with the latest scientific literature,
support the structured nutrition care process to better manage patients with ESKD.
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Figure 1-2 Schematic diagram showing the goals and objectives of nutrition and
lifestyle intervention in all stages of CKD

Renal function CKD stage
(GFR mL/min/1.73m2)
1
(>90)

2
(90)

3
(60)

4
(30)

• Control disease progression
• Reduce CV risk
• Control BP
Consideration:
• Optimal body weight and
composition
• Regular exercise
• Healthy balanced eating
(including sodium and fats
modification)
• Smoking cessation
Plus:
• Bone disease
• Anaemia
• Prevent PEW
• Electrolytes and fluid balance
Consideration:
• Optimal protein and energy intake
• Control of minerals, e.g., Na, K,
Pre-Dialysis Stage
PO4,, fluids
Plus:
• Vitamin and mineral
• Symptom control
supplements
• Prevent and treat
PEW

5
(<15)

• Preparation for
dialysis

Progressive Deterioration of Renal Function

1.6

Dialysis

Time

Early referral – pre-dialysis multidisciplinary care and the role of nutrition

management
There is increasing evidence that timely referral of patients with CKD stages 4 to 5 to
nephrologists26,

258, 259

and the multidisciplinary renal unit260 for intervention was

associated with improved outcomes.261,

262

Depending on the structure of the

intervention, the outcome measures could be clinical (e.g., rate of decline of kidney
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function, morbidity, mortality or hospitalisation), behavioural, psychological or
knowledge-based. However, the reported benefits have been controversial.
As shown in Table 1-16, the structure of intervention, clinician involvement and the
treatment goals varied tremendously among the studies. The intervention ranged from
a one-off generic education session to ongoing structured clinic settings over many
years until patients started on a dialysis program.
A number of questions have also been raised in an attempt to answer the effectiveness
of multidisciplinary care. What is the definition of multidisciplinary care compared with
multifaceted or multifactorial care? What is the optimal timing to commence the care?
Is generic advice good enough to replace prescriptive intervention? And what is the
optimal frequency and duration of intervention and monitoring? Depending on the
outcome measures and discipline-specific goal orientation, the ideal “model of care” is
yet to be established for CKD stage 4 to 5, especially when economic constraints are
considered to justify these resource-intense programs. It appeared that the important
elements for success included early referral to the tertiary nephrology unit with
adequate and dedicated pre-dialysis program staff and infrastructure, and the
availability of a dialysis facility to allow smooth transition to the dialysis program.263
However the nutritional components in many studies were limited, or of generic nature,
with either short duration or not mentioned. As discussed above, it appeared that
structured care involving more intense nutrition intervention was associated with better
outcomes.263, 264
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Table 1-16 Multidisciplinary interventions, including nutrition in non-dialysis CKD stages 4 to 5
Study
(ordered by
year)
Binik265
Canada
1993
Longitudinal
RCT
Levin263
Canada
1997
2 studies of 2
hospitals:
Hospital 1:
Prospective nonRCT
Hospital 2:
Retrospective
analysis –
compared to
historic control

Patient/ renal
function

Intervention

Team involvement

Nutrition component

Outcome measures and
findings

n =204
age:50.2yr
Cr >350 µmol/L with
rapid increase within
recent months

C: standard education
(n =92)
I: enhanced education
(75 min lecture by
trained research
assistant) (n =87)
Non study group (n =25)

Referred by nephrologists blinded to
study.
I: education given by trained
research assistant and interviewed
by psychologist

Diet (LP) “discussed” in lecture.
Many pt did not inform dietary
modifications before
Dietitian intervention not
specified

Hospital 1
n =76

C: standard care (n =37) C: Nephrologist
I: MDC (n =39)
I: MDC – nurse educator, physician,
social worker, nutritionist
No. of hours per patient- All pt attended session re Dx (RN +
year: 15–33
social worker)

In MDC – initial & regular f/u

Time to initiation of dialysis
Results:
4.6 mth difference in time to Dx
C: 14.9±12.4 mth
I: 10.3±11.8 mth
Non-study group: 11.1±15.2 mth
2 =6.32, P <0.05. after adjusting
for creatinine, P =0.07
  Dialysis starts (13% vs. 35%;
P <0.05)
  Outpatient training (76% vs.
43%; P <0.05)
  Hospital days in first month of
dialysis (6.5 vs. 13.5; P <0.05)
 Cost saving >$4,000 per patient

One-off education
program in 2 sessions,
plus subsequent
ongoing follow-up by
primary nephrologist

In one-off group program (30
min)

patient info n/a

Hospital 2
n =141
patient info n/a

No. of hours per patientyear: 6.5–10

Met individually with:
 dialysis physician (30 min)
 renal nurse coordinator (30 min)
 social worker (1 hr) with focus on
modality selection and access
planning.
Then followed by group session with
renal dietitian (30 min)

 Success in pre-dialysis access
creation (86.3%)
However, due to lack of
haemodialysis facility, was NOT
possible to:
  Urgent dialysis starts
  Hospital admissions/days
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Table 1-16 continued
Harris 266
USA
1998
Longitudinal
RCT
Goldstein267
Canada
2004
Retrospective
case control

n =437 (primary
care)
age: 68.5±11.5 yr
CrCl: 34±10
mL/min/1.73m2
f/u: 24 mth

C: academic GP
practice (n =231)
I: intensive case
management (n =206)

C: GP+ referral to nephrologist if
required
I: renal nurse, renal dietitian, social
worker

C (did not attend
clinic): age =60
(42–70) yr, CrCl =9.8
(7.4–13.8)
mL/min/1.73m2
I (attended clinic):
age =57 (44–71) yr,
CrCl =9.8 (7.3–12.8)
mL/min/1.73m2
Exclusion: AKI
progressing to CKD,
previous RRT, failed
renal transplant, or
<3 mth specialist
medical care before
starting dialysis

C: not specified (n =26)
I: in clinic to meet team
individually to discuss
management plans with
goals set by Canadian
National Kidney
Foundation (n =61)

C: not specified
I: dietitian, nephrologist, nurse
educator, pharmacist, social worker.
Education: to reduce rate of decline
in kidney function, manage
biochemical and clinical sequelae of
CRI, educate on dialysis modalities
and transplantation, arrange dialysis
access and smooth transition to preemptive living donor transplantation
or outpatient dialysis therapy, when
indicated

When referred renal dietitian
took detailed dietary history
and prescribed low protein, low
potassium renal diet
individualised to enhance
compliance. Assuming 10%
dietitian staffing to attend onceweekly clinic
Not specified

Outcome: renal function, health
care use, mortality in 5 yr,
medication.
Results: no differences to all of
the above parameters

Intervention vs. control group:
 at start of dialysis has higher
s-alb, median (IQR) 3.6
(3.3–3.9) vs. 3.3 (2.7–3.5) g/dL,
P <0.01
 hospitalisations at 1 yr
(7.0 vs. 69.7 d/patient/y,
P <0.01) and during study (10.8
vs. 57.4 d/patient/y, P <0.05).
  Deaths at 1 yr (2% vs. 23%;
P <0.01) and during study (21%
vs. 42%; P <0.05)
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Table 1-16 continued
Curtis264
Canada & Italy
2005
Case control

Hemmelgarn262
Canada
2007
Case control

Total Canadian +
Italian (n =288)

Combined Canadian
+Italian data:

Canada (n =152)
age: 64±16 yr
mean nephrology
care prior to Dx:
40±33 mth
f/u after Dx start:
median 14 mth
Italy (n =136)
age: 60±17 yr
mean nephrology
care prior to Dx:
43±34mth
f/u after Dx start:
median 14 mth

C: standard
nephrologist care
(n =156)
I: formalised
multidisciplinary care
clinic (MDC) in
addition to standard
nephrologist (n =132)

n =374
age:75.8±6.2 yr
GFR:<60
mL/min/1.73m2 (86%
<30 mL/min/1.73m2)
duration: 3.5 yr

C: standard
nephrologist care (n
=187)
I: Initial education +
f/u (n =187)

Canada:
I (MCD group): regular, protocolised
clinic and laboratory follow-up of
patients with CKD. Nurse educator,
physician, social worker, nutritionist,
pharmacist

Canada:
Regular

Italy:
C: programme-dedicated
nephrologists and multidisciplinary
nurses responsible for
implementation of recommended
diagnostic and intervention
strategies, information, education
and support. Formal team accesses
nutritionist, psychologist and social
worker when necessary
Nephrologist, clinic nurse, registered
dietitian, social worker

Italy:
Access to nutritionist when
necessary – no definition given
regarding “necessary”

Discussion re diet in initial
session and f/u not specified.
Stated discussion of medical
management and lifestyle
modification to delay progression
of CKD and target cardiovascular
risk factor reduction

Combined analysis:
MCD group (I) at dialysis initiation:
  Hb (102 vs. 90 g/L,
P <0.0001)
  s-alb (37.0 vs. 34.8 g/L,
P =0.002),
  Calcium (2.29 vs. 2.16
mmol/L, P <0.0001).
Standard vs. MDC: Adj. HR (95%
CI) for survival 2.17 (1.11–4.28),
P =0.026

Survival, and risk for
hospitalisation
Results: 50% reduction of survival
risk. HR (95% CI) =0.50 (0.35–
0.71), P <0.05. No differences in
all-cause HR, 95% CI: 0.83 (0.64–
1.06) and CV hospitalisation HR
(95% CI): 0.76 (0.54–1.06)

Abbreviation: mth = month; C = control group; I = Intervention group; n = number; yr = year; cr = creatinine; CrCl = creatinine clearance; GFR = glomerular
filtration rate; Dx = dialysis; IQR = interquartile range; HR = hazard ratio; CI = confidence interval; Hb = haemoglobin; s-alb = serum albumin;
CV = cardiovascular; vs. = versus; MDC = multidisciplinary care. Expression of figures: n±SD – standard deviation; n(n1-n2) - range

56

While it is not possible to isolate the effects of the nutrition components to deduce any
advantages from these studies, promising results from controlled194-196 and
uncontrolled257 nutrition intervention studies, and a case control study268 supported
early intervention in pre-dialysis stages.

Therefore, a properly designed and

adequately powered RCT is needed to formulate the roles of nutrition intervention in
renal disease care. Since the nature of nutrition issues in ESKD is complex and longstanding, ongoing structured care should form the essential part of multidisciplinary
care.

1.7

Special consideration for elderly patients

With the aging population, there has been a higher prevalence of older patients with
ESKD, with many of them accepted into maintenance dialysis programs.5, 269 Evidence
has suggested that dialysis does not suit everybody and may not offer significant
survival advantage or better QOL for these patients.16, 270, 271 Therefore, a conservative
or no dialysis pathway could be a feasible alternative option to reduce disease, social
and societal burdens. Patients with advanced ESKD have a high level of symptom
burden,85,

272

such as anorexia, nausea and taste change, which may impair dietary

intake of energy, protein and other nutrients. Poor nutritional status, such as
malnutrition, low s-albumin, low body muscle and fat stores, are common in ESKD.85
The presence of comorbidities such as CV disease273 and poor nutrition98 are strong
predictors of poor outcomes in patients with ESKD not on dialysis. To date, few
controlled trials have been conducted to examine the efficacy of nutrition intervention in
patients on a conservative pathway. Anecdotally and in clinical practice, nutrition
interventions – in particular, low or controlled protein diets – have been used to
ameliorate high blood urea level and uraemic symptoms.9,

180, 195

In the secondary

analysis of the MDRD study,202 patients in the study group (low protein diet)
experienced less uraemic symptoms and commenced dialysis at lower levels of GFR.
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Furthermore, older patients have additional nutritional considerations due to comorbidities and age-related factors – such as sarcopenia or osteoporosis – and more
demanding psychosocial needs, including provision of food. Patients may decide on
the conservative pathway early on in the course of CKD. The challenging question is if
aggressive nutrition intervention fulfils the role of nutritional support and symptoms
control and if these are appropriate at end of life stages.

1.8

What is known – a summary of the evidence and the need for further

knowledge

The literature review has revealed the prevalence of nutritional abnormalities is high in
ESKD patients (Tables 1-7, 1-8 and 1-9), in particular, malnutrition measured by SGA
(score B or C) and low s-albumin. The presence of these factors at the initiation of
dialysis is associated with morbidity, mortality and hospitalisation. However,
background uraemic conditions and medical events affecting the baseline nutrition
status are largely unknown. In addition, over the last decade there has been much
debate on the obesity paradox, that is, if obesity is protective to counteract the effect of
malnutrition in the dialysis population. These questions remain unanswered, with data
especially lacking for the Australian population. The combination effect of factors has
seldom been investigated; it would be useful to examine such effects on mortality, e.g.,
the combination of malnutrition, s-albumin and overweight/obesity. Furthermore, these
abnormalities emerge during the course of gradual decline in kidney function and
predicted mortality and hospitalisation. Up to the planning stage of our studies, little
was known about the nutritional characteristics of patients who were referred to the
multidisciplinary clinic for pre-dialysis education, including the option of conservative
treatment. The majority of nutritional studies in CKD were focused on patients who
were younger and with higher levels of GFR, and the relationships between renal
function, presence of symptoms and dietary intake were seldom explored. The
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rationale for the need of further knowledge will be expanded in Section 1.9.2 after the
discussion of the hierarchy of study designs in Section 1.9.1.

In view of the high social, clinical and health care financial burden of ESKD, it is
necessary to investigate the role of nutritional factors – ranging from blood or
laboratory to bedside assessment parameters – on clinical outcomes of patients with
CKD stages 4 to 5.

1.9

Special considerations for gaining new knowledge

1.9.1 Hierarchy of study designs

The gold standard of study design to examine the effect of factors or interventions
affecting health outcome is a RCT. However, there are limitations in RCTs, and welldesigned observational studies such as cohort and case control studies may
complement the RCTs274, 275 by providing estimates of treatment effects, or even having
similar effects of treatment as RCTs.276, 277

Table 1-17 summarises the hierarchy of study designs, and their strengths and
limitations, as well as the evidence hierarchy recommended by the National Health and
Medical Research Council (NH&MRC).226 It is extremely challenging to conduct
nutritional research of “high hierarchy” in patients with CKD. Firstly, the vast
heterogeneity of baseline clinical and nutritional statuses with many confounders and
multifaceted treatments should be considered. Often it is unethical to not treat patients
to meet basic physiological requirements or to provide well-accepted best practice; one
example is to provide nutritional support to malnourished patients. Moreover, an
intervention may take a long time to show significant effects or an intervention to
reverse a deep-rooted (e.g., previous long exposure) nutrition problem, such as severe
malnutrition, could be futile. Often patients with advanced medical conditions are less
likely to consent to studies which demand efforts to participate in intervention, or

59

require regular blood tests or assessment procedures that are considered burdensome.
Therefore, selection bias may occur and results may be of low generalisability.

Table 1-17 Hierarchy of study design and evidence level

Study design
(Level of evidence)
Meta-analysis of RCTs
(Level I)

Important for establishing causal relationship

RCTs (Level II)
Including pseudorandomised control trail
(Level III-1)

Strengths
 Increased precision of
exposure to outcome
measured
 Gold standard
 Random allocation of
treatment which avoids
selection bias or
cofounding
 Similar distribution of
known and unknown
variables

Cohort studies (Level III2)
Including comparative
study with concurrent
control, non-randomised
trial

 Can study multiple
exposures
 Useful in hypothesis
generating

Case-control studies
(Level III-2)
Including comparative
study without concurrent
control, retrospective
cohort study, historic
control study

 Suitable for studying rare
outcomes and outcomes
that need long follow-up
 Can study multiple
exposures
 Relatively inexpensive
 Useful in hypothesis
generating
 Fast and inexpensive
 Hypothesis-generating
 Cross-sectional study
assesses prevalence of
disease, useful in health
care planning

Case reports (Level IV)
Also including case
series, cross-sectional
studies pre- and postcomparison

Adapted from Black

274

Limitations
 Need number of RCTs to
perform analysis
 High cost
 Trial may be: (1) “unnecessary”
if treatment effect is dramatic,
confounder can be ignored;
(2) “inappropriate” when longterm follow-up is required;
(3) “impossible” due to ethical
reasons; or (4) “inadequate”
due to extensive inclusion and
exclusion criteria and may
cause low generalisability
 Selection bias in comparison
between treated and untreated
groups
 Some potential to make causal
inference
 Prospective study may take
long time to complete
 Selection bias
 Recall bias
 Unlikely to infer causal
relationship

 Selection bias
 Unlikely to infer causal
relationship

275

and Jager et al.
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1.9.2 Framework of research in practice
One of the main roles of health professionals is to implement evidence based practice
to improve the health outcomes of patients. This involves the application of research to
policy development and service delivery. However, it is challenging to translate
research findings into practice because “practitioners are criticized for failing to base
actions on research evidence, while academic research is sometimes condemned as
`irrelevant' to practice.” 278
1.9.2.1 What is evidence based practice (EBP)?
One of the pioneers in this field defined evidence based medicine “is the conscientious,
explicit, and judicious use of current best evidence in making decisions about the care
of individual patients.279 The practice of evidence based medicine means integrating
individual clinical expertise with the best available external clinical evidence from
systematic research” and considering “patient values and expectations” to optimise
outcomes. Over the years, this concept has been extended beyond the medical
profession and adopted by other health professionals to guide evidence based
practice. Individual clinical expertise is the skill acquired through experience and
practice; whereas best practice is an adaptation of external evidence from basic
science to patient-centred clinical research. In 2012, the International Confederation of
Dietetics Association (ICDA) endorsed the consensus statement of a dietetic specific
evidence based practice.280 These guidelines built upon the above concepts and
include code of ethics and code of practice for dietitians. Evidence based practice is
not just restricted to systematic review, meta-analyse and RCT which are considered
as the gold standard of clinical evidence, such as the Cochrane Review,281 rather it
involves tracking down the best external evidence to help answer clinical questions. As
discussed in section 1.9.1, some questions about therapy do not require or are suitable
to be answered by RCT, especially in chronic diseases, such as CKD management
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that require long term longitudinal follow through and involves a vast number of
confounding factors.
1.9.2.2 Outcome research
Outcomes research seeks to understand the end results of particular health care
practices and interventions.282-284 It integrates epidemiological, sociological, economic
and other analytical sciences to study health services concerning the relationship
between need, demand, supply, use and outcome; in particular, to evaluate the
structure, process, output and outcome.283, 284 Or simply, “the process of obtaining data
to measure the effect of a intervention on patient care”.285 Examples of four main types
of nutrition –related outcome measures in CKD are (1) clinical /medical outcomes: e.g.
mortality, weight status, BMI, SGA and CRP; (2) functional outcomes: e.g. ability to
prepare meals; (3) economic outcomes: e.g. length of stay, hospitalisations and delays
in CKD progression; and (4) Psychological/satisfactory outcomes; e.g. health related
QOL and perception of care received.286
1.9.2.3 Research in practice
Research in practice is vital to generate nutrition data on which to base practice, and
involves examining the health care processes that occur in practices. Indeed “the
strength of a discipline, whether in health sciences or management, is associated
closely with its research base. Strong research supports a strong profession”.

287, 288

There are two types of practice-related research, practice-based and practice-led.
Practice-based research is an original investigation undertaken in order to gain new
knowledge partly by means of practice and the outcomes of that practice; whereas
Practice-led research is concerned with the “nature of practice” and leads to new
knowledge that has operational significance for that practice.

289

Often both types of

research appear together but there is usually one that is more dominant.
In simple terms, practice-based research is to contribute new knowledge. In clinical
settings, it often serves to examine the health care processes. Examples in renal care
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are: (1) to survey the adoption of evidence based guidelines (K/DOQI)23 by general
practitioners in primary care using semi-structured interviews.290 Some of the key
findings were lack of awareness of the guidelines; expectation for more practice
guidance in CKD, persistence of conventional and long-established practice, and
uncertainty of timing of nephrologist referral. (2) Survey of renal dietitians regarding the
barriers of implementing clinical guidelines (K/DOQI)216 recommendations and practice
recommendations were made as a result of the survey.291
If research leads primarily to new understandings about practice, e.g. to advance
knowledge about practice, or to advance knowledge within practice, it is classified as
practice-led research. This research method is commonly used in the creative and
performing arts.289 In clinical settings, to build upon EBP and to make the health
practitioner profession more accountable, patient engagement as partners in health
research has also led to the concept of practice-led research. Examples of practice-led
research in healthcare are: (1) in the field of medical engineering, a new generation of
upper limb prostheses was developed through practice-led research. This research
evolved through a number of prototypes and models involving the design team and
other interested parties.292 (2) development of an algorithm for dietitians to manage
serum phosphate in dialysis patients.293 (3) various dietary methodologies to estimate
energy and protein intakes, e.g. food frequency questionnaire,

247

food record,243 and

structured diet history methods.242, 245

1.9.2.4 Closing the gap between research and practice

Despite the considerable resources that have been put into clinical research, relatively
little of the research findings are implemented in routine clinical practice. The transfer
of evidence to clinical practice requires skill, determination, time, money and
planning.294

Success relies on the integration of four major elements as shown in

Table 1-18
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Table 1-18 Elements required for transfer of evidence to clinical practice
Element

Application

Good information

Sound research results that can withstand critical scrutiny and
answer practical questions
Accessible and user friendly system for all stakeholders e.g.
practitioners, managers, administrators and consumers
Conducive physical and intellectual environments which value
research and uptake of research-based knowledge
interventions that promote the uptake of knowledge and lead to
behaviour change

Good accessibility
Supportive environments
Evidence-based promotion of
knowledge uptake

Adapted from “How to put the evidence into practice: implementation and dissemination
294
strategies” NH&MRC, 2000

Bridging the gap between research evidence and practice is not a cookbook style
process; it involves innovation, creativity and a range of strategies while taking into
account local conditions for making local solutions. The action plan to achieve a
change of practice in line with the evidence is outlined in Table 1-19

Table 1-19 Action plan for implementing and disseminating of clinical practice
guidelines
Question asked to drive Action plan and steps taken during the progress
the process
1
What is the
To develop a statement of purpose: what am I or the team trying to achieve
purpose?
with rationale
2

Who can help?

Form a working party with relevant expertise to drive the implementation and
dissemination process along: system leadership, technical expertise and
day-to-day leadership

3

What is the
situation?

Develop a formal situation statement: while ideal clinical practice is difficult
to achieve, it is important to identify the current and ideal situations to make
possible improvement.

4

Who should be
involved?

Determine target audiences and include representatives of all groups on the
committee/working party: these may include relevant stakeholders and key
players, e.g. healthcare professionals in the team, consumers/patients,
managers and administrators

5

What are the key
messages?

Formulate and prioritise key messages: to close the gap between the
research evidence and or clinical practice guidelines recommendations by
identifying, ranking and prioritising the key messages for further action.
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6

What are the aims?

Set specific objectives: and avoid broad goals, e.g. to maintain blood
pressure < 120/75 rather than “improving blood pressure” control.

7

Is the available
information
suitable?

Ensure information suitable for different groups is available: this means,
does it suit the majority of target audience, namely patients, practitioners
etc? Examples of different needs for different groups could be due to
competing interest of the treatment options (e.g. surgery vs. medication) or
homogeneity of the expectation of audience (e.g. different education booklet
for different literacy levels)

8

What are the
barriers?

Identify barriers to successful implementation: it is easier to overcome
barriers if they have been identified and described systematically. There are
two types of barrier; the first type may occur at various levels – system,
professional, community and consumer levels. (e.g. lack of reporting of a
ineffective practice) The second type of barrier is that experienced by
various target audience within each level (e.g. lack of knowledge of health
professionals)

9

Are things on
track?
What are the
options

Review progress of all of the above steps regularly

11

Designing a
program

Decide which strategies to use: designing a program and putting the
program into action

12

Is support
available?

Ensure support is available at a number of levels: systemic, professional and
consumer supports

13

What is the cost?

Determine costs and cost-effectiveness of strategies:

10

Consider the options available: weighing various strategies vs. effectiveness
 Educational outreach visit or academic detailing
 Decision-support systems and other reminders
 Interactive educational meetings
 Multifaceted interventions
 Mass media campaigns
 Audit and feedback
 The use of local opinion leaders
 Local consensus processes
 Consumer-mediated interventions
 Educational materials
 Didactic educational sessions
 Incentives and penalties
 Administrative interventions

Adapted from “How to put the evidence into practice: implementation and dissemination
294
295
strategies” NH&MRC, 2000,
Bero et.al.
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In summary, research in practice serves to indentify clinical problems, generate data,
gain new knowledge, translate and transfer available knowledge to practice. The
ultimate goals are to optimise care thus improving the clinical outcome of the patients.

1.9.3 Special considerations in current thesis

This thesis was built within the framework of research in practice, a combination of
practice-based and practice-led research to close the gap between research and
practice in managing patients with ESKD. The first study in this thesis was a
retrospective cohort analysis that examined the association of demographic, clinical
and nutritional parameters at commencement of dialysis and mortality risk; in particular,
subjects with conditions such as malnutrition and overweight/obesity. The survival
studies presented in Table 1-7 did not clearly define if the subjects commenced dialysis
after an uneventful decline of kidney function, or were combined with those who started
dialysis

unexpectedly

for

other

reasons,

including

heterogeneous

nutritional

implications, such as acute kidney injury (AKI) due to trauma, post-operative
complications that have higher metabolic demand, or ex-transplant patients exposed to
years of steroid therapy, which is known to increase muscle catabolism and fat stores.
Therefore, the nutrition history of those patients was very different from those exposed
to chronic uraemia alone. The study in this thesis only included patients who
commenced a planned dialysis program after a gradual decline of renal function. The
results could therefore have implications for health care modelling if nutrition
abnormalities could be identified and rectified before dialysis is needed.

In addition, a number of previous studies had strict patient selection criteria, e.g., not
older than 70 years of age, expected to survive for more than 6 months, consent to
participate in the study was required, etc. Our study considered “all” patients who
commenced dialysis in our unit. Therefore our data was more inclusive, reflecting
reality, and therefore have much broader implications.
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The “obesity paradox” has created much controversy in the renal community, i.e., if it is
protective in patients with ESKD. The effect of overweight (BMI ≥ 26 kg/m2) and obesity
(BMI ≥ 30 kg/m2) on mortality risk was examined in our study. From previous
observations, it could be expected that many overweight or obese patients could
become malnourished according to the SGA rating criteria; therefore the combination
effects of overweight/obesity and malnutrition were also examined for this thesis. From
our understanding, the combinations of effects of nutrition parameters on mortality
have been seldom studied.

The timing of when dialysis should start has been subject to much debate. We
reviewed the effect of GFR levels at which dialysis should start, and found this was not
often considered in previous studies. A multi-centred clinical trial, the Initiating Dialysis
Early and Late (IDEAL) trial,296 set out to answer this question in the year 2000 by
randomly assigning patients to start dialysis at 10–14 mL/minute/1.73m2 (“early start”)
or 5–7 mL/min/1.73m2 (“late start”) with 3 years of follow-up. Patients entered that RCT
only with strict selection criteria, so the results could not be generalised. The results of
our study may therefore complement the IDEAL trial.

The results of our analyses would potentially provide level III-2 evidence.

The second part of the thesis was a cross-sectional study to examine the baseline
clinical and nutrition characteristics of patients enrolled in the pre-dialysis assessment
clinic. The majority of studies in the literature (Tables 1-8 and 1-9) were conducted in
younger subjects (50–55 years) and were in the earlier stages of CKD (GFR 20–50
mL/min/1.73m2), whereas our patients were older – with a mean age of 65.7±13.6
years – and had much lower level of GFR – less than 30 mL/min/1.73m2 (mean
=17.0±6.0 mL/min/1.73m2). In many of the previous studies, dietary protein intake (DPI)
was estimated using the urinary nitrogen methods and dietary EI was seldom
assessed. Since optimal protein nutrition or nitrogen balance must be accompanied by
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adequate EI, the interpretations of adequate intake in these studies were considered to
be incomplete. Furthermore, despite poor nutrition status being associated with the
presence of uraemic symptoms, the relationship of dietary intake and symptoms was
seldom investigated. Therefore, there was a need to examine the relationship of
various nutrition factors encompassing GFR, nutritional status, dietary intake of energy,
protein micro- and macronutrients, symptoms and eating behaviour in one study. To
our understanding, our study was the first to conduct such an examination. Table 1-20
summarises the comparison of study characteristics between the current study and
those in the similar studies in literature.

Table 1-20 Comparison of study characteristics of current study and similar
studies in the literature
Characteristics
Age (years)

50-55

Current study (Study 2)
with pre-dialysis patients
Mean age about 66

GFR (mL/min)

15-60

Mean ~ 17

Setting

Research cohorts

Dedicated clinic for predialysis management
To
be
assessed
by
structured
diet
history
method and nutrient analysis
software

Intake assessment
Energy
Protein
Vitamin and minerals
Dietary pattern/food groups
Symptoms and eating
behaviour

In the literature

Often missing
Often use urinary
protein appearance
Rarely examined
Rarely examined
Limited data, especially
in relation to dietary
intake

To be assessed and relate to
dietary intake

In our preliminary evaluation 18 months after the clinic started297 (Appendix B), patients
were reported to enrol in the clinic with a low GFR plus high prevalence of malnutrition.
It was suggested to the team to refer patients at higher levels of GFR with possible
better nutritional status. Therefore, the next question was if patients were referred
earlier at higher levels of GFR, and if the prevalence of nutrition abnormality at
enrolment, such as malnutrition, decreased over time. In addition, we examined if the
prevalence of obesity and diabetes at clinic enrolment mirrored the obesity and

68

diabetes epidemics in the general population. The association of nutrition and future
choices of RRT by patients was also examined.

The results of the second part of the thesis will provide level IV evidence which would
have significant implications to health care planning, in particular, to justify the predialysis assessment program.
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Chapter 2 Thesis Design and Methods
2.1

Structure and style of thesis

The current thesis includes chapters that are written in both traditional monograph style
and in a format that is consistent with journal article styles. The University of
Wollongong Research Student Centre handbook “Guidelines for higher degree
research (HRD) candidates on the preparation and submission of HDR theses” 298 was
followed.

Chapters that are written in the traditional monograph style are listed as follows:

Chapter 1: Introduction

Chapter 2: Thesis design and methods

Chapter 6: Conclusions, recommendations and future research

Chapters that are written in a format that is consistent with journal article styles are:

Chapter 3: Nutritional and clinical factors of ESKD patients at initiation of dialysis
and survival over a ten-year study period (this chapter has been
published in Journal of Renal Nutrition)

Chapter 4: Nutritional characteristics of patients attending the pre-dialysis
assessment clinic (this chapter has been submitted for publication in
Journal of Renal Nutrition)

Chapter 5: Clinical and nutritional characteristics of patients attending the predialysis assessment clinic, a comparison of two five-year periods from
2002 to 2012 (this chapter has been prepared for submission for
publication in Nephrology, Asian Pacific Society of Nephrology)

70

Materials included in each of the journal article-style chapters include:
 Publication status (published, submitted for publication, manuscript prepared for
submission, or any combination thereof)
 Where publications are included, details provided include:


details of publication, journal where research is published



principal author and co-authors, their individual contribution to both the research
and journal article



abstract and body of the research, which include aims, background, methods,
results, discussion, conclusions, practical implications and future directions for
the research area



relevant supplementary material such as calculations, figures and tables used
for the preparation of the manuscript but not included in the final published
article



summary of the latest evidence since the initial literature review to support
research findings and direction of future research.

2.2

Introduction

The literature review indicated that nutritional abnormalities at the initiation of dialysis
are associated with adverse outcomes. Many of these factors emerge during the
course of deteriorating kidney function well before dialysis is needed and may have
carry-on effects that can influence outcomes after starting dialysis. There was a need
to gain a broader understanding of how the clinical and nutritional factors in the predialysis stage affect post-dialysis outcomes.
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2.3

Aim of the thesis

The aim of this thesis was to examine the relationships between clinical and nutritional
factors in ESKD and clinical outcomes.
Study framework – background

2.4

This thesis consists of a series of retrospective analyses of data obtained from routine
nutritional assessment records in the renal unit of St. George Hospital in Sydney over
time. It is in the framework of ‘research in practice’ encompassing clinical science,
practice research, continuous practice improvement (CPI) and epidemiological
methods as discussed in section 1.9.:


To describe the nutritional problems of ESKD patients from the time of starting
dialysis using epidemiological methods



Nutritional problems appeared to emerge before the start of dialysis. The
preliminary data from the first study led to a change of practice (or behaviour)
with the establishment of a multidisciplinary pre-dialysis assessment clinic
allowing early assessment and intervention.



To translate research to practice, baseline nutritional data of a “purposed
established” pre-dialysis clinic were described, and compared to the clinical
practice guidelines recommendations in a cross-sectional – descriptive and
analytical study



Ten years on, through various CPI activities, were we able to identify nutritional
problems in a timely manner as the clinic became more mature? A crosssectional descriptive, comparative and analytical study was conducted to
answer this question.

These studies are of post hoc nature and broadly divided into 2 major parts. The
schematic diagram in Figure 2-1 outlines the framework of the research and shows the
steps and sequence of the sub-studies carried out at the defined stages of CKD. The
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X-axis represents time and events. The trajectory of deteriorating renal function over
time indicates the inevitable consideration of dialysis in ESKD patients once renal
function falls below 15% or when GFR is less than 15 mL/min/1.73m2 (Figure 2-2). A
pilot study prior to the commencement of the studies described in this thesis was
undertaken in incident dialysis patients (new dialysis patients) from 2000 to 2002. In
that study approximately 55% of patients were rated as malnourished (SGA score B or
C) at the start of dialysis and less than 30% of the incident dialysis patients were
referred for CKD nutrition intervention before dialysis was started 297 (see Appendix B).
A preliminary analysis of these data revealed the 1-year mortality rate was
approximately 40% in malnourished patients and 10% in well-nourished patients (in
house audit; no published data available). It was apparent that poor nutrition status at
the initiation of dialysis was associated with adverse outcomes.

In April, 2002, a multidisciplinary pre-dialysis assessment clinic was established by the
director of Renal Medicine at the St. George Hospital for timely clinical, nutritional and
psychosocial management of patients with advanced CKD. The referral criteria were
patients with CKD stage 4 or 5 (or GFR less than 30 mL/min/1.73m2) who were under
the care of St. George Hospital nephrologists. The clinic was coordinated by a renal
nurse consultant (CNC) and primarily provided patients with education about CKD
management and dialysis options. A social worker, pharmacist and dietitian provided
other discipline-specific assessment and preliminary education in this 1-point contact
system; further interventions were arranged if required. In particular, the dietitian would
arrange further appointments in the Nutrition and Dietetics Department if further
nutrition intervention was required.

Broadly, the purpose of this research was to examine the clinical and nutritional
characteristics of patients at different stages of treatment pathway in advanced CKD
(Figure 2-2)
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Figure 2-1 Schematic diagram showing the research framework

2000 to 2010: Nutritional status at the initiation of dialysis and
survival (Study I)

2002 to 2008: Nutritional profile of
patients at enrollment in the
pre-dialysis assessment clinic
(Study IIa)

2002 to 2012: Comparison of nutritional profile of patients
enrolled in the pre-dialysis assessment clinic over two 5-year
periods (April 2002 to March 2007 vs. April 2007 to March
2012) (Study IIb)

2000

2002

Pre-Dialysis
Assessment Clinic
established

2008

2010

2012
Year
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Figure 2-2 Schematic diagram showing the sequence of the research framework

Renal function
(CKD stage)
3

4

Study II
Study IIa (2002 to 2008) &
Study IIb (2002 to 2012)
Pre-dialysis clinic
Nutritional characteristics

Study I
(2000 to 2010)
Nutritional at initiation of
dialysis and outcomes

5

Time

Progressive Deterioration of Renal Function

Dialysis

Study I: A retrospective audit was undertaken by reviewing dialysis patient records
from year 2000 to 2010. The patients reported in this study were limited to
patients who started dialysis between August 2002 and July 2005 and
excluded CKD patients who did not progress to require dialysis in this period.
The aim of this study was to assess the relationship between measurements
obtained at baseline nutritional assessment undertaken at the time of starting
dialysis and subsequent survival on dialysis.

Study II: A retrospective study of all patients enrolled in the pre-dialysis assessment
clinic established in April 2002. Part a) was a baseline cross-sectional
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descriptive study of the nutritional characteristics of patients attending the
clinic from 2002 to 2008. Part b) was an analytical study to examine the
possible change of baseline initial clinic assessment parameters over a 10year study period, in particular, between two 5-year periods from April 2000
to March 2007 versus from April 2007 to March 2012.

2.5

Objectives of the thesis

The objectives of the thesis were to:

1) examine the associations of demographic, clinical and nutritional parameters at the
initiation of dialysis and survival over a 10-year study period
2) examine the demographic, clinical and nutrition characteristics of patients attending
the pre-dialysis assessment clinic
3) evaluate an appetite assessment tool used to assess patients’ energy and protein
intake in the pre-dialysis assessment clinic
4) examine the change of the prevalence of clinical and nutritional abnormalities of
patients attending the pre-dialysis assessment clinic over a 10-year period - first vs,
second 5 year period, in particular obesity and malnutrition.

2.6

Hypotheses tested during the thesis

Hypothesis 1: nutritional abnormalities at the initiation of dialysis would be associated
with high mortality risk (Chapter 3).

Hypothesis 2: abnormal nutrition would be prevalent in advanced CKD before dialysis
was required (Chapter 4).

Hypothesis 3: the subjective rating of a good appetite using the Appetite and Diet
Assessment Tool (ADAT)238,

299

appetite score would be useful in

reflecting adequate intakes of protein and energy (Chapter 4).
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Hypothesis 4: as the clinic became more established over the 10-year study period,
patients with ESKD would be referred to the clinic earlier or at higher
levels of GFR for management. Earlier referral may be associated with a
lower prevalence of nutritional abnormalities at the time of initial
assessment in the pre-dialysis clinic in the second half of the study
period (Chapter 5).

Hypothesis 5: in view of the obesity and diabetes epidemics, there would be a higher
prevalence of overweight/obese and diabetic patients in the second half
of the study period (Chapter 5).

Hypothesis 6: nutritional status would be associated with the future choice of RRT
(Chapter 5).

2.7

Study framework and methods

The study rationales, design and methods of various stages are presented under the
respective chapters (Chapters 4, 5 and 6). An overview of the study methods is
provided in this section.

2.7.1 Study I: Nutritional factors at the initiation of dialysis and mortality
2.7.1.1 Study population and data collection

In Study I, patients of interest were incident dialysis patients. As part of routine care in
our unit, patients were referred to the renal dietitian for nutrition assessment and
intervention as per clinical practice guidelines recommendations.205, 216 All assessment
and intervention records were kept in the clinical and nutrition records. In this study,
records of patients who commenced dialysis between 1st August 2000 and 31st July
2005 were examined, including the all-cause mortality data by 31st July 2010 obtained
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from the Australia and New Zealand Dialysis & Transplant Registry (ANZDATA). 5 The
ANZDATA registry office was contacted for permission to use the data.

Data were included for analysis from ESKD patients who were older than 18 years of
age and commenced a planned dialysis program after gradual decline of renal function.
Patients who had started dialysis due to acute kidney injury (AKI) or who had a
previous history of RRT were excluded for analysis as their nutritional status was
affected by factors other than chronic uraemia, for example, by surgical complications,
trauma or use of steroids in the case of ex-transplantation. Other exclusion criteria
were those patients who had a planned exit from the dialysis program, for reasons
such as living donor transplantation or planned transfer to another unit, and therefore
had incomplete assessment by the dietitian within 4 weeks of dialysis initiation.

Data collected were:

 Demographic: age (year) and gender (male or female)
 Clinical data: cause of ESKD; smoking history (current or ex-smoker classified as
having “positive smoking history”); presence of comorbidities, including coronary
artery disease (CAD), CVD, DM, chronic lung disease (CLD) and peripheral
vascular disease (PVD) – ANZDATA classified the presence of co-morbidity as
“yes”, “suspected” or “no”, with “yes” and “suspected” combined as “presence of” for
analysis in this study; mortality and cause of death were also extracted
 Nutrition assessment: anthropometric measures; biochemistry; and SGA. Details of
these assessments will be discussed in Section 2.7.1.2. Dietary intake assessment
was routinely performed but these data were not used in this study
 Other data: “late referral” defined as <3 months of specialist care by nephrologists;

dialysis modality at the start of RRT program – defined as the dialysis modality
treated at 3 months as present in the ANZDATA; a change of dialysis modality
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during the observation period; patients who had moved away from the unit; and date
of transplantation (if applicable).

All data were entered into Microsoft Excel and then imported into SPSS version 18
(SPSS Inc, Chicago IL) statistical software program for analysis.

2.7.1.2 Nutrition assessment
For anthropometric measures, the patient’s height was measured by the dietitian or
nursing staff using a wall-mounted or portable stadiometer (Seca) to the nearest 0.5
cm. Weight was measured using the Tanita BWB-600 scale to the nearest 0.1 kg and
oedema free or “dry weight” was obtained from the dialysis chart.
BMI = weight (kg)  [height (m)]2
BMI levels were then compared to the clinical practice guidelines,205 with a healthy
range for BMI defined as 22–26 kg/m2 and BMI ≥ 26 kg/m2 treated as overweight or
obese. Weight history was also recorded, especially the presence and percentage of
unintentional weight loss over time. Biochemical data was obtained from the results
provided by the pathology services of the hospital, South Eastern Sydney Area
Laboratory

Services.

Data

collected

were

serum

creatinine

(µmol/L)

and

s-albumin using bromcresol purple (BCP) methods.
Glomerular filtration rate (GFR) was calculated using Cockcroft-Gault equation:300

GFRCG (mL/min) = (140 – age) x oedema-free body weight (kg)
serum creatinine (µmol/L) x 0.815

x0.85 if
female

GFR was also corrected for body surface area (BSA):
BSA (m2) = [weight (kg)]0.425 x [height (cm)]0.725 x 0.007184
corrected GFRCG (mL/min/1.73m2) =

GFRCG (mL/min) x 1.73m2
BSA (m2)
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Malnutrition assessment was performed by the dietitian using the 7-point scale
SGA.147, 149 SGA is a diagnostic tool for malnutrition; once the subject is scored as B or
C according to the tool specification, they are categorised as malnourished.

That

particular version was chosen for longitudinal clinical monitoring in our routine care as it
is well-validated in the renal population and used in a number of significant studies.
149, 150, 256, 301, 302

13,

The original SGA148 rated patients into three categories: A = well

nourished; B = mildly to moderately malnourished; and C = severely malnourished. The
7-point scale SGA tool (Appendix C) further divides each category into sub-categories
which can be used as continuous variables, with lower numbers indicating more severe
degrees of malnutrition. These sub-categories are: A = well nourished (7 and 6); B =
mildly to moderately malnourished (5, 4 and 3); and C = severely malnourished (2 and
1). In addition to the medical history and physical examination components explained in
Section 1.5.2, the strength of the 7-point SGA is that it also takes into account the
“estimated” energy and protein intake compared to the recommended intake.147 For
example, a sustained intake of less than 85% of the recommendation over 2 months
would lead to a further deduction of 1-point rating. This method gives more objective
measures and strength to rate patients who are likely to fall between two categories.
For example, a “healthy looking” patient with <5% weight loss over the last 6 months,
but who has sustained dietary intake <85% recommended over the last 3 months,
would be scored as B5 or B4 (mildly to moderately malnourished) on the 7-point scale
instead of as A (well nourished) on the 3-point scale. For statistical and reporting
purposes in this study we only report 3 categories: A = well nourished, B = mildly to
moderately malnourished and C = severely malnourished; ratings of B and C were
further combined as one “malnourished” group. We didn’t consider using the version of
patient generated SGA (PG – SGA)101 because it was not validated in the renal
population until in 2005, well after our initial data collection from 2000. Another 2
reasons why we did not consider using PG-SGA were (1) this tool has a built in additive
scoring for co-morbidities e.g. cardiovascular disease and haemodialysis etc that affect
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our multivariate survival analysis. (2) The version with a 7 point scale used in our
studies was superior that the scoring is based on actual diet intake estimation whereas
PG-SGA relies on the patients’ subjective reporting of eating well or not.

The PhD candidate is the principal renal dietitian of the unit at St George Hospital and
performed >95% of the nutritional assessment for patients in this study. The remaining
assessments were undertaken by other dietitians in renal rotation from the Department
of Nutrition and Dietetics at St. George Hospital. Regular SGA training was conducted
for all dietitians within the Nutrition and Dietetics Department. SGA undertaken by
different dietitians were compared, with an inter-rater agreement (Kappa statistic) of
>0.7.

2.7.1.3 Sample size consideration

In the preliminary analysis, high 1-year mortality in malnourished incident dialysis
patients was observed (in-house audit; no published data available). Approximately
30–40% of patients started dialysis due to unexpected events, e.g., AKI with or without
previous history of CKD, and with or without subsequent recovering of kidney function;
these patients were not considered in our study. Of all the patients (n =330) who
commenced dialysis between 1st August 2000 and 31st July 2005, 167 patients (50.6%)
met the selection criteria.

Although this could be considered “convenience sampling”

as these patients were accessible to the PhD candidate, the sample included “all”
patients who commenced dialysis in our unit over a 5-year period. In the literature,
univariate or multivariate analyses of the association of malnutrition based on SGA
score have sample sizes between 91 to 680 with approximately 39–50% prevalence of
malnutrition13, 14, 99, 153 (see Table 1-6). The closest studies14, 153 had a total sample size
of 206 and 153 subjects respectively. Therefore, our sample size of 167 patients with
well-defined nutrition background was considered to be appropriate. A retrospective
attempt was made to calculate the sample size; unfortunately, none of these
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publications reported the median survival time or proportion of death/mortality of the
well nourished Vs. malnourished groups to allow sample size calculation for our study.

2.7.1.4 Statistical analyses

Phase I of the study examined the relationship of the baseline clinical and nutritional
factors at the initiation of dialysis on survival. Survival was determined from the date of
starting dialysis until death, or censored at transplant or at end of the observation
period of 31st July 2010. All causes of mortality or death were considered. Reasons that
may have altered nutritional status or mortality data during the observational period,
such as nutrition intervention, hospitalisation, development of infection or other
disease, were not examined.

In our initial analysis and report in the literature, mortality of HD and peritoneal dialysis
(PD) was comparable;14,

303

therefore all data were combined for analysis. Race or

ethnicity is often thought to be an important factors affecting survival on dialysis. A
higher risk of death has been reported in the Canadian Caucasian patients compared
with the minority groups;304 and in Australia, Indigenous Aboriginal compared with nonIndigenous Australians.305

However, the differences could be explained largely by

measurable case-mix and treatment characteristics.306 When health care is accessible,
survival in aboriginals and Caucasians is similar after adjusting for co-morbidities.
308

307,

Or studied population consisted of approximately 83 .3% Caucasians, the

distribution of non – Caucasians was small among different ethnic groups: Australian
Aboriginals (1.0%), Chinese (6.6%), Egyptian (1.0%), Indian (3.0%), Maori / New
Zealander (3.1%), Pacific Islander (1.0%), Pilipino (1.0%). All patients accessed
planned dialysis program with 85.0% attended our nephrologists for at least 3 months
prior to starting dialysis. Therefore all data were combined for analysis. Age, s-albumin
and BMI were analysed as both continuous and categorical variables; for example, age
< or ≥65 years, s-albumin < or ≥33.0 g/L and BMI < or ≥26 kg/m2. The combined
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effects of malnutrition (SGA score B and C), s-albumin (<33.0 g/L vs. ≥33.0 g/L) and
BMI (<26 kg/m2 vs. 26 kg/m2) were also examined. The combined effects of SGA and
BMI were determined using the following forms of categorisation:
 Group 1: SGA = A + BMI <26 kg/m2
 Group 2: SGA = A + BMI ≥ 26 kg/m2
 Group 3: SGA = B and C + BMI <26 kg/m2
 Group 4: SGA = B and C + BMI ≥26 kg/m2

Similar forms of categorisation applied to combinations of SGA and s-albumin, and salbumin and BMI. The effects of other parameters on mortality were also examined,
including obesity and the levels of GFR at which dialysis should start.

All tests were performed using the statistical software SPSS version 18 (SPSS Inc,
Chicago IL). Continuous variables were expressed as mean ± standard deviation for
normally distributed data and as medians with interquartile ranges (IQR, 25th to 75th
percentile) for non-normally distributed data. For continuous variables, comparisons
between groups were performed using unpaired sample t test for normally distributed
variables or the Mann-Whitney test for non-normally distributed variables; categorical
variables were compared using the 2 test. Survival analyses were performed using the
Kaplan-Meier method (univariate analysis) and Cox proportional hazard analysis
(multivariate analysis) was used to assess the independent association of baseline
parameters and mortality.

A P value <0.05 was considered to be statistically significant.

2.7.1.5 Outcome measures

Primary outcome measures were the association of baseline nutritional parameters, in
particular, malnutrition, s-albumin, overweight/obesity and all-cause mortality risk.
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These are expressed as hazard ratio (HR) and adjusted hazard ratio (adj. HR) with
95% confidence interval (CI). The secondary outcome measures were the association
of other baseline clinical factors and the risk of all-cause mortality, in particular GFR
and co-morbidities. Other outcome measures were prevalence of various baseline
nutritional abnormalities and comorbidities.

2.7.1.6 Ethics approval

The study protocols were approved by the ethics committee of the South Eastern
Sydney and Illawarra Area Health Service, NSW, Australia (03/115 Chan) (Appendix
D)

2.7.2 Study II: Nutritional parameters in patients attending the pre-dialysis
assessment clinic
2.7.2.1 Study population and data collection

These studies were retrospective analyses of data collected from the routine nutritional
assessment of the pre-dialysis assessment clinic. All patients were referred to this
clinic by nephrologists of the St. George Hospital, using recommended referral criteria
for patients with ESKD, GFR <30 mL/min/1.73m2. The clinic attendance was voluntary;
therefore not all ESKD patients being prepared for dialysis attended the clinic or
patients may have been referred to individual health care professionals for
management without going through the clinic. Only data of patients who attended the
pre-dialysis clinic were included in analyses. In addition to the routine nutritional
assessment records, data were also extracted from doctor’s referral letters and clinic
and nutrition records. Data collected were:

 Demographic: age (in year) and gender (male or female)
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 Clinical data: cause of ESKD, smoking history, presence of comorbidities as
described in Section 2.7.1.1
 Nutrition assessment: anthropometric measures, biochemistry, clinical signs and

symptoms, dietary intake assessment and SGA. Details of these assessments will
be discussed in Section 2.7.2.2. Data of reliable dietary intake assessment was
used for further evaluation and analyses.
 Other data: patient’s initial preferences for RRT after education by the clinical nurse

consultant.

All data were entered into Microsoft Excel then imported into SPSS for statistical
analysis.

2.7.2.2 Nutritional assessment
Anthropometric data – measurements of height, weight and BMI – were the same as
those described in Section 2.6.1.2. MAMC was taken at the mid-point of the acromial
and olecranon processes of patients’ right forearms using a non-stretchable steel tape.
Measurement was recorded to the nearest 0.1 cm. TSF was then measured at the midarm level using a Harpenden skinfold calliper; the average of 3 repeat measures to the
nearest 0.2 mm was used. MAMC was calculated using the following formula:
MAMC (cm) = MAC (cm) – 0.314 x TSF (mm)
The results were then compared to the reference standards.309, 310

Biochemical data collected were serum creatinine and s-albumin. Calculation of
corrected GFR was described in Section 2.6.1.2. A large proportion of our patients
(approximately 50%) visited nephrologists in private consulting rooms and had blood
tests performed by non-hospital pathology providers using different laboratory methods
for s-alb analysis with various reference ranges, e.g., bromcresol purple (BCP) and
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bromcresol green (BCG), etc. Therefore, in addition to recording the actual figures,
whether the result was above or below reference range was also recorded.
Patients’ clinical signs and symptoms in relation to nutrition were recorded. In addition
to the criteria for assessing SGA – such as presence of anorexia, nausea, diarrhoea
and vomiting – patients were also assessed for the presence of taste change or
aversion to foods, a classic symptom of uraemia. Furthermore, patients were asked to
rate their appetite using the “Appetite and Diet Assessment Tool” (ADAT) 5-point Likert
scale:238

Question: Overall, how would you describe your appetite?
(1) Very good
(2) Good
(3) Fair
(4) Poor
(5) Very poor
Dietary intake assessment was performed using a detailed diet history interview
method or structured diet history method.242-244 Patients and their carers were asked to
give a detailed description of quantity, quality and frequency of food and beverage
consumption. Estimating quantity was assisted by drawings of the protein food serving
size, food models and household measuring metric cups and spoons. Detailed
assessment was performed in line with best practice while also generating results for
use in research analyses. This assessment method was later validated in a pilot study
in the pre-dialysis CKD patients by nutrition research students,245 and showed good
agreement with the 3-day food diary for assessing energy and protein intakes. It is
considered to be less burdensome to patients as it does not required pre-clinic
preparation and limits recording bias. The diet histories were then entered into a
computerised nutrients analyses program (FoodWorks Professional Model 2009, Xyris,
Brisbane, Australia) to estimate EI, DPI and intake of other macro- (fats, carbohydrates
and alcohol) and micronutrients (vitamins and minerals). Patients’ daily activities were
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questioned with enough detail to score a physical activity level (PAL)311 for estimating
EE and energy requirements using the Schofield equation.312

The average daily intake of core foods such as fruit and vegetables was extracted.
Records of patients who were unable to report or estimate food intake properly were
excluded from analyses, with reasons including language barrier without interpreter
service or poor mental status.
The intake of energy and protein was expressed as kcal and g per kg IBW per day –
kcal/kg IBW/d and g/Kg IBW/d respectively. For overweight patients, adjusted BW was
used205, 230
Adjusted BW = IBW + [(oedema-free BW – IBW) x 0.25]

The PhD candidate is the principal renal dietitian of the unit and performed >95% of the
nutritional assessment for the patients in this study. In addition, regular SGA training
was conducted for all dietitians within the Nutrition and Dietetics Department and
achieved high inter-rater agreement (Kappa statistics) of >0.7.

2.7.2.3 Sample size consideration

As these studies were of a post hoc nature a sample size calculation was not
performed. Study IIa considered the data of all patients enrolled (n =227) in the clinic
over a 6-year period; approximately 210 patients were seen by the dietitian with usable
data on 205 patients. Studies of a similar nature had sample sizes ranging from 27 to
approximately 1,786 (Tables 1-7 and 1-8). Therefore, we considered our sample size
was optimal. A retrospective sample size estimate calculation313,

314

indicated the

sample size used was appropriate:

Sample size =

Z1-/22 x p (1-p)
d2
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Z1-2 = standard normal variate at 5% type 1 error (P <0.05) =1.96
p = expected proportion in population based on previous study. The primary nutrition
parameter of interest was malnutrition. A previous study conducted in our
hospital98 indicated a prevalence of ~28% or 0.28. Similar studies also indicated ~
28 to 35% malnutrition rate (Table 1-9). Therefore, ~30% or 0.3 was chosen.
d = margin of error or precision or error rate = 6% or 0.06

Sample size =

(1.96) 2 x 0.30 (1- 0.30)
(0.06)2

= ~ 225
OR
Sample size =

DEFF x N x p(1-p)
d /Z1-/22 x (N-1) + p(1-p)
2

DEFF = design effect =1
N= population size – it was difficult to estimate the true sample size as many patients
had a GFR < 30mL/min and may or may not come through the clinic. Over the 6
year study period, at least 600 patients with a GFR of < 30 mL/min were estimated
to be under the care of our unit.
p = proportion or frequency, ~30% or 0.30was used discussed as above
d= confidence limit as % of 100 (absolute ± %) = 5% or 0.05
Z1-/2 = 1.96
_______1 x 600x 0.30 (1-0.30)______
Sample size = (0.05)2/(1.96)2 x (600-1) + 0.30x(1-0.30)
= 211
Therefore our sample size was considered appropriate.
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Phase IIb of the study was to examine the “nature” of the clinic so data of all patients (n
=550) enrolled in the clinic over a 10-year period were reviewed, and data from 501
patients with sufficient nutrition data were analysed.
2.7.2.4 Statistical analyses
All statistical tests were performed using the statistical software SPSS© Statistics.
Descriptive statistics were used to examine the prevalence of nutrition abnormalities;
continuous variables were expressed as mean ± standard deviation for normally
distributed data and comparisons between groups were performed using unpaired
sample t-test. Categorical variables were compared using the 2 test. Correlations
between GFR and dietary energy and protein intakes were estimated using Pearson
correlation coefficients. Analysis of variance (ANOVA) was used to compare the
parameters among three to four categories. The positive predictive values (PPV) of
appetite score for adequate energy (≥25 g/kg IBW/d)178,

310

and protein intake (≥0.75

g/kg IBW/d)205 were assessed using the two-way contingency analysis table.315

A P value <0.05 was considered to be statistically significant.

2.7.2.5 Outcome measures

The main outcome measures were the prevalence of nutritional abnormalities of
patients attending the pre-dialysis assessment clinic. The secondary outcomes were
the relationships between various demographic, clinical and nutritional parameters.

2.7.2.6 Ethics approval

The study protocols were approved by the ethics committee of the South Eastern
Sydney and Illawarra Area Health Service, NSW, Australia (03/134 Chan,
LNR/12/STG/104 and LNRSSA/12/STG/105). (Appendix E)
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2.7.3 Patients flow between studies

There were considerable overlapping of patients flow between treatment (dialysis),
clinic and studies. Figure 2-3 indicates the flow of patients between various studies in
relation to their treatment and clinic attendance. All data were from convenience
sample. In study 1, all patients (n=330) commenced dialysis during the defined period
were considered, with 167 patients met the selection criteria.

In study II, study

population was patients attending the clinic itself, so this meant everyone was
considered but not all data could be used due to missing dietitian assessment or
incomplete records.

Figure 2-3 Patient flow between studies

8-2000 to 7-2005
Total 330 patients commenced dialysis

n=163
did not meet
study criteria

4-2002 to 3-2008
227 (all) patients
attended pre-dialysis
clinic

n=50
attended clinic
and subsequently
started dialysis

n= 167
met study criteria

Study I
Nutritional status at
commencement of
dialysis and survival

n=11

4-2008 to 3-2012
323 (all) patients
attended pre-dialysis
clinic
n=28

Missed dietitian
assessment or
incomplete record

n= 206
Assessed by
dietitian

Study IIa
Nutritional status at
enrolment to the predialysis clinic

n= 295
Assessed by
dietitian

Study IIb
n=501, Change of
nutrition profiles over
2 five year periods
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Chapter 3 Nutritional and Clinical Factors of ESKD Patients at the Initiation of
Dialysis and Survival over a Ten-Year Study Period
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Abstract

Objective: To examine the associations between demographic, clinical, lifestyle, and
nutritional parameters at the start of dialysis and mortality, including the combined
effects on nutritional parameters which were seldom investigated in the literature.

Design: 10 year retrospective clinical cohort study.

Setting: Dialysis unit of a metropolitan tertiary teaching hospital in Sydney, Australia.

Subjects: Incident dialysis patients (n =167; hemodialysis, 57.5%; male, 61.7%; age
65.3±13.6 years; diabetic, 24.5%) who commenced on a planned dialysis program.

Methods: Associations were examined between all-cause mortality and baseline
demographics, including age and gender; clinical and lifestyle characteristics, including
glomerular filtration rate, smoking habits, presence of co-morbidities (e.g., coronary
artery disease, diabetes mellitus, and peripheral vascular disease); and nutritional
parameters, including body mass index (BMI), serum albumin (s-albumin) levels, and
subjective global assessment score (SGA). Associations with combination values for
malnutrition, s-albumin (<3.3 vs. 3.3 g/dL) and BMI (<26 kg/m2 vs. 26 kg/m2) were
also examined.

Results: Median survival was 54.2 months (interquartile range, 23 to 83), and 52.1% of
patients were malnourished (SGA score B and C) at the start of dialysis. Older age
(>65 years, P <0.0001), presence of peripheral vascular disease (P <0.0001), reduced
s-albumin levels (P =0.01) and malnutrition scores (P =0.02) independently predicted
mortality. Being overweight and obesity (BMI: 26 kg/m2) did not show any advantage
on survival (P =0.73). Being malnourished and overweight (or obese) was associated
with a 3-fold increase in mortality risk (adjusted hazard ratio [HR], 2.96; 95%
confidence interval [CI], 1.12–7.33, P =0.02) compared with being well nourished with a
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BMI <26 kg/m2 (referent). Compared with being well nourished (SGA = A), being
malnourished with normal or low s-albumin was associated with higher risk, (HR, 2.06;
95% CI, 1.06 to 4.00; P =0.03 and HR, 2.86; 95% CI, 1.65–4.94; P <0.0001,
respectively). There was no statistical difference between mortality risks through any
combination of s-albumin and BMI values (P =0.54).

Conclusion: Malnutrition and reduced s-albumin levels were found to be independent
predictors of mortality, whereas overweight and obesity did not show protective effects.

3.1

Introduction

Protein energy wasting (PEW) and poor nutritional status are common in patients with
end stage kidney disease (ESKD) on maintenance dialysis.75, 318, 319 These are strong
predictors of mortality and morbidity and are associated with poor quality of life. 13, 107
Factors affecting nutrition in uremic patients include (1) disturbance of energy, protein
and nutrients metabolism,320 (2) metabolic acidosis,115 (3) anorexia, taste change and
poor appetite that may lead to suboptimal dietary intake,11,

321, 322

(4) dialysis

procedures per se,13 such as bio-incompatibility, inadequate dialysis, protein and other
nutrient losses, and peritoneal dialysis (PD)

323

dialysate-induced glucose loading and

sense of fullness,324 (5) hormonal derangement,325 (6) co-morbidities, such as
cardiovascular disease and diabetes mellitus, (7) infection and intercurrent illnesses,
(8) chronic inflammation,75 (9) altered muscle metabolism326 and physical inactivity,327
(10) loss of residual renal function,328 (11) psycho-social issues329 and poor food
management skill, and (12) conditions associated with various stages of lifecycle that
require additional nutritional attention, such as menopause, aging-related sarcopenia
and poor dentition. Many of these nutrition abnormalities emerge during the
progressive decline of renal function before dialysis is required.11, 98
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In the dialysis population, nutritional factors found to predict mortality risk are
anthropometric measures, e.g., low weight to height ratio,105 low body mass index
(BMI) and unintentional weight loss330; abnormal laboratory results, such as high level
of C-reactive protein (CRP)74 and low levels of lymphocytes, parathyroid hormone,
serum albumin, pre-albumin and hemoglobin104,

330-334

; poor appetite,97 muscle

wasting,252 suboptimal intakes of energy and protein,321 low exercise capacity,327 poor
functional capacity measured by hand grip strength252; and malnutrition score using
subjective global assessment (SGA).14 Many of these abnormalities present at the start
of dialysis and predicted poor outcomes.13, 14, 252 However, there has been much debate
on the prognostic significance of s-albumin-CRP,14, 335 BMI128, 129,
initiation of dialysis.145,

337

133, 336

and timing of

It is necessary to understand the relationships between

mortality and these modifiable factors, so that pre-dialysis intervention can be
considered to improve outcomes.

3.2

Aim

The aims of the present study were (1) to describe the demographic, clinical and
nutritional characteristics in a cohort of ESKD patients who commenced on planned
dialysis program in our unit, (2) to examine the associations between these factors and
mortality, and (3) to examine the combined effects of nutritional factors on mortality
risk, as these methods were seldom investigated in the previous studies.

3.3

Patients and methods

This was a retrospective clinical cohort study involving all incident hemodialysis (HD)
and PD patients at the renal unit of The George Hospital, Sydney, Australia between
August 1, 2000 and July 3, 2005. All patients were followed until death, or they were
censored at transplant or at the end of the observational period of July 31, 2010. This
means all patients completed at least 5 years of follow-up over the 10-year study
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period. Inclusion criteria were ESKD patients who were older than 18 years and who
commenced a planned dialysis program after gradual decline of renal function without
history of acute kidney injury (AKI) and renal replacement therapy (RRT). Initiation of
dialysis was recommended by the patients’ primary nephrologists based on clinical
judgments (e.g., when glomerular filtration rate [GFR] was <7 mL/minutes/1.73m2 or
indication of uncontrolled uremic symptoms, e.g., volume overload). Exclusions criteria
were patients in whom dialysis was initiated because of AKI with or without recovering
renal function, previous history of RRT, planned early discontinuation of dialysis
program from our unit (e.g., living donor transplantation or transfer to another units)
and incomplete assessment by the dietitian within 4 weeks of dialysis initiation.

Clinical and demographic data extracted from the hospital clinical notes and the
Australia and New Zealand Dialysis & Transplant Registry (ANZDATA) included age;
gender; race; smoking history (never smoked or combined ex- and current smokers);
late referral to nephrologists, defined as <3 months under specialist care before
starting dialysis; and co-morbidities such as coronary artery disease (CAD), cerebral
vascular disease (CVD), diabetes mellitus (DM), chronic lung disease (CLD), and
peripheral vascular disease (PVD). ANZDATA classified the presence of co-morbidity
as “yes”, “suspected” or “no”; data of “yes” and “suspected” were combined as
“presence of” for analysis in this study. Mortality and cause of death were also
extracted.
In line with the clinical guidelines205 which are based on the latest best evidence and
expert opinion if a high level of evidence did not exist or was inconclusive, all patients
were assessed by the renal unit dietitians, including the author M.C., as part of the
routine care. Anthropometric measures included for analysis were height (m), edemafree body weight (kg), BMI = weight÷height2 (m/kg2) and weight history (in particular if
any unintentional weight loss occurred over the previous 6 months for SGA rating). The
previous routine blood results before the first dialysis session were extracted from
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clinical notes. These included s-albumin (reference range, 3.3 to 5.3 g/dL) and serum
creatinine to calculate GFR using the Cockcroft-Gault equation. The survival risk
between the early and late starting groups were compared using the Initiating Dialysis
Early and Late (IDEAL) trial intended cutoff of 7 and <7 mL/minutes/1.73m2 as early
and late initiation, respectively338; further analyses were performed at cutoffs of 8, 9
and 10 mL/minutes/1.73m2. To elimination the negative effect of acute-phase response
of s-albumin due to the insertion of PD catheter, the most recent s-albumin readings
before the procedures were used. Other assessment performed by the renal dietitian(s)
was SGA149 which categorises patients as A = well nourished, B = mild-moderately and
C = severely malnourished based on the patient’s medical history and physical
examination. Urea kinetic studies were routinely performed to all patients throughout
the study period to meet the optimal national dialysis targets.339 The clinical practice
guidelines205 defined healthy range for BMI as 22–26 kg/m2; we considered BMI ≥26
kg/m2 as obese or overweight. Additional analyses were performed according to the
World Health Organization defined categories121 of underweight, healthy weight range
overweight and obese (BMI: <18.5, 18.5 to 25.0, 25 to 30, and ≥30 kg/m2, respectively)
as well as renal-specific BMI categories205,
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of undernourished, ideal range,

overweight and obese (BMI: <23, 23 to 26, 26 to 30 and ≥30 kg/m2, respectively). The
combined effects of malnutrition (classified by SGA score B or C), s-albumin (<3.3 vs.
≥3.3 g/dL) and BMI (<26 vs. 26 kg/m2) were also examined. For example, the
combined effects of SGA and BMI were determined using the following forms of
categorisation: group 1 (SGA = A + BMI: <26 kg/m2), group 2 (SGA = A + BMI: ≥26
kg/m2), group 3 (SGA = B and C + BMI: <26 kg/m 2) and group 4 (SGA = B and C +
BMI: ≥26 kg/m2). Similar forms of categorisation applied to SGA and s-albumin, as well
as s-albumin and BMI combinations.

All tests were performed using the statistical software SPSS version 18 (SPSS Inc,
Chicago IL). Continuous variables were expressed as mean ± standard deviation for
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normally distributed data and as medians with interquartile ranges for non-normally
distributed data. For continuous variables, comparisons between groups were
performed using unpaired sample t-test for normally distributed variables or the MannWhitney test for non-normally distributed variables, whereas categorical variables were
compared using the 2 test. Survival analysis was performed using the Kaplan-Meier
method (univariate analysis) and Cox proportional hazard analysis (multivariate
analysis) was used to assess the independent association between baseline
parameters and mortality. Effect of age (>65 years), GFR (<7 mL/minutes/1.73m 2), salbumin (<3.3 g/dL) and BMI (≥26 and ≥30 kg/m2) as continuous and categorical
variables were also examined. P <0.05 was considered to be statistically significant.

The study was approved by the ethics committee of the South Eastern Sydney and
Illawarra Area Health Service, NSW, Australia.

3.4

Results

Dialysis was initiated in 330 patients in the defined period. Of these, 167 patients
(50.6%) met the inclusion criteria. One hundred and sixty three (49.4%) were excluded
for analysis because of AKI with or without recovering renal function (32.8%), previous
history of RRT (2.1%), planned early discontinuation of dialysis program from our unit
(10.3%) and other causes (e.g., <18 years of age, incomplete dietitian assessment
within 4 weeks of enrollment, or missing data; 4.2%). The mean age (±standard
deviation) of the studied subjects was 65.3±13.6 years (male, 61.7%). Of these
patients, 57.5% were on HD and the rest were on PD at day 90 after enrollment; 64
patients (38.3%) switched dialysis modality during the study period. Similar survival
rates were reported in the literature for both modalities14, 303 even after switching from
one to the other.340 As we found similar results by the Kaplan-Meier analysis (P =0.89),
all HD and PD data were combined for analysis. Twenty-eight patients (16.8%)
received a kidney transplant after entry to the study.

98

The baseline demographic, clinical and nutritional characteristics of the studied patients
at the initiation of dialysis are listed in Table 3-1.

Table 3-1 Demographic, clinical and nutritional characteristic of the studied
subjects at baseline
Parameters

Total

Male

Female

Number (%)
Demographics
Age (year)
**Race, Caucasian (%)
Clinical and co-morbidities
Haemodialysis at 3 month (%)
Serum creatinine (μmol/L)
Glomerular filtration rate (mL/minutes/1.73m2)
Late referral† (%)
Smoking (positive history)‡ (%)
Chronic lung disease§ (%)
Coronary artery disease¶ (%)
Peripheral vascular disease** (%)
Cerebral vascular disease†† (%)
Diabetes mellitus (%)
Nutritional
Serum albumin (g/dL)
Weight (kg)
Body mass index (kg/m2)
Malnourished, subjective global assessment score
B and C (%)

167

103 (61.7%)

64 (38.3%)

65.3±13.6
83.3

65.8±13.9
83.5

64.±13.1
82.8

57.5
800.6±288.1
8.0±2.7
8.5
43.7
15.8
46.2
24.5
23.9
33.5

62.1
867.4±314.4
7.8±2.7
10.6
47.3
15.5
48.5
24.5
22.4
34

50.0
683.0±199.3*
8.2±2.7
4.7
35.0
16.4
42.6
24.6
26.3
32.8

3.1±0.5
69.517.1
25.9±6.9
52.1

3.1±0.5
73.614.5
25.9.±4.4
48.5

3.15±0.5
62.818.9*
25.9±7.7
57.8

P value is for comparison of the gender groups
*
P <0.0001
†
Data missing in 2 patients
‡
Data missing in 10 patients
§
Data missing in 9 patients
¶
Data missing in 9 patients
**
Data missing in 9 patients
††
Data missing in 9 patients
Expression of figures: n±SD – standard deviation
** Remark: Australian Aboriginals (1.0%), Chinese (6.6%), Egyptian (1.0%), Indian (3.0%),
Maori / New Zealander (3.1%), Pacific Islander (1.0%), Pilipino (1.0%).
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Late referral (<90 days) to the nephrologists was noted in 8.5% of patients, and dialysis
was commenced with a mean GFR of 8.0±2.7 mL/minutes/1.73m2. Apart from body
weight and serum creatinine, there was no statistical difference between male and
female patients for all other demographic, clinical and nutritional parameters. In all, 111
patients (66.6%) died including 2 of the transplanted patients, by the end of the
observation period. Three patients were transferred to the other hospitals, but their
survival data were obtained from the ANZDATA for analysis. Median follow up time
was 53.0 (interquartile range 23 to 83) months with 96.5 (76.3 to108.8) versus 29
(17.0–53.0) months for survivors and non-survivors respectively. The causes of ESKD
and death are listed in Table 3-2.

Table 3-2 Causes of end stage kidney disease and mortality

Cause
Causes of end stage kidney disease (n =167)
Chronic glomerulonephritis
Diabetic nephropathy
Renovascular disease/ hypertensive
nephrosclerosis
Adult polycystic kidney disease
Analgesic nephropathy
IgA nephropathy
Reflux nephropathy/congenital abnormality
Other or unknown causes
Causes of death (n =111)
Myocardial infarction
Cardiovascular accident
Cardiac arrest
Sepsis/infection
Other causes and illnesses
Withdrawal due to:
Refusal/QOL measures
Cerebrovascular co-morbidities
Peripheral vascular co-morbidities
Malignancy
Unknown causes

%
21.6
24.0
18.6
5.4
9.6
6.0
4.8
10.0
9.0
1.8
11.7
15.3
18.0
21.6
12.6
4.5
2.7
2.7

The main cause of ESKD was diabetic nephropathy (24%). The most common cause
of death was withdrawal of dialysis due to refusal and quality of life measures (21.6%).
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Among

the

patients

studied,

dialysis

was

initiated

early

in

37.2%

(7

mL/minutes/1.73m2) and late in 62.8% (<7 mL/minutes/1.73m2), with a mean GFR of
9.4  2.2 versus 5.51.0 mL/minutes/1.73m2, respectively; P <0.0001. The early-start
group in comparison to the late start group had significantly higher BMI (27.5±6.3 vs.
23.3±3.9 kg/m2, P <0.0001) and included fewer malnourished patients (43.8% vs.
66.1%, 2=7.8, P =0.005). There was no statistical difference between the 2 groups for
all other variables. Kaplan-Meier analysis showed no statistical difference in mortality
between the two groups (P =0.79). Further analysis did not show any statistical
difference in mortality between the early- versus late-start groups with the GFR cutoff
of 8 mL/minutes/1.73m2 (10.21.2 vs. 6.12.2), P <0.0001; 9 mL/minutes/1.73m2
(11.11.5 vs. 6.62.1), P <0.0001; or 10 mL/minutes/1.73m2 (12.01.6 vs. 6.92.1), P
<0.0001. Our data indicated that GFR levels at which dialysis started were not found to
have any association with mortality risk.

Among the lifestyle and co-morbidity parameters, PVD was independently associated
with higher mortality risk (P <0.0001), whereas the significance of CAD disappeared in
the adjusted analyses (P =0.10). Smoking and all other co-morbidities did not show any
statistically significant effect on mortality risks (Table 3-3).

Fifty-eight percent of patients had s-albumin <3.3 g/dL (reference range, 3.3 to 5.3
g/dL). The low s-albumin group, when compared with patients with normal s-albumin
levels, has significantly lower s-albumin (2.80.3 vs. 3.50.3 g/dL, P <0.0001), lower
GFR (7.32.3 vs. 8.82.9 mL/min/1.73m2, P <0.0001) and higher prevalence of
malnutrition (66.3% vs. 34.2%, 2=16.9, P <0.0001). There was no statistical difference
between the two groups for all other variables. Cox proportional hazard model revealed
that the measure of s-albumin, as both a continuous and categorical variable, was
independently associated with survival; with P =0.01 and 0.01 respectively (Table 3-3).
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Table 3-3 Cox proportional hazards analysis (multivariate model) of factors
affecting mortality
Parameters
Age (per year increase)
Age (>65 years)
Gender (male)
Glomerular filtration rate
(per mL/minutes/1.73m2 increase)
Hemodialysis
s-albumin (per g/dL increase)
s-albumin (<3.3 g/dL)
Body mass index (per kg increase)
Body mass index (30 kg/m2)
Body mass index (26 kg/m2)
Malnourished, subjective global
assessment score B and C
Smoking (positive history)
Chronic lung disease
Coronary artery disease
Peripheral vascular disease
Cerebral vascular disease
Diabetes mellitus

Unadjusted hazard
ratios (95% CI)
1.08 (1.05–1.11)
2.76 (1.51–5.06)
1.31 (0.84–2.04)
1.09 (0.98–1.21)

P value
<0.0001
<0.001
NS (0.23)
NS (0.10)

Adjusted hazard
ratios (95% CI) *
1.08 (1.05–1.12)
3.06 (1.70–5.51)
1.33 (0.86–2.06)
1.07 (0.97–1.17)

P value
<0.0001
<0.0001
NS (0.20)
NS (0.10)

0.67 (0.43–1.06)
0.92 (0.87–0.98)
1.60 (0.95–2.71)†
0.97 (0.92–1.03)
0.68 (0.36–1.29)
0.91 (0.52–1.59)
1.76 (1.01–3.05)

NS (0.09)
0.01
0.08
NS (0.30)
NS (0.23)
NS (0.73)
0.046

0.75 (0.48–1.16)
0.93 (0.89–0.98)
1.86 (1.17–2.97) †
0.97 (0.92–1.03)
0.67 (0.36–1.27)
0.91 (0.52–1.59)
1.74 (1.11–2.72)

NS (0.19)
0.01
0.01
NS (0.30)
NS (0.22)
NS (0.73)
0.02

1.46 (0.95–2.23)
0.85 (0.50–1.45)
1.71 (1.04–2.81)
2.62 (1.57–4.37)
1.01 (0.61–1.67)
1.10 (0.68–1.75)

NS (0.09)
NS (0.56)
0.04
<0.0001
NS (0.98)
NS (0.71)

1.45 (0.96–2.19)
0.86 (0.50–1.45)
1.45 (0.94–2.19)
2.42 (1.57–3.73)
1.01 (0.61–1.67)
1.09 (0.69–1.74)

NS (0.08)
NS (0.56)
NS (0.10)
<0.0001
NS (1.01)
NS (0.71)

NS, non-significant
*
Analysis with age as categorical variable unless stated otherwise. Hazard ratio adjusted for all
other variables including age, gender, dialysis modality, s-albumin, body mass index, subjective
global assessment, smoking and all co-morbidities
†
Analysis with age as continuous variable

More than half of the patients (55.1%) were overweight or obese (BMI: 26 kg/m2), and
17.4% of patients were obese (BMI: 30 kg/m2). Kaplan-Meier analysis indicated no
statistical difference in mortality risk between BMI <26 and  26kg/m2 (overweight and
obese), P =0.08 and <30 or 30kg/m2 (obese) groups, P =0.11. After adjusting for all
other variables, Cox proportional hazards analysis indicated similar effects, (P =0.73
and .22 respectively; Table 3-3). Kaplan-Meier analysis showed no statistical difference
in mortality between the 4 World Health Organization BMI categories121 (P =0.26) nor
among the renal specific BMI categories(P =0.72).205, 310

Within the cohort, 47.9%, 41.9% and 10.2% of patients were rated as well nourished
(SGA = A), mildly to moderately malnourished (SGA = B) and severely malnourished
(SGA = C) respectively. Kaplan-Meier analysis indicated a significant difference in the
mortality risk between the three groups (P <0.0001). After adjusting for all other
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variables using the Cox proportional hazard model, the survival curves of SGA B and C
merged, and the combined malnourished group (SGA = B and C, 52.1%) showed
significantly higher mortality risk compared to the well-nourished group (SGA = A)
(adjusted hazard ratio [HR], 1.74; 95% confidence interval [CI], 1.11 to 2.72; P =0.02;
Table 3-3 and Figure. 3-1). Therefore, malnutrition was found independently associated
with mortality.

Figure 3-1 Adjusted survival curves for SGA evaluated at the start of dialysis

SGA, subjective global assessment: A = well nourished;
B & C = malnourished.
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It is worth noting that the well-nourished group had significantly more diabetic patients
than the malnourished group (41.4% vs. 26.4%, 2 =4.1 P =0.04). The SGA A group
had significantly higher BMI (28.9±6.3 kg/m2) compared with the SGA B and C group
(23.1±3.7 kg/m2), P <0.0001. It was important to note that 24.5% of overweight or
obese patients (BMI ≥26 kg/m2) were rated as malnourished (SGA B and C) and within
the malnourished group (SGA = B and C), 21% of patients were overweight or obese
(BMI ≥26 kg/m2).

When the combined effects SGA and BMI were examined, after adjusting for all other
variables, the SGA = B and C + BMI: ≥26 kg/m2 group was associated with almost 3fold increase in mortality risk (HR, 2.96; 95% CI, 1.12 to 7.33, P =0.02) compared with
SGA = A + BMI: <26 kg/m2 (referent) (Figure 3-2), although the mean BMI of the SGA =
B and C + BMI ≥26kg/m2 group was significantly higher than the SGA = A + BMI <26
kg/m2 group (28.4±1.9 vs. 23.3±2.3 kg/m2), P <0.0001. The SGA = B and C + BMI ≥ 26
kg/m2 group has almost 2-fold higher mortality risk (HR of 1.77; 95% CI:0.95 to 3.30; P
=0.07) compared with the SGA = B and C + BMI <26 kg/m 2 group despite a significant
higher mean BMI of 28.4±1.9 kg/m2 vs. 21.8±2.8 kg/m2, P <0.0001. This means, among
the malnourished groups, those overweight or obese tended to perform worse.

When the combined effects of SGA and s-albumin were examined (Figure 3-3), no
statistical difference in mortality risk was observed between the SGA = A + s-albumin
≥3.3 g/dL or SGA = A + s-albumin <3.3 g/dL (HR, 1.25; 95% CI, 0.65 to 2.4, P =0.51)
although the latter had significantly lower level of s-albumin (3.5±0.2 vs. 2.9±0.4 g/dL,
P <0.0001). In comparison to SGA = A + s-albumin ≥3.3 g/dL group (referent), the
SGA = B and C + s-albumin ≥3.3 g/dL group was associated with a 2-fold (HR, 2.06;
95% CI, 1.06 to 4.00, P =0.03) increase in mortality risk despite no difference in salbumin levels (3.5±0.2 vs. 3.5±0.3 g/dL, P <0.90). Among the SGA B and C groups
with s-albumin ≥3.3 g/dL or <3.3 g/dL, no statistical difference on mortality risk (P
=0.26) was observed despite the statistical difference in s-albumin levels (3.5±0.3 vs.
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2.8±0.3 g/dL P <.0001). An almost 3-fold increase in mortality risk was observed for
SGA = B and C + s-albumin <3.3 g/dL compared with the SGA = A + s-albumin ≥3.3
g/dL group (HR, 2.86; 95% CI, 1.66–4.94; P <.0001).

There was no statistical difference in mortality risk among any combinations of salbumin (< or ≥3.3 g/dL) and BMI (< or ≥26 kg/m2) categories (P =0.53).

In summary, after adjusting for all variables including age, gender, dialysis modality,
GFR level at which dialysis started, s-albumin, BMI, malnutrition score (SGA B and C),
smoking and all co-morbidities; older age (>65 years; P <0.0001), presence of PVD (P
<0.0001), reduced s-albumin levels (P =0.01) and malnutrition scored as SGA B and C
(P =0.02) independently predicted mortality. Combined effects of SGA A with BMI <26
kg/m2 or s-albumin ≥3.3 g/dL were associated with better survival.

105

Figure 3-2 Adjusted survival curves of the combined effects of SGA and BMI
evaluated at the start of dialysis

Note:
Group 1 versus 2 (P =0.73), group 1 versus 3 (P =0.19), group 1 versus 4
(P =0.02), group 2 versus 3 (P =0.14), group 2 versus 4 (P =0.007),
group 3 versus 4 (P =0.07).
SGA, subjective global assessment: A = well nourished, B & C = malnourished;
2
BMI, body mass index in kg/m .
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Figure 3-3 Adjusted survival curves of the combined effects of SGA and salbumin evaluated at the start of dialysis

Note:
Group1 versus 2 (P =0.51), group 1 versus 3 (P =0.03), group 1 versus 4 (P <0.0001),
group 2 versus 3 (P =0.16), group 2 versus 4 (P =0.004),
group 3 versus 4 (P =0.26).
SGA, subjective global assessment: A = well nourished, B&C = malnourished; Alb =
s-albumin (g/dL).
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3.5

Discussion

Our cohort represented a relatively homogenous group of ESKD patients who showed
an uneventful but gradual decline of renal function with no history of AKI and RRT. We
observed a high prevalence (52.1%) of malnutrition (SGA score B and C) at the start of
dialysis. Malnutrition, together with older age (>65 years), reduced s-albumin levels
and presence of PVD independently predicted mortality over the 10-year study period.
Gender, dialysis modalities, GFR level at which dialysis was commenced, BMI, positive
smoking history, and co-morbidities other than PVD did not show any statistical
significant difference on mortality risk.
In search of the optimal timing for when dialysis should start, the IDEAL trial338
compared the mortality between early (10 to 14 mL/minutes/1.73m2) and late-start (5–7
mL/minutes/1.73m2) groups. The mean GFR of the early- and late-starting group
resulted at 12.0 mL/minutes/1.73m2 and 9.8 mL/minutes/1.73m2, respectively, in the
study because of various clinical and social decisions. No statistical difference in
survival or clinical outcomes was observed between the early- or late-starting groups.
Our cohort study, which included patients with a wider range of clinical implications,
also showed no difference in mortality risk when the analyses were performed at the
GFR cutoff of 7 mL/minutes/1.73m2, as initially planned in the IDEAL trial, or at the cut
off of 8, 9 and 10 mL/minutes/1.73m2. Our results supported the recommendations of
the IDEAL trial and other observational studies337,

341

that with careful clinical

management of ESKD, including nutritional inputs, dialysis can be started at lower
levels of GFR (<7 mL/minutes/1.73m2).145, 342 In agreement to the literature, we found
no significant difference in mortality risk between HD and PD. 14,

303

This suggests

patients should be able to start on either modalities based on their clinical and
psychosocial needs when the time is right.
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The effects of hypoalbuminemia on mortality have been inconsistent in the
literature343-345 because of reasons such as the presence of inflammation (duration and
magnitude), duration and the severity of hypoalbuminmia. The present study indicated
that s-albumin levels were an independent predicator of mortality. This result was
consistent with the findings of a number of studies,15, 332, 344, 346 but differed to others.14,
345, 347

In the latter studies, the predictive effect of s-albumin was ameliorated after

adjusting for CRP, and this may be a limitation of our study because CRP was not
routinely measured. Therefore, the independent predictive effect of s-albumin as solely
nutritional could not be concluded. However, we did consider for other study variables
including the known associates of inflammation such as history of AKI, surgery (PD
catheter insertion), obesity and other co-morbidities. Thus, it is reasonable to speculate
the strong role of poor nutrition, or type I malnutrition caused by a reduced protein and
energy intake75 plays in the predictive effect of s-albumin levels in our study, similar to
other reports in the literature. 330, 335

Similar to previous findings, the SGA rating of malnutrition was found to be an
independent predictor of mortality.14, 346, 348 A sustained reduction of dietary intake is a
major determinant of SGA rating, and as we considered sustained intakes of protein
and energy of less than 80% of requirements as inadequate, it was reasonable to
deduce that the predictive effect of low s-albumin levels constituted a significant
nutrition component. It is possible that type I and type II malnutrition coexist with
nutritional and inflammatory factors compounding the effects on each other, and their
significance cannot be mutually exclusive. We did not examine the effect of the
individual components of SGA on survival, but it is known that these individual
components reflect long-term changes and are highly predictive of mortality and
morbidities, such as unintentional weight loss,330,
poor appetite95,

97

349

reduced dietary intake,15,

159, 350

and muscle wasting.351 Our study supports the use of SGA at the
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start of dialysis as a powerful independent predictor of survival, as previously reported
by other researchers.14, 346, 348
In contrast to the literature,14,

15, 346

diabetes was not observed to be associated with

higher mortality risk in our study. This may be explained by a higher proportion of our
patients with diabetes being well nourished, possibly counteracting the effects of the
uremic wasting on mortality over time. Our results were similar to those of the Dialysis
Outcomes and Practice Patterns Study (DOPPS)

352

which reported diabetic patients

had significantly lower odds of cachectic appearance than non-diabetic patients.
Cardiovascular disease was found to be an independent predictor of mortality in
several studies.14, 153, 346 We found CAD to be significant in the unadjusted analyses
but the significance disappeared in the adjusted analyses (HR, 1.45; 95% CI, 0.94 to
2.1, P =0.10). This can possibly be explained by the unknown duration and severity of
cardiovascular conditions in our cohort. Also our patients were much older (mean age,
was 65.3±13.6 years compared with 50 to 56 years in these studies), and the age
factors may explain some of the variation in our findings. Other reasons could be the
varied observational periods or the heterogeneity of uremia-related nutrition effects
before starting dialysis in previous studies. Such reasons include unplanned initiation of
dialysis due to unforeseen events (e.g., AKI caused by infections and surgical
complications), duration of malnutrition and previous transplantation. It is not clear
whether dialysis was initiated for the same reasons in all patients in reported studies.
The obesity paradox129,

336, 353, 354

has created much debate in the renal community

regarding the protective effect of obesity in ESKD patients. A recent systematic
review355 of the relationship between BMI and mortality supported the inverse
association between BMI and all-cause mortality in adult HD patients, especially in
elderly patients. In other studies,

15, 143, 356

it has been argued that when body

composition was also considered, the possible protective effect of high BMI is limited to
subjects with normal and high muscle mass only. Similar to previous findings,133, 357 our
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study revealed overweight or obesity was not found to have any protective effects, and
when combining with malnutrition scores, it was associated with the worst outcome.
Our findings echoed the high mortality risk found in those with obese sarcopenia. 144 In
addition, the combined effects SGA = A and BMI <26 kg/m 2 were found to have the
best survival advantage. Again, higher BMI did not show protective effects with either
low or normal levels of s-albumin. Most importantly, being well nourished (SGA = A)
was found to be associated with lower mortality risk irrespective of the levels of salbumin and BMI. Our study highlighted the usefulness of the combined effects of
nutritional parameters in predicting outcomes.

There are limitations to our study, the main ones are the lack of measurement of
inflammatory biomarkers (CRP), small sample size, and unknown duration and severity
of lifestyle factors such as smoking history and co-morbidities (e.g., CAD). We also did
not measure the effect of nutrition interventions before and after dialysis initiation.
Patients may respond to nutritional management differently depending on the type,
severity and duration of their nutritional issues, and the degree of exposure to
intervention. Our study points to the need for timely access to structured nutritional
care to prevent and manage nutrition abnormalities well before dialysis is required, and
if it is required, to help maintain nutrition status on the conservative management
pathway.

The strength of this study is the long follow up time in a well defined cohort of patients
experiencing relatively homogeneous nutrition effects before dialysis started. It is a
good example of how informative research can be conducted within the practice of
renal disease care.
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3.6

Conclusions

In the study reported here, a high prevalence of malnutrition among patients with ESKD
at the initiation of dialysis was observed. During a 10-year period, older age (>65
years), reduced s-albumin levels, presence of PVD, and malnutrition scores were found
to independently predict mortality. Other studied factors, such as gender, dialysis
modality, GFR level at which dialysis was initiated, BMI, positive smoking history and
presence all other co-morbidities were not found to be associated with higher mortality
risk. A high BMI was not associated with any survival advantage, and when combined
with the presence of malnutrition, it was associated with the highest mortality risk. The
combined effects of these simple, readily available nutritional parameters were
effective in predicting mortality independently and are highly informative for practice
management and evaluation.

Practical Application:

Malnutrition scored by SGA (B and C) at the start of dialysis was associated with high
mortality risk irrespective of the levels of BMI and s-albumin levels. Being overweight or
obesity did not show any protective effect and was associated with the worst outcome
with the presence of malnutrition. These findings suggest nutrition intervention to
optimise nutritional status should be considered in patients with ESKD well before
dialysis is required.
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3.7 Supplement to Chapter 3

This section (Table 3-4) presents the analyses for the hazard ratios (HR) of the
mortality risks for the combination effects of SGA, s-albumin and BMI. The graphical
presentations are shown in Figures 3-2 and 3-3
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Table 3-4 Cox proportional hazards analysis (multivariate model) of combination factors affecting mortality
Parameters
SGA
A

BMI
<26

A
B&C
B&C
SGA
A
A
B&C
B&C
s-alb
≥33
<33
≥33
<33

≥26
<26
≥26
s-alb
≥33
<33
≥33
<33
BMI
<26
≥26
<26
≥26

n (%)
25 (15.0)
55 (32.9)
69 (41.3)
18 (10.8)
46 (27.5)
34 (20.4)
27 (16.2)
60 (35.9)
41 (24.5)
32 (19.2)
57 (34.1)
37 (22.2)

Parameter
(mean±SD)
BMI
23.2±2.2
31.5±5.8
21.8±2.8
28.4±1.9
s-alb
34.9±2.2
29.1±4.0
35.4±3.4
27.8±3.3
s-alb/ BMIb
35.7±2.8/23.2±2.3
35.0±1.9/31.6±5.7
27.5±3.8/21.7±2.8
28.9±3.3/30.7±4.8

Adjusted HR
(95% CI)a

P

Adjusted HR
(95% CI)a

P

Adjusted HR
(95% CI)a

P

Referent

-

-

-

-

-

1.15 (0.53–2.52)
1.67 (0.78–3.61)
2.96 (1.20–7.33)

0.73
0.19
0.02

Referent
1.45 (0.89–2.38)
2.57 (1.29–5.14)

0.14
0.01

Referent
1.77 (0.95–3.30)

0.07

Referent
1.25 (0.65–2.41)
2.06 (1.06–4.00)
2.86 (1.66–4.94)

0.51
0.03
<0.0001

Referent
1.65 (0.82–3.31)
2.29 (1.30–4.06)

0.16
0.004

Referent
1.39 (0.78–2.46)

0.26

Referent
1.62 (0.83–3.15)
1.33 (0.74–2.36)
1.27 (0.62–2.61)

0.16
0.34
0.58

P
(among groups)
0.04

0.001

0.53

Abbreviations: HR, hazard ratio; CI, confidence Interval; SGA, Subjective Global Assessment, SGA A, well nourished; SGA B&C, malnourished; BMI, body
2
mass index in kg/m ; s-alb, serum albumin (g/L)
a
HR adjusted for age, gender, GFR, albumin, smoking habits, co-morbidities
b
Adjusted survival curves for serum albumin and BMI combination all fell on one line, and show no statistical difference in mortality among any combination.
Therefore, further analysis using different referent(s) were not performed
Expression of figures: n±SD–standard deviation
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Abstract

Objective: To examine the nutritional characteristics of a cohort of pre-dialysis end
stage kidney disease (ESKD) patients.

Setting: Outpatient clinic of a metropolitan tertiary teaching hospital in Sydney,
Australia.

Subjects: All ESKD patients attending the multidisciplinary pre-dialysis assessment
clinic over a six year period between April 2002 and March 2008.

Methods: Retrospective analysis of data extracted from the routine initial nutrition
assessment records. These included anthropometric and biochemical measures,
subjective global assessment (SGA), appetite score, presence of symptoms, dietary
energy, protein, other macro- and micronutrient intakes.

Results: Of the 210 patients assessed, 60.5% were male; mean age was 65.7±13.6
years with a mean glomerular filtration rate (GFR) of 17.3±6.5 mL/min/1.73m2. 17.1%
and 62.4% were underweight (BMI <23 kg/m2) and overweight or obese (BMI ≥26
kg/m2) respectively. 40.5% were rated as malnourished (SGA score B and C) with
19.0% overweight/obese and malnourished. Energy and protein intakes correlated
positively with GFR, being r =0.17, P =0.01 and r =0.29, P <0.0001 respectively. Mean
energy and protein intakes were 23.7±6.7 kcal/kg IBW/d and 1.18±0.42 g/kg IBW/d,
with 62.6% and 13.1% not meeting the recommended intake respectively. 51.0% of
patients experienced symptoms, while 17.5% of patients self-imposed a dietary
regimen inappropriately due to mistaken belief of dietary needs in ESKD. 41.3% and
80.4% did not consume adequate servings of two fruit and five vegetables per day.
Examples of high prevalence of sub-optimal nutrient intake observed were vitamin B2
(41.2%), vitamin E (61.8%), folate (67.6.2%), vitamin D (100.0%), vitamin A (52.9%),
magnesium (94.1%), zinc (64.2%) and dietary fibre (80.4%).
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Conclusion: patients presented to the current pre-dialysis assessment clinic with high
prevalence of abnormal nutrition parameters associated with decreased renal function,
symptoms burden, habitual intake and in some individuals, self-imposed inappropriate
diets. This clinic may provide an opportunity to optimise nutritional status of ESKD
patients before dialysis is required.

4.1

Introduction

Poor nutritional status and presence of protein energy wasting (PEW) at the start of
dialysis are associated with morbidity, mortality and hospitalisation13-15, 99, 133 (including
results of Chapter 3317). Thus, timely nutrition intervention is important in end stage
kidney disease (ESKD) well before dialysis is required. Indeed, nutritional status
deteriorates during the course of decline of renal function,11,

85

and the presence of

nutrition abnormalities is known to associate with adverse outcomes, including
accelerated atherosclerosis,74 mortality and hospitalisation.98 Cross-sectional12,
161, 165

and longitudinal11,

158

85, 160,

studies have established that spontaneous intakes of

protein and energy decline as GFR falls. Furthermore, poor appetite, commonly found
in dialysis-dependent ESKD patients, has been associated with mortality, morbidity and
hospitalisation.95, 96 On the other hand, over-nutrition, such as the presence of obesity
at the start of dialysis, is associated with high mortality risk. 133 However, other
researchers found the protective effect of obesity in patients with ESKD, which is
known as the “obesity paradox”.129 Historically, nutritional intake studies in ESKD
patients have been focused on energy and protein intake. Other nutrients, food
patterns or intake of specific foods such as fruit and vegetables have received relatively
little attention. In order to establish sound clinical practice, it is necessary to gain a
broader insight into nutritional parameters, including dietary intake of energy, protein
and other nutrients, information on food patterns, the presence of symptoms and
clinical indicators of the nutritional status of these patients. Previous studies have
seldom encompassed many of these parameters in one study. It is also worth noting
118

the growing number of elderly patients entering the advanced renal disease care
program4 with additional age-related nutritional health concerns, such as osteoporosis
and sarcopenia.

4.2

Aim

The aim of this study was to examine the baseline demographic, clinical and nutritional
characteristics of a cohort of ESKD patients who attended an outpatient pre-dialysis
assessment clinic. These included the prevalence of various clinical and nutritional
parameters as well their relationship with the decline of renal function.

4.3

Methods

This retrospective study examined clinical and initial nutrition assessment records of all
patients attending an outpatient pre-dialysis assessment clinic established in April 2002
through March 2008. Patients referred by renal physicians to this multidisciplinary clinic
were predominantly in CKD stages 4 and 5 (GFR <30 mL/min/1.73m2) and were
assessed by the clinical nurse consultant, pharmacist, social worker and dietitian.
Exclusion criteria were those patients who missed the dietitian assessment, incomplete
or unreliable assessment data, or late referral to the pre-dialysis assessment team
during acute hospital admission, with dialysis expected to start within next 1–2 months.

Demographic, clinical and nutrition data collected from hospital records included age,
gender, race, smoking habits and presence of co-morbidities, e.g., coronary artery
disease (CAD), diabetes mellitus (DM), chronic lung disease (CLD) and peripheral
vascular disease (PVD). Nutritional data included for analyses were: anthropometric
measures, e.g., height (m); oedema-free body weight (kg); body mass index (BMI
weight  height2, [kg/m2]) and weight history; mid-arm circumference (MAC) and triceps
skinfold (TSF). Mid-arm muscle circumference (MAMC) was calculated using the
following formula: MAMC (cm) = MAC (cm) – 0.314 x TSF (mm). The clinical practice
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guidelines205 define a healthy range for BMI of 22–26 kg/m2; therefore BMI ≥26 kg/m2
was treated as overweight. Prevalence of renal-specific BMI categories205, 310 were also
examined with undernourished, ideal range, overweight and obese defined as BMI
<23, 23–26, 26–30 and ≥30 kg/m2 respectively. Muscle wasting was classified as
MAMC >10% and <50th percentile of the reference standard for age and gender.309, 310
Blood results closest to and within 2 months of the clinic were extracted from clinical
notes; these included serum-albumin (s-albumin) and serum creatinine to calculate
GFR using the Cockcroft-Gault equation.300 Approximately 50% of the blood tests were
analysed in private providers instead of the hospital-based laboratory; thus, different
analytical methods used for s-albumin with different reference ranges. Therefore, for
the s-albumin levels, both actual figures plus whether they were below or within
reference ranges were recorded for analysis. The renal dietitian(s) (mainly the author
MC) performed the subjective global assessment (SGA),147,

149

which categorised

patients as A = well nourished, B = mild-moderately and C = severely malnourished,
based on the patient’s medical history and physical examination. The prevalence of
combined malnutrition (SGA score = B and C) and BMI (<26 kg/m2 vs. 26 kg/m2) were
also examined. Patients’ subjective rating of appetite was assessed using the Appetite
and Diet assessment Tool with a 5-point Likert scale:238 (1) very good, (2) good, (3) fair,
(4) poor and (5) very poor; its relationship with energy and protein intake was also
evaluated (see supplement to Chapter 4). For easy comparison, appetite scores were
combined into “good appetite” (very good and good) versus “reduced appetite” (fair,
poor and very poor). The presence of other nutrition-related symptoms were also
assessed, e.g., nausea and taste aversion. A “typical day’s dietary intake” was
assessed by the dietitian using a structured diet history or diet interview method,242-245
taking into account food frequency and weekend variations. Food pictures and models,
household metric measuring cup and spoons were used to assist serving size
estimation. Structured diet history method is considered to be a feasible method for the
initial outpatient clinic visit compared with the 3-day food record used in other
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studies.12, 165 Urinary nitrogen excretion was not routinely collected in our unit, so we
were not able to measure nitrogen appearance to estimate protein intake as in previous
studies.158,

160

Dietary intake data were analysed using a computerised nutrient

analyses program (FoodWorks Professional Model 2009, Xyris, Brisbane, Australia) to
estimate energy intake (EI), dietary protein intake (DPI) and intake of other nutrients. EI
and DPI intakes were expressed in kcal and g per kg IBW (ideal body weight) per day
or kcal/kg IBW/d and g/Kg IBW/d respectively. For overweight patients, adjusted body
weight (adjusted BW) was used instead of IBW; adjusted BW = IBW + [(oedema-free
BW – IBW) x 0.25].205, 230

To evaluate possible underreporting, the ratio of EI to resting energy expenditure
(REE) was calculated using the Schofield equation.312 An EI:REE ratio less than 1.27
(known as the Goldberg cut-off value)358, 359 may indicate possible underreporting of EI;
if an EI:REE <1.27 was present, other explanations of low EI were also reviewed, e.g.,
presence of symptoms and physical inactivity defined as physical activity level (PAL)
equal or less than 1.5. PAL is the estimated total energy expenditure (TEE) divided by
basal metabolic rate (BMR).227,

311

In the current study, PAL was rated according to

patients’ description of their typical daily physical activity including any participation in
leisure or structured exercise programs. Average daily consumptions of fruit, vegetable
and fish were surveyed and compared to the Australian Guide of Health Eating
recommendations of “two fruit and five vegetables”360 and the American Heart
Association’s “Healthy diet goals”361 of at least two servings of fish per week
(equivalent to approximately 30 grams per day).
All statistical tests were performed using the statistical software IBM© SPSS© Statistics
version 20. Continuous variables were expressed as mean ± standard deviation for
normally distributed data and comparisons between groups were performed using
unpaired sample t-tests. Categorical variables were compared using the 2 test.
Correlations between GFR and dietary energy and protein intakes were estimated
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using Pearson correlation coefficients. Analysis of variance (ANOVA) was used to
compare the parameters among three to four categories. The positive predictive values
(PPV) of appetite score for adequate energy (>25 g/kg IBW/d)310 and protein intake
(>0.75 g/kg IBW/d)205 were assessed using the two-way contingency analysis table.315
P values <0.05 were taken as showing a statistically significant difference. This study
was approved by the ethics committee of the South Eastern Sydney and Illawarra
Area Health Service, NSW, Australia.

4.4

Results

Two hundred and twenty-seven patients attended the pre-dialysis assessment clinic
during the study period. Two hundred and ten patients were assessed by the dietitian
with 206 reliable dietary assessment records available for computerised nutrient
analysis. Patients were predominantly (56.5%) in CKD stage 4 (GFR 15–30
mL/min/1.73m2) followed by 38.2% in stage 5 (GFR <15 mL/min/1.73m2) with a mean
GFR of 17.3±6.5 mL/min/1.73m2. Table 4-1 summarises the demographic and clinical
characteristics of these patients. The majority of patients (64.3%) were older than 65
years of age (range 17.7 to 88.1) and diabetic nephropathy was the main cause of
ESKD (24.2%).

122

Table 4-1 Demographic and clinical data of patients attending the pre-dialysis
assessment clinic
Parameters
Demographic
Age (year)
Age >65 year (%)
Age >75 year (%) in total sample
Gender (% male)
* Race (% Caucasian)
Clinical and co-morbidities (%)
GFR (mL/min/1.73m2), n =207
CKD stages 3:4:5 (%), n =207
Smoking (% positive history), n =188
Coronary artery disease (%)
Diabetes mellitus (%)
Peripheral vascular disease (%)
Cerebral vascular disease (%)
Chronic lung disease (%)
Cause of ESKD
Chronic glomerulonephritis (%)
Diabetic nephropathy (%)
Renovascular disease/ hypertensive nephrosclerosis (%)
Adult polycystic kidney disease (%)
Analgesic nephropathy (%)
IgA nephropathy (%)
Reflux nephropathy/congenital abnormality (%)
Other or unknown causes (%)

n =210
65.7±13.6
64.3
28.1
60.5
85.7
17.3±6.5
5.3:56.5:38.2
45.7
34.8
35.2
17.1
16.2
10.5
16.7
24.3
21.4
5.2
4.8
9.5
6.2
11.9

Remark: Chinese (6.2%), Egyptian (1.9%), Indian (2.4%),
Maori / New Zealander (2.4%), Pilipino (1.0%), Others (1.4%)
Expression of figures: n±SD–standard deviation

A high prevalence of nutrition abnormalities was found in this cohort. As shown in
Table 4-2, 21.5% of patients’ body weights were within the ideal weight range of BMI
(23.0–26.0 kg/m2) and 31.4% of patients were obese. The prevalence of malnutrition
was high, with 36.7% and 3.8% rated as mildly to moderately (SGA = B) and severely
(SGA = C) malnourished respectively. 19.0% of patients were overweight and
malnourished.

Within

the

malnourished

group,

47.1%

of

patients

were

overweight/obese, and within the overweight/obese group, 30.5% of patients were
rated as malnourished. 29.1% of patients reported various degrees of unintentional
loss of BW 6 months prior to the clinic with an additional 3.8% of patients reporting a
sustained weight loss of more than 5% in the past, but stabilised in the 6 months prior
to the clinic. 37.3% of patient had s-albumin levels below the reference range.
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According to the PEW criteria310 based on MAMC <90% standard, 28.4% of patients
were classified as muscle-wasted, whereas under the SGA physical examination
component, 46.7% of patients scored various degrees of muscle wasting, including
mild (31.9%), moderate (8.1%) and severe (6.7%) categories.

Approximately 14.8% of patients reported having previous contact with dietitian(s) for
various diet interventions, such as lipid lowering and diabetes disease management as
an outpatient or acute inpatient of undefined history, duration and frequency. However,
these contacts rarely (<5%) related to CKD stage 4 or 5 dietary management with
structured care and regular follow-up. Therefore, all of these data were considered as
spontaneous intake. As expected, energy and protein intake correlated significantly
with GFR: r =0.17, P =0.01 (Figure 4-1) and r =0.29, P <0.0001 (Figure4-2)
respectively. However, as shown in Table 4-4, energy and nutrient intake and food
habits varied vastly among individuals. Mean EI was low at 23.7±6.7 kcal/kg IBW/d with
87.9% of patients having an EI below the recommended ~35 kcal/kg IBW/d for <60
years of age and ~30 kcal/d for >60 years of age. 205,

216

According to the PEW

classification310 of no less than 25 kcal/kg IBW/d, 62.6% of patients had insufficient EI.
76.2% of patients had an EI:REE ratio (Goldberg cut-off) <1.27 and 41.7% had an EI
below REE (ratio <1.00). However, further analysis indicated that these patients, when
compared to those with an EI:REE ratio >1.27, had significantly higher prevalence of
malnutrition (45.2% vs. 26.5%, 2=5.4, P =0.02). Furthermore, the majority of patients
(88.3%) were very inactive, with a PAL of 1.5 (sedentary) or less (very sedentary or
bed-/chair-ridden), and 22.8% reported a reduced physical function under the SGA
sub-category of physical function rating.
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Table 4-2 Nutritional characteristics of patients attending the pre-dialysis
assessment clinic
Nutritional parameters (n missing)
n = 210
Anthropometry
Weight (kg)
76.1±17.0
Unintentional weight loss (presence of) in last 6 months (%)
29.1
Unintentional weight loss >5% in last 6 months (%)
8.1
Unintentional weight loss >5% in the past but stabilised
3.8
6 months before clinic (%)
Body mass index (kg/m2)
28.1±5.7
BMI <23 kg/m2 (underweight)
17.1
2
BMI >26 kg/m (overweight & obese)
62.4
BMI >30 kg/m2 (obese)
31.4
MAMC (cm) (n =14)
24.9±3.7
MAMC % reference standard (%) (n =14)
97.8±14.1
MAMC 10% < reference standard (%) (n =14)
28.6
TSF (mm) (n =14)
16.1±8.6
TSF % reference standard (n =14)
108.5±55.5
Biochemistry
Serum creatinine (µmol/L) (n =1)
389.3±121.7
Serum albumin (g/L) (n =1)
34.4±6.0
Serum albumin below reference range (%) (n =1)
37.3
Malnutrition score
( %)
SGA A:B:C (%)
59.5:36.7:3.8
Malnourished (SGA B and C)
40.5
2
Malnourished + BMI >26 kg/m
19.0
Malnourished + BMI >30 kg/m2
9.5
Expression of figures: n±SD–standard deviation

Table 4-3 Appetite score and presence of symptoms
Appetite score: self-rated
n =210 (%)
(1) Very good
31.0
(2) Good
39.0
(3) Fair
23.3
(4) Poor
5.7
(5) Very poor
1.0
Combined:
(1)+(2) = Good appetite
70.0
(3)+(4)+(5) = Reduced appetite
30.0
Symptoms and behaviour
(%)
Presence of symptom (self-reported):
Nausea
20.0
Taste aversion
20.0
Total (compromised appetite and/or nausea and/or taste aversion)
38.6
Presence of symptom (self-reported + prompting by dietitian during
51.0
intake assessment)
Inappropriate self-imposed diet
Restrictive
15.7
In excess
1.4
Total
17.1
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Table 4-4 Dietary Intake of patients attending the pre-dialysis assessment clinic
Energy/ nutrients/ foods
(n =206 for protein and
energy; n missing =2 for all
other parameters)
Energy (kcal/d)
Energy (kcal/kg IBW/d)
EI:REE
Protein (g/d)
Protein (g/kg IWB/d)
Protein (% energy)
Fat (% energy)
Carbohydrate (% energy)
Alcohol (% energy)
Monounsaturated fat (%
total fat)
Polyunsaturated fat (% total
fat)
Saturated fat (% total fat)
Thiamine, Vit. B1 (mg)
Riboflavin Vit. B2 (mg)
Niacin (mg)
Folate (µg)
Vitamin A (µg)
Vitamin C (mg)
Vitamin D (µg)
Vitamin E (mg)
Calcium (mg)
Phosphorous (mg)
Iodine (µg)
Iron (mg)
Magnesium (mg)
Phosphorous (mg)
Zinc (mg)
Dietary fibre (g/d)
Fruit (serves/d)
Vegetable (serves/d)
Fish (g/d)

Recommendation

Intake/day
mean±SD

Mean, %
recommended

30 for >60 yr*‡
35 for <60 yr*‡
>25†‡
>1.27
(Goldberg cutoff)
0.75–1.00*‡

1575.2±240
23.7±6.7

-

% below
recommendation
(or above if
indicated)
87.9

1.06±0.27

-

62.6
42.7

79.2±31.5
1.18±0.42

119.0±51.3

15–20‡
~30‡
~50‡
~45‡

20.3±4.3
31.7±7.5
46.8±8.7
1.2±3.5
42.5±8.2

-

13.1
(61.2 >
recommendation)
-

~45‡

22.9±8.8

-

-

<7§
1.1–1.2¶
0.9–1.6¶
14–16¶
400¶
700–900¶
45¶
5.0 (19–50yr)¶
10–15 (>50 yr)¶
7–10¶
1000–1300¶
1000 ¶
150¶
8¶
18 for female
(19–50yr) ¶
310–400¶
1000‡
8–14¶
25–30¶
2**
5**
30g§

34.7±10.3
1.6±1.2
1.7±1.4
44.7±26.6
395.1±356.3
890.4±553.7
100.3±72.6
3.1±2.5

137.6±99.7
132.5±112.9
280.8±120.1
98.8±89.1
108.4±67.0
222.6±160.4
31.8±33.6

36.8
41.2
1.0
67.6
52.9
22.1
100.0

8.2±4.0
543.4±277.5
1136.4±441.2
77.7±44.6
10.46±5.6

94.1±45.5
47.8±27.5
114.0±43.5
52.6±29.7
120.1±47.9

61.8
96.6
40.7
94.6
36.3

247.8±83.8
1129.2±458.3
11.2±9.0
21.4±8.4
2.0±1.5
2.8±1.5
33.6±52.5

65.2±20.5
116.8±78.6
90.6±39.3
76.0±29.3
101.7±70.0
54.75±29.7
110.7±175.0

94.1
41.6
64.2
80.4
41.3
89.2
60.8

216

* K/DOQI guidelines
310
† PEW classification
205
‡ Evidence-based practice guidelines for the nutritional management of chronic kidney disease
361
§ American Heart Association
¶
362
NH&MRC nutrient reference values for the general Australian population
360
** Go for 2 fruit & 5 vegetables™ campaign
Expression of figures: n±SD–standard deviation; n(n1-n2)- range
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Figure 4-1 Energy intake and glomerular filtration rate
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r =0.17, P =0.01
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▲ Denotes patients with self-imposed inappropriate intake

Figure 4-2 Protein intake and glomerular filtration rate
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r =0.29, P <0.0001
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The mean protein intake was 1.18±0.42 g/kg IBW/d with 13.1% below and 61.2%
above the ideal range of 0.75–1.00 g/kg IBW/d.205 4.9% of patients consumed less than
the 0.6 g/kg IBW/d level traditionally prescribed for a low protein diet.206
For self-rated appetite scores of “very good” (31.0%), “good” (39.0%), “fair” (23.3%),
“poor” (5.7%) or “very poor” (1.0%), the mean EI were 25.4±6.0, 24.2±6.7, 22.0±6.8,
19.4±6.2 and 14.9±1.8 kcal/kg IBW/d respectively (P =0.002), whereas the mean
protein intakes were 1.32±0.36, 1.17±0.44, 1.13±0.44, 0.86±0.25 and 0.57±0.18
respectively (P =0.001). For the combined appetite scores, 70.0% rated “good appetite”
(“very good” and “good”) whereas 30.0% rated “reduced appetite” (“fair”, “poor” and
“very poor”) with mean energy and protein intakes of 24.7±6.5 vs. 21.3±6.7 kcal/kg
IBW/d (P =0.001) and 1.24±0.42 vs. 1.06±0.42 g/kg IBW/d (P =0.006) respectively. The
PPVs of “good appetite” score for adequate energy and protein intakes were 0.41 (95%
CI: 0.36–0.45, P =0.104) and 0.92 (95% CI: 0.88–0.95, P =0.005) respectively. This
means, among those who rated “good appetite” (n =143), approximately 41% of
patients consumed adequate energy and the rest perceived “good appetite” but did not
consume adequate energy. Appetite score for identifying adequacy of protein intake
appeared satisfactory (see Section 4.7, supplement to Chapter 4).

In addition to the reduced appetite, patients also reported the presence of classic
symptoms of uraemia, including nausea (20.0%) and taste aversion to food (20.0%).
These led to approximately 38.1% of patients reporting the presence of symptoms
including reduced appetite, and/or nausea and/or taste aversion. However, with further
prompting during the in-depth dietary intake assessment by the dietitian, a total of
51.0% of patients and/or their carers disclosed “problems” with eating of various
degrees. The mean intakes of energy and protein between the “no symptom” versus
“presence of symptom” groups were 25.7±6.3 vs. 21.8±6.3 kcal/kg IBW/d (P <0.0001
and 1.33±0.42 vs. 1.05±0.39 g/kg IBW/d (P <0.0001) respectively.
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Between the BMI <26 kg/m2 and the overweight/obese (BMI ≥26 kg/m2) groups, energy
intake was 25.1±7.2 vs. 22.9±6.3 kcal/kg IBW/d (P =0.02), and protein intake was
1.24±0.47 vs. 1.15±0.39 g/kg IBW/d (P =0.14) respectively. It appears that
overweight/obese patients consumed significantly less energy per kilogram of weight
compared to patients with BMI <26 kg/m2 while protein intake was similar. However,
there was no difference in the total intake of energy (1589.2±491.7 vs. 1569.1±476.0
kcal/d, P =0.75) or protein (79.3±34.2 vs. 79.2±30.0 g/d, P =0.98).

Furthermore, during the in-depth dietary intake assessment, 17.1% of patients were
found to impose inappropriate dietary regimens due to misconceptions of nutrition
knowledge for ESKD. Examples of inappropriate restriction (15.7%) included: severe
reduction of total fat and sugar intake being mistaken for good eating habits or for lipidlowering or weight management; limiting fruit and vegetables to control serum
potassium when it was not required; and/or severe limiting of protein foods, especially
red meat, in an attempt to manage kidney disease. Inappropriate excess food intake
(1.4%) was found in diabetic patients to avoid hypoglycaemia (“hypos”) and the use of
a high protein-low carbohydrate diet for controlling weight. The sources of confusion
mainly came from advice from relatives or friends, other health care practitioners and
from misinterpreting information from the Internet. The inappropriate intake group,
when compared with the spontaneous intake group, had significant reduced mean
intake of energy and protein of 21.2±4.0 vs. 24.2±7.1 kcal/kg IBW/d (P =0.02) and
1.02±0.33 vs. 1.22±0.44 g/kg IBW/d (P =0.01) respectively. The “▲” symbol shown in
Figures 4-1 and 4-2 represents the inappropriate energy and protein intakes among all
patients, and the majority of self-imposed dietary restrictions had led to suboptimal
intake. Within this group of 33 patients, 54.5% were rated as malnourished, mainly as a
consequence of self-induced poor intake.

Regarding the other nutrient intakes, the mean intakes of folate, vitamin D, vitamin E,
calcium, iodine, magnesium, zinc and dietary fibre were below the RDI. 311 A high
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proportion of patients did not meet individual nutrient requirements, in particular for
vitamin B1 (36.8%), vitamin B2 (41.2%), vitamin E (61.8%), folate (67.6.2%), vitamin D
(100.0%), vitamin A (52.9%), magnesium (94.1%), zinc (64.2%) and dietary fibre
(80.4%). 41.3% of patients did not consume the recommended two serves of fruit and
89.2% did not consume five serves of vegetables each day. 40.1% of patients had less
than five daily serves of bread/grain products, and consumed predominately refined
forms of carbohydrates, e.g., white bread and pasta. 60.8% of patients consumed less
than the recommended servings of fish (equivalent to 30 g/day). Many of these patients
reported inadequate fruit, vegetables and fish intake as their food habits. However the
prevalence was not available for all patients due to the retrospective nature of the
study.
Across the four categories of GFR range: <10, 10–15, 15–20 and >20 mL/min/1.73m2
(Table 4-5), patients in later stages of CKD or lower GFR levels were generally older,
had lower protein intake, lower BMI and other anthropometric measures. The
prevalence of malnutrition and presence of symptoms were also increased as GFR
decreased; and were high in all groups. No statistical difference was observed across
all groups for the mean EI (P =0.18), which was suboptimal in the majority of patients.

Among the three age groups: <65, 65–75 and >75 years (Table 4-6), anthropometric
measures such as BMI and MAMC (% standard) were lower in the >75 year age group,
but no statistical difference was found in the TSF (% standard) among the three
groups. This reflected that older patients were more likely to be muscle-depleted, but
not necessarily lower in their fat stores. No statistical difference was observed for
dietary protein and energy intakes between the 65–75 vs. ≥75 year age groups, but
these were significantly lower than the <65 year age group (P <0.05).
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Table 4-5 Demographic, clinical and nutritional parameters in different GFR
ranges
GFR (mL/min/1.73m2)
n (% of 209 total)
(n missing)
Mean GFR
(mL/min/1.73m2)
Age (year)
Serum creatinine (µmol/L)
s-alb (g/L)
s-alb below reference
range (%)
BMI (kg/m2)
MAMC (% of standard)
(n =14)
TSF (% of standard)
(n =14)
Malnourished, SGA score
B and C (%)
Presence of symptom (%)
Energy (kcal/kg IBW/d)
(n =15)
Protein (g/kg IBW/d)
(n =15)

<10
20 (9.5%)

10–15
62 (29.7%)

15–20
69 (33.0%)

>20
58 (27.8%)

P value

8.4±1.4

12.5±1.4

17.4±1.4

25.1±5.7

n/a

71.2±13.9
604.3±152.4
30.4±6.6
65

70.8±12.4
437.6±79*
34.9±6.2*
38.7

66.9±11.8
361.2±72*†
34.0±6.4
39.1

57.4±13.3*†‡
297.5±71.0*†‡
35.7±4.4*
24.1

<0.0001
<0.0001
0.006
0.01

22.7±2.9
87.7±8.4

26.1±4.3
95.1±13.2

29.0±4.9*†
99.4±13.5*

30.8±6.7*†
103.0±15.4*†

<0.0001
<0.0001

68.0±24.9

95.0±47.1

118.0±53.5*

126.4±64.9*†

<0.0001

80.0

48.4

29.0

31.0

75.0
21.6±8.5

56.5
23.0±6.0

45.0
23.64±6.6

43.1
25.10±6.8

0.05
0.18

0.95±0.37

1.08±0.34

1.24±0.46*

1.31±0.44*†

0.001

<0.0001

Abbreviation: GFR = glomerular filtration rate; s-alb = serum albumin; BMI = body mass index;
MAMC = mid-arm muscle circumference; TSF = triceps skinfold; SGA = subjective global
assessment
For the continuous variables:
2
* P <0.05 as compared with the GFR <10 mL/min/1.73m group
2
† P <0.05 as compared with the GFR =10–15 mL/min/1.73m group
2
‡ P <0.05 as compared with the GFR =15–20 mL/min/1.73m group
Expression of figures: n±SD–standard deviation
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Table 4-6 Demographic, clinical and nutritional parameters across different age
categories
Age group (year)
<65
n (% of 210 total)
75 (35.6)
(n missing)
Age (year)
50.6±10.4
GFR (mL/min/1.73m2)
20.3±6.8
Serum creatinine (µmol/L)
400.0±146.0
s-alb (g/L)
35.4±6.9
s-alb < reference range (%)
29.7
BMI (kg/m2)
28.4±6.9
MAMC (% of standard)
100.6±16.2
(n =14)
TSF (% of standard)
108.7±55.4
(n =14)
Malnourished, SGA score B or C
21.3
(%)
Presence of symptom (%)
32.0
Energy (kcal/kg IBW/d)
27.9±6.8
(n =4)
Protein (g/kg IBW/d)
1.44±0.44
(n =4)

65–75
77 (36.7)

>75
58 (26.7)

P value

70.3±3.0*
16.7±4.8*
376.2±0.094
36.0±5.5
37.7
29.3±4.9
98.7±12.7

79.1±3.0*†
13.5±4.9*†
394.2±120.6
35.7±3.4
46.4
26.0±5.7*†
93.5±12.2*

<0.0001
<0.0001
0.48
0.85
0.14
0.003
0.02

117.7±54.4

95.8±55.6

0.08

48.1

55.2

66.2
21.2±5.9*

55.2
21.8±4.9*

<0.0001
<0.0001

1.07±0.39*

1.01±0.43*

<0.0001

<0.0001

Abbreviation: GFR = glomerular filtration rate; s-alb = serum albumin; BMI = body mass index;
MAMC = mid-arm muscle circumference; TSF = triceps skinfold; SGA = subjective global
assessment
For the continuous variables:
* P <0.05 as compared with the age <65 year group
† P <0.05 as compared with the age =65–75 year group
Expression of figures: n±SD–standard deviation

The relationship of demographic, clinical and nutritional parameters between the wellnourished and malnourished groups are summarised in Table 4-7. Patients in the
malnourished group were older and had lower GFR, s-albumin and anthropometric
measures such as BMI, MAMC and TSF. A significantly higher proportion of these
patients experienced symptoms and had reduced intake of protein and energy.
However, there was no statistical significance in the presence of co-morbidities except
a trend of a higher prevalence of CAD (P =0.06) in the malnourished group.

Prevalence of malnutrition (SGA B or C) and presence of symptoms were higher in the
older groups, probably due to lower GFR. No statistical difference was observed for
serum creatinine and s-albumin among the two groups.
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Table 4-7 Subjective global assessment score and demographic, clinical and
nutritional parameters
SGA
(n =210)
(n missing)
n (%)
Age (year)
Gender (% male)
GFRCG (mL/min/1.73m2)
(n =1)
Serum creatinine (µmol/L)
(n =1)
s-alb (g/L)
(n =1)
s-alb < reference range (%)
(n =1)
BMI (kg/m2)
MAMC (% of standard)
(n =14)
TSF (% of standard)
(n =14)
Presence of symptom (%)
Energy (kcal/kg IBW/d)
(n =5)
Protein (g/kg IBW/d)
(n =5)
Smoking, positive history (%)
Co-morbidities
Chronic lung disease (%)
Coronary artery disease (%)
Peripheral vascular disease (%)
Cerebral vascular disease (%)
Diabetes mellitus (%)

A
(well-nourished)
125 (59.5%)
62.7±13.8
58.4%
18.8±6.5

B&C
(mildly to moderately
malnourished)
85 (40.5%)
70.3±12.0
63.5%
14.9±5.7

P value
<0.0001
0.46
<0.0001

0.371±92.9

416.3±151.6

0.008

35.1±5.9

33.3±6.0

0.04

32.0

45.2

0.05

29.3±5.4
101.1±14.6

26.2±5.6
93.3±12.0

<0.0001
<0.0001

120.5±58.4

91.5±46.5

<0.0001

28.0
25.7±6.7

84.7
20.8±5.6

<0.0001
<0.0001

1.31±0.43

1.00±0.35

<0.0001

46.6

44.6

0.78

10.4
29.6
16.0
15.8
36.0

10.6
42.4
18.8
15.3
34.1

0.97
0.06
0.59
0.77
0.78

Abbreviation: GFR = glomerular filtration rate; s-alb = serum albumin; BMI = body mass index;
MAMC = mid-arm muscle circumference; TSF = triceps skinfold; SGA = subjective global
assessment
Expression of figures: n±SD–standard deviation

4.5

Discussion

The main goals of nutrition management in ESKD are to maintain optimal nutritional
status, to preserve renal function and to achieve therapeutic targets. Findings of the
current study indicated that patients presented to the pre-dialysis assessment clinic
with high prevalence of suboptimal intake, nutrition abnormalities, malnutrition and
parameters indicative of poor nutritional health. The magnitude of these nutritional
issues increased as renal function deteriorated.
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Our cohort was more advanced in age (65.7±13.6 years) and stages of CKD (mean
GFR =17.3±6.5) compared with the majority of previous studies (mean age of 50–55
years and GFR of 20–55 mL/min/1.73m2 except in one study).85 In our study, nutritional
status deteriorated as renal function decreased, in particular once GFR levels fell
below

mL/min/1.73m2;

20

literature.12, 85,
individuals;

165

the

this

is

in

line

with

the

findings

in

the

GFR levels at which symptoms emerged varied enormously among
prevalence

increased

dramatically

once

GFR

fell

below

15 mL/min/1.73m2. However, we also found 45% of patients with a GFR of
>20 mL/min/1.73m2 experienced symptoms. Presence of symptoms was found in a
patient with a GFR as early as 41.6 mL/min/1.73m2, while some patients appeared
fairly symptom-free with a GFR below 10 mL/min/1.73m2.
Consistent with the literature,11, 12, 85, 158, 160, 163, 165 spontaneous DPI decreased as GFR
fell, with an average DPI of 1.18±0.42 g/kg IWB/d. The mean EI was comparable to
that reported in the literature,12, 161, 163, 165, 363 with a significant number of our patients
consuming less energy than recommended.205, 206, 310 Despite 76.2% of patients having
an EI:REE ratio of less than 1.27 – the Goldberg cut-off indicating possible
underreporting as described by other researchers,163,

359

the suboptimal intake of our

patients could largely be explained by the high prevalence of malnutrition accompanied
by unintentional weight loss, muscle wasting, high symptom burden and physical
inactivity. These observations were supported by a previous finding112 that lean body
mass (LBM), bone mineral content and basal EE were lower in patients with CKD
(mean GFR 23.9±2.6 mL/min/1.73m2) compared with pair-matched controls. This
observation is further supported by a study that showed the commonly-used REE
equations were found to over-predict REE in CKD patients.364 Since no inflammatory
marker, such as C reactive protein (CRP), was measured, the inflammation state of our
patients was not known to interpret its effect on appetite, EI, REE, nutritional status, or
its relationship with co-morbidities. Unfortunately, from observation, many of our
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patients mistakenly perceived a low EI was an acceptable effect of aging on lower food
intake and physical inactivity and failed to recognise the presence of uraemic
symptoms. Even more confusing was that in the overweight/obese patients, a reduced
intake could be a combination of intentional limiting of EI to control weight and
unintentional reduction due to uraemia. Similar to a previous finding,359 our overweight
and obese patients had a significant lower EI than the healthy weight group.
Malnutrition within the overweight/obese group was prevalent at 30.5%; this
observation could not be ignored as being overweight and malnourished at the start of
dialysis has been associated with high mortality risk.317
An optimal level of protein in the diet of 0.75–1.00 g/kg IBW/d205 is recommended for
this population to control uraemia and symptoms;178, 184 most importantly, this must be
accompanied by an adequate intake of energy to maintain nitrogen balance. 178, 205, 216
37.9% of patients met the protein requirements but the majority (90.6%) did not meet
energy requirements. On the other hand, 43.7% of patients consumed protein above
this level but EI was poor. The undesirable combination of excess protein and low
energy intakes has been associated with adverse parameters in patients with
advanced CKD.166, 365

It appears that the significant protein intake reduction occurred after GFR fell below
20 mL/min/1.73m2; this is in line with the findings that normalised protein catabolic rate
(nPCR) dropped when creatinine clearance (CrCl) fell below 25 mL/min11 and ended in
a dramatic decline when CrCl reached 15 mL/min.158 It is generally accepted that
uraemia causes spontaneous reduction or self-limiting of DPI; however in our cohort,
despite a total reduction of total energy or food intake, protein intake remained
excessive in 61.2% of patients, even those with reported reduced appetite and
symptoms. This could partly be explained by the high habitual protein intake of the
average Australian adult as reported in the national dietary survey – almost twice the
RDI level of 0.75 g/kg/d.366, 367 Again, excess protein intake has been associated with
135

more rapid renal function deterioration and mortality even in early CKD,368,

369

and

increased uraemic toxins.184 Therefore, timely intervention to optimise dietary intake is
recommended.
Both the ADAT 5-point Likert scale appetite score and the combined “good appetite”
vs. “reduced appetite” score were found to be useful in ranking energy and protein
intake, and were useful in identifying adequate protein intake but not EI (see Section
4.7). These findings suggested subjective rating of appetite is insufficient to reflect
adequate intake in a population with a gradual onset of symptoms; thus skilled diet
history-taking and structured interview should form an essential part of nutritional
assessment.

Abnormal vitamin and mineral status, including retention and deficiency, are common
in patients with ESKD,370, 371 and are associated with increased morbidity and mortality.
Examples include low vitamin D levels and increased CVD risk,372-374 folic acid
deficiency relating to anaemia,375 elevated homocysteine and increased CVD risk,375
and iron deficiency relating to resistance to recombinant erythropoietin (rHuEPO) to
correct anaemia.376 Despite the “mean” intake of many nutrients appearing satisfactory,
a significant percentage of patients did not meet the RDI of these nutrients (Table 4-4).
The Lipid Lowering and Onset of Renal Disease (LORD) trial163 baseline data
suggested underreporting was responsible for the low levels of nutrient intake.
However, we consider our results close to the true intake as our patients were more
advanced in age (65.7±13.6 vs. 60.0±15.0 years) and in later stages of CKD (GFR
17.3±6.5 vs. 40.3±19.4 mL/min/1.73m2) compared to those in the LORD study, and
also had high symptom burden.

Obesity and diabetes in CKD stages 2–5 are strongly associated with hypovitaminosis
D;377 our cohort had high prevalence of obesity and suboptimal vitamin D intake, thus
their vitamin D statuses were likely to be poor. However, further study is required to
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confirm such deduction with estimates on sunlight exposure and blood vitamin D levels.
Consumption of the core foods such as fruit and vegetables, the key contributors of
antioxidants, phytochemicals, folates and dietary fibre, were poor in a large number of
our patients. Thus, these patients were likely to have elevated levels of oxidative stress
due to deficiency of these nutrients and antioxidants.378 It was challenging to identify
the duration and reason of such suboptimal intake, if these were a result of uraemia
and/or long-term poor eating habits similar to that reported in national health surveys in
the general population.379,

380

An adequate fruit and vegetable consumption is

recommended as it has an alkali-inducing effect that is comparable to sodium
bicarbonate in decreasing markers of kidney injury.381, 382 A high dietary fibre intake has
also been associated with reduced risk of inflammation and mortality in patients with
CKD.383, 384 Moreover, the promising results of a prospective randomised study with a
Mediterranean diet further convince healthy eating to improve dyslipidaemia, markers
of inflammation and lipid peroxidation in stages 1–3 CKD patients.385 Data collection for
vitamin and mineral supplementation was incomplete for discussion. While some of
these supplements are necessary to correct certain clinical conditions in ESKD, they
cannot replace optimal intake of adequate energy, essential nutrients and food
components from diet.
The majority of our patients were on a “free” diet prior to the initial clinic visit and
presented with parameters indicative of poor nutritional health. The possible cause was
a combination of advancing age, presence of uraemia and other symptoms, poor
eating habits and self-induced inappropriate diet regimens. It is a common stigma in
the renal community that dietary intervention in CKD implies restriction, which could
cause malnutrition. Based on the evidence from the literature and results of the current
study, for CKD patients to stay on a “free” diet or “free” from nutrition intervention is
unlikely to achieve optimal nutrition; worse, this may even cause a missing diagnosis of
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malnutrition and “self-induced” nutrition abnormality in these patients. All these factors
will have carry-on effects after dialysis initiation and predict poor outcomes.

Malnutrition is common in this population, with 40.5% of the studied patients rated as
malnourished, a result similar to those reported in the literature.85 Nutrition
requirements are indeed altered in ESKD and change over time. Although there is
much debate about the timing of initiation and type of nutrition intervention in ESKD,
before all the answers from high level of evidence are available, it appears logical to
incorporate

“healthy

eating”

explicitly

with

renal

nutrition

guidelines

and

recommendations to improve outcomes. The need for the other traditional and
inseparable CKD nutrition management of sodium, potassium, phosphorous and fluid
controls was also identified in this study, but was beyond the scope of discussion in this
publication.

The main limitation of our study was the lack of data on inflammatory markers, such as
CRP, which is known to be closely associated with malnutrition and is a marker of
CVD.74 It is worth noting that CRP did not associate with low fat stores, which in fact
reflects poor EI.164 Once again, this supports optimal EI being needed for optimal body
composition.

In summary, this pre-dialysis assessment clinic provided a platform to identify patients
at nutritional risk and to initiate nutrition intervention irrespective of future choice of
dialysis or conservative care programs. The results of this study also point to the needs
for earlier structured intervention to encourage “healthy eating” to prevent, and to
manage, the complex nutritional abnormalities found in people with ESKD.

4.6

Conclusions

Patients presented to the current pre-dialysis assessment clinic with a high prevalence
of abnormal nutrition parameters, including under- (malnutrition) and over-nutrition
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(overweight and obesity), compounded with a dietary intake of undesirable quality and
quantity, either voluntarily or involuntarily. While this clinic may provide an opportunity
for nutrition intervention pre-dialysis, it appears that earlier referral for nutrition
intervention is required. Further studies are needed to gauge how to effectively
implement the complex and multifaceted aspects of nutrition management in ESKD.

Practical Application

There is a high prevalence of nutritional abnormalities in non-dialysis ESKD patients.
The pre-dialysis assessment clinic provides a platform to assess the nutritional status
of ESKD patients and to identify nutritional abnormalities for further intervention well
before dialysis is required.

4.7

Supplement to Chapter 4: Evaluation of the self-rated appetite score and

adequacy of energy and protein intakes in non-dialysis CKD patients

4.7.1 Introduction
Loss of appetite or anorexia is common in uraemic patients with ESKD,97,
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and is

multi-factorial.386 PEW is thought to link to defective central nervous system control of
appetite111 and subsequent reduction in dietary intake.

Therefore, assessment of

appetite is an essential part of the routine nutrition assessment. Furthermore, in HD
patients, self-rating of appetite reflects inflammation state,95 relates to poor QOL387 and
predicts hospitalisation.96 Subjective assessment of appetite using the ADAT with a 5point Likert scale has been used to screen patients for suboptimal intake and it also
predicted the hospitalisation rate in patients on maintenance dialysis.96,
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The

usefulness of this tool in non-dialysis CKD patients to measure adequacy of protein
and energy intakes has yet to be examined.
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4.7.2 Aim

The aim of this study was to examine the relationship between self-rated appetite
score, and intake of energy and protein in a cohort of ESKD patients attending a predialysis assessment clinic. We hypothesised that appetite score is effective in reflecting
adequacy of energy and protein intakes.

4.7.3 Methods

This was a retrospective analysis of data from the nutrition assessment records of
patients who attended the pre-dialysis assessment clinic (Chapter 4). As part of the
routine nutrition assessment, patients were asked to rate their appetite according to the
ADAT with a 5-point Likert scale:

Question: Overall, how would you describe your appetite?
(1) Very good
(2) Good
(3) Fair
(4) Poor
(5) Very poor
Dietary intake of patients was assessed by the dietitian(s) using a structured diet
history method242-244 which had been validated in a small sample of non-dialysis CKD
patients.245 In term of the interview structure of assessing dietary intake, the structured
diet history method is similar to the 24-hour recall method, but it also takes into account
the frequency of food consumption and food patterns. In our practice, patients were
asked to give a detailed history of a “typical day’s intake” of the week (last 7 days) with
prompting, and assisted by measuring devices such as metric measuring cups and
spoons and pictures showing food portion sizes. Of the 210 patients assessed, 206
patients had reliable diet intake records available for analysis. Subsequently, the diet
history was analysed using a nutrients analysis software program (FoodWorks
Professional Model 2009, Xyris, Brisbane, Australia) to estimate EI and DPI. In
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addition, for easy comparison, appetite scores were grouped as (1) + (2) = “good” and
(3) + (4) + (5) = “reduced appetite”. Fair appetite = (3) was grouped into “reduced
appetite” as the patients’ usual appetite had been compromised. Energy and protein
intake ≥25 kcal/kg IBW/d310 and ≥0.75g/kg IBW/d205 were considered to be adequate.
The PPV of the appetite score in relation to the mean intakes of energy and protein
were examined.

Statistical analyses included analysis of variance (ANOVA), t-tests and calculation of
PPV using the 2x2 contingency table.315 P values <0.05 were as considered to be
statistically significant.

4.7.4 Results
As shown in Table 4-8, the appetite score was found useful in ranking both the EI and
DPI. Patients’ self-rating of appetite according to the 5-point Likert scale – (1) Very
good, (2) Good, (3) Fair, (4) Poor and (5) Very poor, correlated with an EI of 25.4±6.0,
24.2±6.8, 22.0±6.8, 19.4±6.2 and 14.9±1.8 kcal/kg IBW/d (P =0.002) respectively. The
same applied for protein intake of 1.32±0.36, 1.17±0.45, 1.13±0.44, 0.86±0.25 and
0.57±0.18 g/kg IBW/d (P =0.001) respectively. The 5-point Likert scale correlated the
incremental changes of both energy and protein intakes. For the combined scores of
“good” and “reduced” appetite for protein and energy intakes, the rating showed
statistical difference between the energy and protein intake of 24.7±6.5 vs. 21.2±6.7
kcal/ kg IBW/d (P =0.001) and 1.24±0.42 vs. 1.06±0.42g/kg IBW/d (P =0.006)
respectively.
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Table 4-8 Appetite score and intake of energy and protein
Appetite score
(% of patients)
Energy intake
(kcal/kg IBW/d)
Protein intake
(g/kg IWB/d)
Combined
appetite score
Energy intake
(kcal/kg IBW/d)
Protein intake
(g/kg IWB/d)

1
Very good
(31.0%)
25.4±6.0

2
Good
(39.0%)
24.2±6.8

3
Fair
(23.3%)
22.0±6.8

4
Poor
(5.7%)
19.4±6.2

5
Very poor
(1.0%)
14.9±1.8

P
value

1.32±0.36

1.17±0.45

1.13±0.44

0.86±0.25

0.57±0.18

0.001

0.002

Good
(70.0%)
24.7±6.5

Reduced
(30.0%)
21.2±6.7

0.001

1.24±0.42

1.06±0.42

0.006

Expression of figures: n±SD–standard deviation

When the PPVs were examined (Tables 4-9 and 4-10), the PPV of appetite score for EI
was 0.41, which reflects 41% of patients rated a “good appetite” and consumed
adequate energy, while the remainder (59%) rated “good appetite” but did not consume
adequate energy. The PPV for protein intake was 0.92 reflecting 92% of patients rated
a “good appetite” and consumed adequate protein and the remainder (8%) rated “good
appetite” but did not consume adequate protein.

Table 4-9 Positive predictive value of appetite score for energy intake

Appetite

Good
Reduced
Total

Energy intake*
Adequate
Inadequate
59
85
18
44
77
129

* EI ≥25 kcal/kg IBW/d was considered to be adequate

Total
144
62
206
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PPV = outcome occurred/total number of subjects tested
=59/144
=0.41 (95% CI: 0.36–0.45)

Table 4-10 Positive predictive value of appetite score for protein intake

Appetite

Good
Reduced
Total

Protein intake*
Adequate
Inadequate
132
12
48
14
180
26

* Protein intake ≥0.75 g/kg IBW/kg was considered to be adequate

Total
144
62
206
205
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PPV = outcome occurred/total number of subjects tested
=132/144
=0.92 (95% CI: 0.88–0.95)

In summary, the ADAT, with a 5-point Likert scale, and the combined appetite score
were found to be useful in ranking both energy and protein intakes with incremental
changes. However, the appetite score was not useful in identifying adequate EI,
whereas it was satisfactory in identifying adequate protein intake.

4.7.5 Discussion

Our results indicated the ADAT, with a 5-point Likert scale, was useful in ranking the
intake of energy and protein; this is in line with the findings of a previous study with
patients on HD.96 In the current study with pre-dialysis CKD patients, despite the selfrated appetite scores being useful in ranking energy and protein intakes, the scores
rated by patients were only related to adequate protein but not EI. A possible
explanation

is

recommended,366,

that
367

the

average

Australian

consumes

more

protein

than

so a “reduced” protein intake in uraemic patients could still be

adequate or in excess, but this is not the same for total EI. During the gradual decline
of kidney function, patients often fail to recognise the onset of uraemic symptoms, and
may confuse a reduced appetite and decreased dietary intake with the effects of aging,
especially in elderly patients. The possibility of underreporting of EI was discussed in
the body of Chapter 4. The diet interview or structured diet history used in the current
study was validated against other dietary methods such as a 3–7 day food
record.243,

245

It is known that many diet estimation methods underestimate EI by

approximately 20% when compared to the estimated EE in the non-renal disease
population.243 For reasons previously explained, a number of factors, including altered
EE in uraemia, loss of muscle mass, high symptom burden, self-imposed dietary
restriction and low PA level, all could contribute to the suboptimal EI in our patients.
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Based on our findings, in studies using a self-rated appetite in patients with stage 5
pre-dialysis ESKD (mean GFR 7±2 mL/min/m2) and on a HD program (dialysis vintage
12±2 months), it was not surprising to see results that poor appetite rating (as part of
the subjective global assessment component) was not associated with mortality risk in
the 12-month follow up.388 This was possibly explained in the nature of subjective
rating, which does not necessarily reflect actual dietary intake and duration. In addition,
any subsequent nutrition intervention or changes in clinical conditions that may affect
mortality were not considered in the analyses. Interestingly, not all patients’ appetite
rating improved after dialysis started; and some even got worse. Furthermore, in the
pre-dialysis ESKD group, even though the good appetite group had a significantly
lower level of CRP compared to the poor appetite group, 3.1 (1.4–9.5) vs. 6.0 (2.2–
15.5) mg/L, P <0.05, the prevalence of malnutrition was the same, at 50% in both
groups. Contrary to previous findings, poor appetite and high CRP levels did not predict
mortality risk.95 Again, the actual intake of energy and protein15 and nutritional status15,
346, 348

appear to be more superior to appetite rating alone in predicting mortality risk.

The cause of poor appetite could be multifactorial in patients with CKD, such as
uraemia and/or inflammation,97, 386 which could explain the inconsistent findings. 62.4%
of our patients were overweight or obese, so perhaps some of these patients had
reduced total caloric intake in an attempt to lose weight. However, EI intake <25
kcal/kg IBW/d was still considered to be inadequate.178,
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In our pre-dialysis cohort,

23.0% patients reported poor appetite but still consumed higher than RDI levels of
protein (0.75g/kgIBW/d),176 and possibly accumulated high levels of uraemic toxins
while EI remained poor.

To our knowledge, no previous study has analysed the PPVs of appetite score and
dietary intakes of energy and protein in patients with non-dialysis CKD.
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4.7.6 Conclusions

While the self-rated appetite scores were useful in ranking energy and protein intakes,
subjective reporting of a good appetite was likely to associate with adequate protein
intake but not EI. This means a self-rated “good appetite” does not always equate to
adequate intake in non-dialysis ESKD patients with high levels of uraemic
complications. Therefore skilled dietary assessment by a dietitian should form part of
the routine care for managing patients with ESKD.

Implications for clinical practice:
Self-rated “good” appetite score does not necessary reflect adequate energy or protein
intake. Therefore, dietary intake assessment by a dietitian should form part of the
routine nutrition care in patients with ESKD.
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Abstract

Aim: Pre-dialysis management is important for the timely management of patients with
end stage kidney disease (ESKD). We investigated the trend of clinical and nutritional
characteristics of patients enrolled in a pre-dialysis assessment clinic of our renal unit
over a 10-year study period.

Methods: Data were extracted for analysis from the clinical and nutrition records of
patients at enrolment to the pre-dialysis clinic from April 2002 to March 2012.
Parameters included: demographics, such as age and gender; co-morbidities; and
nutritional data, including body mass index (BMI), serum albumin (s-albumin) and
subjective global assessment (SGA). Data were also divided into two 5-year periods for
comparison, namely April 2002 to March 2017 vs. April 2007 to March 2012.

Results: Records of 501 patients were examined. The mean age was 66.0±14.7 years
with a mean glomerular filtration rate (GFR) of 20.2±8.6 mL/min/1.73m2, and 60.1%
were male. 40.1% of patients were rated as overweight and 41.1% were malnourished.
When comparing the two study periods, patients were enrolled to the clinic at an earlier
point in the latter period, with a higher GFR: 16.7±6.7 vs. 22.1±9.1 mL/min/1.73m2 (P
<0.0001). The prevalence of obesity and diabetes were significantly higher in the
second study period, being 32.0% vs. 44.7% (P =0.01) and 33.0% vs. 51.4% (P
<0.0001) respectively. However, the malnutrition rate scored by SGA remained high at
39.7% vs. 42.0% (P =0.64), despite earlier referral. Patients who preferred a
conservative or no-dialysis pathway were significantly more advanced in age (77.3 vs.
63.9 years, P <0.0001) and with a higher prevalence of malnutrition (64.6 vs. 36.8%, P
<0.0001).

Conclusions: A significant increase in the prevalence of obesity and diabetes over the
10-year study period was observed. There was no significant difference in the
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prevalence of malnutrition, which remained high despite an increase in patients who
were enrolled at a high level of GFR.

5.1

Introduction

Chronic kidney disease (CKD) has reached epidemic proportions in Australia4-6 and
worldwide.1, 2 Approximately 11.4% of the Australian population has stage 3 to 5 CKD
with a dramatic increase in the incidence of end stage kidney disease (ESKD) (GFR
<15 mL/min/1.73m2) due to an aging population and growing prevalence of diabetes.6,
389, 390

ESKD imposes a tremendous clinical and societal burden and is associated with

high morbidity, mortality and hospitalisation. Inevitably many people with CKD progress
to ESKD and require dialysis to sustain life. There is ample evidence showing that
malnutrition and other nutrition abnormalities present at the initiation of dialysis are
associated with adverse outcomes.13-15,

346, 348

Furthermore, the benefits of elderly

patients and patients with a high number of co-morbidities commencing dialysis
programs have been questionable.16 In light of these findings, a multidisciplinary and
multifaceted pre-dialysis program, including nutrition assessment and education, may
provide a platform to identify patients for early intervention,260 such as those at
nutritional risk, including malnutrition and overweight/obesity. The majority of nutritional
studies in patients with ESKD have been focused on those who have already
participated

in

a

renal

replacement

program

(RRT),

namely

dialysis

and

transplantation; limited information is available regarding patients in the pre-dialysis
stage.
The prevalence trend of various clinical parameters in stage 4 to 5 non-dialysis CKD
patients over time has seldom been studied; in particular, to see if it mirrors the trend of
obesity124,

125

and diabetic epidemics391 globally and those reported in the Australian

Diabetes, Obesity and Lifestyle Study (AusDiab).389,

392

This knowledge is very

important as obesity and diabetes mellitus (DM) are linked to disease progression and
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cardiovascular disease,29 and cause premature mortality in patients with ESKD.393 Tto
evaluate current practices and to formulate strategic planning of a future pre-dialysis
assessment clinic, it is useful to know the trends of clinical and nutrition characteristics
of people enrolled in a pre-dialysis assessment clinic over time. Another important
question is, as the clinic structure has evolved over time, have patients been referred
earlier? If that is the case, was the prevalence of nutrition abnormalities lower?
5.2

Aim

The aim of this study was to examine the prevalence and trend of various
demographic, clinical and nutritional characteristics of ESKD patients at enrolment in
an outpatient pre-dialysis clinic over a 10-year study period from April 2002 to March
2012. Comparison of these parameters were made over two 5-year periods, namely
from April 2002 to March 2007 and from April 2007 to March 2012. There was a
particular focus on age and the levels of GFR at which patients were referred, as well
as the prevalence of nutrition and related abnormalities, such as obesity and
malnutrition. In addition, the relationship of these parameters and the initial choice of
RRT or conservative care by patients was also examined.

5.3

Methods

This retrospective study examined clinical and nutrition records of all patients enrolled
in the multidisciplinary outpatient pre-dialysis assessment clinic at the St. George
Hospital, Sydney, Australia established in April 2002 and continuing through to March
2012. Patients referred by nephrologists to this clinic were predominantly in CKD
stages 4 and 5 (GFR <30 mL/min/1.73m2). As part of routine care, patients and their
carers were seen by a clinical nurse consultant, pharmacist, social worker and dietitian
for discipline-specific assessment and education. Patients excluded from analysis were
those who were referred to the pre-dialysis assessment team during acute hospital
admission and expected to start dialysis within the next 1–2 months, and those missed
150

the assessment by the dietitian due to reasons such as dietitian was not available to
the clinic session, or patients were unable to be properly assessed due to language
barrier and patient’s lack of interest for nutrition assessment etc

Demographic, clinical and nutritional data collected were: age; gender; race; smoking
habits; and presence of co-morbidities, such as coronary artery disease (CAD),
cerebral vascular disease (CVD), DM, chronic lung disease (CLD) or peripheral
vascular disease (PVD). Ex- and current smokers were combined as having a positive
smoking history while the presence of co-morbidity as “yes” or “suspected” were
combined as “presence of” for analysis.

Nutritional data included for analyses included anthropometric measures, e.g., height
(m), oedema-free body weight (kg), BMI [weightheight2 (kg/m2)] and weight history.
The clinical practice guidelines205 defined a healthy weight range as a BMI of 22–26
kg/m2; therefore a BMI ≥26 kg/m2 was treated as overweight. Prevalence of renalspecific BMI categories205,
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were also examined with undernourished, ideal range,

overweight and obese defined as BMI <23, 23–26, 26–30 and >30 kg/m2 respectively.
Pathology results included serum-albumin (s-albumin) and serum creatinine; GFR was
calculated using the Cockcroft-Gault equation.300 Approximately 50% of the blood tests
were analysed by private providers instead of the hospital-based laboratory; thus,
different analytical methods for s-albumin and reference range. Therefore, for salbumin levels, both actual figures and whether they were below or within reference
range were also recorded for analysis. The renal dietitian(s) (mainly the author MC)
also performed the subjective global assessment (SGA),149 which categorises patients
as A = well nourished, B = mild-moderately and C = severely malnourished based on
the patient’s medical history and physical examination. The combined score of B or C
was used as “malnourished”. The prevalence of combined malnutrition (classified by
SGA score B and C) and BMI (<26 kg/m2 vs. 26 kg/m2) was also examined. The
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difference of these parameters over the two 5-year periods, namely from April 2002 to
March 2007 and from April 2003 to March 2012, were compared to examine the trend
of patient characteristics over time. All patients were seen by the clinical nurse
consultant for options regarding a future RRT program or to be maintained on a
conservative pathway. Relationships between nutrition factors and “initial” treatment
option, such as dialysis modality or conservative care pathway, were also explored.
All tests were performed using the statistical software IBM© SPSS© Statistics version
20. Continuous variables were expressed as mean ± standard deviation for normally
distributed data. Comparisons between groups were performed using unpaired sample
t-tests, whereas categorical variables were compared using the 2 test. P values <0.05
were regarded as statistically significant.

The study was approved by the ethics committee of the South Eastern Sydney and
Illawarra Area Health Service, NSW, Australia.

5.4

Results

A total of 552 patients were referred to the pre-dialysis assessment team for education
during the study period. Of these, 520 attended the outpatient pre-dialysis assessment
clinic and data for 501 patients were available for inclusion in analyses. The
demographics and co-morbidities are summarised in Table 5-1, and Table 5-2
summaries the clinical and nutritional parameters.

Our cohort consisted of 60.1% male patients with a mean age of 66.0±14.7 years;
mean GFR was 20.2±8.6 mL/min/1.73m2. The leading cause of ESKD was diabetic
nephropathy (28.7%), followed by renovascular disease/hypertensive nephrosclerosis
(19.6%), chronic glomerulonephritis (13.2%), IgA nephropathy (7.2%), adult polycystic
kidney disease (5.8%), reflux nephropathy/congenital abnormality (3.8%), analgesic
nephropathy (2.4%) and other miscellaneous causes (19.6%). There was no statistical
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difference between male and female patients for all demographic and co-morbidity
data, except men had a significantly higher prevalence of positive smoking history than
women (56.2% vs. 31.0%, 2 =24.4, P <0.0001) and presence of CAD (37.0% vs.
28.0%, 2 =4.4, P =0.04).

Table 5-1 Demographic data and co-morbidities
Parameters
Age (year)
Age >65 years (%)
Age >75 years (%)
Race (% Caucasian)
Smoking (% positive history)
Co-morbidities
Chronic lung disease (%)
Coronary artery disease (%)
Peripheral vascular disease (%)
Cerebral vascular disease (%)
Diabetes mellitus (%)

All
n =501
(n missing)
66.0±14.7
62.1
30.7
80.8
46.2
(n =103)

Male
n =301
(60.1%)
66.7±14.4
62.8
33.2
80.4
56.2

Female
n =200
(39.9%)
65.0±15.1
61.0
27.0
81.5
31.0

P value
0.22
0.69
0.14
0.76
<0.0001

10.4
(n =3)
33.4
(n =1)
17.2
(n =2)
14.8
(n =2)
44.9

8.7

13.1

0.11

37.0

28.0

0.04

18.7

15.1

0.30

15.3

14.1

0.70

47.2

41.5

0.21

Expression of figures: n±SD–standard deviation

The BMI distribution was 15.7%, 18.4%, 26.2% and 39.7% for underweight (BMI <23
kg/m2), healthy weight range (BMI 23–26 kg/m2), overweight (BMI 26–30 kg/m2) and
obese (BMI ≥30 kg/m2) respectively. The prevalence of CAD was higher in the
overweight/obese (BMI ≥26 kg/m2) group than the BMI <26 kg/m2 group (38.1% vs.
23.6%, 2 =10.2, P =0.001). Similarly, this applied to the prevalence of DM (52.8% vs.
28.9%, 2 =25.2, P <0.0001). When the relationships of obesity (BMI >30 kg/m2) and
CAD or DM were examined, prominent effects continued to apply with 39.2% vs.
29.1%, 2 =5.4, P =0.02 and 60.8% vs. 33.8%, 2 =34.4, P <0.0001, respectively,
compared with the non-obese (BMI 30 kg/m2) patients.
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A high prevalence of malnutrition was observed in 41.1% of the whole cohort. 20.0%
and 11.0% of patients were classified as malnourished and overweight (BMI >26
kg/m2), and malnourished and obese (BMI >30 kg/m2) respectively. Within the
malnourished group, 48.9% of patients were overweight/obese (BMI >26 kg/m2) and
within the overweight/obese group, 30.4% were malnourished. More women were rated
as malnourished compared to men (47.2% vs. 36.9%, 2 =4.5, P =0.04), and there was
also a trend of higher prevalence of combined malnutrition and overweight/obese
(24.4% vs. 17.1%, 2 =3.5, P =0.06).

Table 5-2 Clinical and nutritional parameters
Parameters
Serum creatinine (μmol/L)
GFRCG (mL/min/1.73m2)
CKD stages, 2:3:4:5 (%)
Nutritional parameters
Serum albumin (g/L)
Serum albumin < reference range (%)
BMI (kg/m2)
BMI <23 kg/m2, underweight (%)
BMI >26 kg/m2, overweight/obese (%)
BMI >30 kg/m2, obese (%)
Malnutrition (SGA B or C)
Malnourished + BMI >26 kg/m2 (%)
Malnourished + BMI >30 kg/m2 (%)

All
n =501
(n missing)
0.346±0.121
(n =2)
20.2±8.6
(n =18)
1:12:58:29
(n =18)
35.2±6.4
(n =11)
32.4
(n =11)
29.1±6.5
(n =17)
13.7
(n =17)
65.6
(n =17)
40.1
(n =17)
41.1
(n =62)
20.0
(n =62)
11.0
(n =62)

Male
n =301
(60.1%)
0.364±0.123

Female
n =200
(39.9%)
0.318±0.115

P value
<0.0001

20.0±8.8

20.3±8.4

0.47

1:10:59:30

0:14:57:29

0.37

35.4±6.4

35.3±6.6

0.31

29.7

36.6

0.11

28.8±5.9

29.4±7.3

0.40

18.7

15.7

0.15

65.8

65.7

0.97

41.2

38.3

0.53

36.9

47.2

0.04

17.1

24.4

0.06

9.2

13.6

0.14

n = total sample size; n missing = missing data, Expression of figures: n±SD–standard deviation

The total number of patients (n =325) who attended in the second 5-year period was
almost twice the number of the first period (n =176), reflecting the increased demand of
services (Table 5-3). Over the 10-year study period, patients enrolled to the clinic
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earlier or at higher levels of GFR, with a significant increase of GFR: 16.7±6.7 vs.
22.1±9.1 mL/min/1.73m2, P <0.0001 from the first to second 5-year period (Figure 5-1).
The latter period also had fewer patients in CKD stage 5 (41.4% vs. 23%, 2 =18.1,
P <0.0001). There was no significant change in mean age of patients with
predominately elderly patients older than 65 years of age across the two periods. There
was a significant increase in the number and prevalence of patients with diabetic
nephropathy (20.5% vs. 33.2%, 2 =9.1, P =0.003) that corresponded to an increase in
the prevalence of DM (33.0% vs. 51.4%, 2 =15.7, P <0.0001). Despite the number of
patients with glomerulonephritis remaining constant, it became less prevalent in the
second period (18.8% vs. 10.2%, 2 =7.4, P =0.007), due the growth of patients with
diabetic nephropathy. Figure 5-2 shows the prevalence of diabetes, obesity and
malnutrition

over

the

two

5-year

study

periods.

While

the

prevalence

of

overweight/obesity (BMI >26.0 kg/m2) appeared stable (P =0.16), the prevalence of
obesity increased enormously (32.0% vs. 44.7%, 2 =7.5, P =0.01). The prevalence of
obesity-related causes of ESKD, such as diabetic nephropathy, increased significantly
over

the

two

study

periods,

whereas

renovascular

disease/hypertensive

nephrosclerosis remained similar (P =0.31). Despite patients being enrolled in the clinic
earlier, the prevalence of malnutrition remained high (39.7% vs. 42.0%, P =0.64).
Although there was no statistical difference between the prevalence of malnutrition
among the two periods, the total number of patients rated as malnourished increased
substantially (n =174 vs. 265) due to the increase in clinic enrolment (Figure 5-2).
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Table 5-3 Comparison of demographic, clinical and nutritional parameters over
the two 5-year study periods
Parameters
(n missing)
Number
Demographics
Age (year)
Gender (% male)
Race(% Caucasian)
Clinical and co-morbidities
Serum creatinine (μmol/L)
(n =2)
GFRCG (mL/min/1.73m2)
(n =18)
CKD stage 5 (%)
(n =18)
Smoking, positive history (%)
(n =103)
Coronary artery disease (%)
(n =1)
Diabetes mellitus (%)
Cause of ESKD
Chronic glomerulonephritis (%)
Diabetic nephropathy (%)
Renovascular disease/ hypertensive
nephrosclerosis (%)
Nutritional parameters
s-albumin (g/L)
(n =11)
s-albumin < reference range (%)
(n =11)
BMI (kg/m2)
(n =17)
BMI <23 kg/m2 (%)
(n =17)
BMI >26 kg/m2 (%)
(n =17)
BMI >30 kg/m2 (%)
(n =17)
Malnutrition (SGA B or C) (%)
(n =61)

Time period
(data available per parameter)
April 2002 to
April 2007 to
March 2007
March 2012
n =176
n =325

P value

65.2±13.8
61.9
84.1

66.4±15.2
59.1
79.1

0.39
0.53
0.17

0.399±0.125

0.318±0.111

<0.0001

16.7±6.7

22.1±9.1

<0.0001

41.4

23.0

<0.0001

55.4

52.7%

0.60

36.6

31.7

0.27

33.0

51.4

<0.0001

18.8
20.5
21.6

10.2
33.2
17.8

0.007
0.003
0.31

34.5±5.9

35.5±6.6

0.10

37.4

29.7

0.09

28.1±5.9

29.6±6.8

0.01

17.7

14.6

0.36

61.7

68.0

0.16

32.0

44.7

0.01

39.7

42.0

0.64

n =total data available per parameter
Expression of figures: n±SD–standard deviation
Remark: Chinese (6.0%), Egyptian (1.7%), Indian (2.2%), Maori / New Zealander (2.2%),
Pilipino (0.9%), Others (1.3%)
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Figure 5-1 The trend of patients’ GFR levels at enrolment in the pre-dialysis
assessment clinic over the 10-year study period

Figure 5-2 Comparison of the prevalence of diabetes, obesity and malnutrition
over the two 5-year study periods

60 %

4/2002 to 3/2007

P <0.0001

P =0.01

P =0.64

4/2007 to 3/2012

50

Patient

40
30
20
10
0
Diabetes

Obesity
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Table 5-4 Comparison of patients’ initial choice for future RRT treatment over the
two 5-year study periods
% total
n =501

4/2002 to 3/2007
(n =176)

4/2007 to 3/2012
(n =325)

2

14.8

15.3

14.5

0.07

0.79

PD (home)

47.7

39.2

52.3

7.9

0.01

HD (Home)

13.6

21.0

9.5

12.8

<0.0001

HD (hospital)

18,2

19.3

17.6

0.24

0.62

Early TP

3.8

3.4

4.0

0.11

0.74

Others (unsure)

1.9

1.8

2.2

0.12

0.73

Study period

P value*

Treatment

RRT

Non-RRT

* P value between the two 5-year study periods of 4/2002 to 3/2007 and 8.2007 to 3/2012
Abbreviation: RRT = renal replacement therapy; PD = peritoneal dialysis; HD = haemodialysis;
TP = transplant

Table 5-4 shows that preferences for the future treatment options changed significantly
over time (P =0.008). A preference for home dialysis therapy – namely PD and home
HD – remained high, with PD becoming the first choice, increasing from 39.2% in the
first period to 52.3% in second period (P <0.01). This was accompanied by a
downward shift of preference to home HD, decreasing from 21.0% to 9.5% (P
<0.0001).

The proportion of patients preferring a conservative or no-RRT pathway remained
stable (15.3% vs. 14.5%). This conservative group of patients, when compared to all
other patients combined, were older (77.3±7.0 vs. 63.9±14.7 years, P <0.0001), had
lower levels of GFR (17.5±8.3 vs. 20.7±8.6 mL/min/1.73m2, P =0.004) and a higher
prevalence of malnutrition (64.6% vs. 39.6%, 2 =17.6, P <0.0001).

Within the whole cohort, there was no statistical difference for the stages of CKD,
comorbidities, s-albumin or BMI (Table 5-5). Among the patients who chose to start

158

dialysis, patients who preferred hospital dialysis (HD) were older (68.7±11.5 vs.
64.0±14.2 years, P <0.0001), had a higher prevalence of CAD (49.5% vs. 29.0%,
2=13.2, P <0.0001), DM (60.4% vs. 42.0%, 2 =9.6, P=0.003), and malnutrition (52.1%
vs. 32.7%, 2 =9.0, P =0.003) compared to those preferred home dialysis (PD and HD).
The two most elderly groups were those preferred conservative pathway and hospital
dialysis, apart from age (77.3±7.0 vs. 68.6±11.5 years, P <0.0001) and BMI (28.1±5.9
vs. 30.3±6.8 kg/m2, P =0.04), there was no statistical difference for all other variables
including the high prevalence of malnutrition (51.2 % vs. 64.6%, 2 =2.6, P =0.11).

In summary, the total number of patients enrolled in the clinic almost doubled over the
two 5-year observation periods. Diabetic nephropathy remained the leading cause of
ESKD with an increase in prevalence over time. Prevalence of obesity and diabetes
increased significantly during the study period, whereas the prevalence of malnutrition
remained constant but with an increase in total number reflecting larger numbers
enrolled in the clinic in the second period. Demographic and nutritional parameters
were found to be closely associated with the patients’ choice of treatment options, with
patients who preferred a conservative pathway (or no-RRT) being more advanced in
age with a higher prevalence of malnutrition; this pattern is closely followed by those
opting for a hospital dialysis program.
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Table 5-5 Demographic, clinical and nutritional factors associated with future choice of RRT or conservative care (no-RRT)
n =501
(n missing)
n (% total)
Age (yr)
Age >65 yr (%)
Age >75 yr (%)
Gender (% male)
Creatinine (µmol/L) (n =2)
GFR (mL/min/1.73m2) (n =18)
CKD stage 5 (%) (n =18)
CAD (%) (n =18)
DM (%)
BMI (kg/m2) (n =18)
s-alb (g/L) (n =17)
s-alb < ref. (%) (n =17)
Malnourished (%) (n =62)

No-RRT
PD
74 (14.8)
77.3±7.0†
91.9†
71.6†
55.4
0.351±0.125
17.5±8.4‡
42.3
35.6
47.3
28.1±5.9
34.5±6.6
37.5
64.6*

239 (47.7)
65.6±14.3
61.5
27.2
63.6
0.349±0.130
20.3±8.8
30.3
32.2
46.4
28.7±6.1
35.1±6.7
31.3
34.3

Renal replacement program (RRT)
Home
Hospital
HD
HD
68 (13.6)
91 (18.2)
58.6±12.7
68.6±11.5
32.4
73.6
5.9
28.6
61.8
54.9
0.357±0.115
0.338±0.109
21.2±6.6
19.7±7.2
16.4
29.9
17.6
49.5
26.5
60.4
30.1±8.3
30.2±6.8
36.8±5.6
33.9±6.5
25.4
40.0
27.7
51.9

Early
TP
19 (3.8)
41.1±16.3
5.3
0.0
47.4
0.304±0.100
29.7±13.1
11.1
10.5
10.5
29.2±6.0
37.4±4.8
15.8
33.3

Others
(unsure)

P value*

10 (1.9)
68.3±14.7
60.0
60.0
70.0
0.336±0.115
18.9±7.6
44.4
50
40
27.0±4.9
36.4±5.8
33.3
42.9

n/a
<0.0001
<0.0001
0.46
n/a
n/a
0.01
<0.0001
<0.0001
n/a
n/a
0.20
<0.0001

2

Abbreviation: GFR = glomerular filtration rate in mL/min/1.73m ; s-alb = serum albumin
no-RRT group vs. the combined RRT group (PD + home HD, Hospital PD and early transplant)
†
‡
*P value for categorical variables, P <0.0001, P=0.004
Expression of figures: n±SD–standard deviation
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5.5

Discussion

The current study indicated a substantial growth of enrolment of ESKD patients to the
pre-dialysis assessment clinic over a 10-year study period. This reflected the increased
need of patients considering dialysis over time in our unit similar to the national
Australian statistics.4, 5 As the clinic became more established, patients were referred
by nephrologists significantly earlier or at higher levels of GFR. Even though the mean
age at enrolment remained fairly stable at 66.0±14.7 years, there was a significant
growth of patients with obesity and diabetes, which paralleled the global obesity
epidemic.124, 125 These trends were also associated with an increase in the prevalence
of diabetic nephropathy, which remained the leading cause of ESKD in our cohort.
These observations were in agreement with analysis of the Australia and New Zealand
Dialysis and Transplant Registry (ANZDATA) data, that diabetic nephropathy
accounted for a substantial increase in incident dialysis patients between 1990 and
2009.394 The mean GFR of those incident dialysis patients was 8.2 mL/min1.73m2 while
patients enrolled in our pre-dialysis clinic had a mean GFR of 20.2±8.6 mL/min/1.73m2,
that reflected similar characteristics well before dialysis was required.

Overweight and obese patients have metabolic derangements that compound on the
effect of uraemia and related complications to accelerate disease progression,138,

393

and cardiovascular events.29 The substantial growth of patients with obesity may also
lead to high prevalence of obese patients starting dialysis, and subsequently
transplantation, similar to a study from the United States.395 Although there have been
many debates on the “obesity paradox”,128, 129 which supports the survival advantage of
obesity in dialysis patients, other research has found obesity was associated with high
mortality risk.133 In light of the negative effects of obesity on disease progression and
cardiovascular events in the pre-dialysis stage, structured weight reduction intervention
through diet207, 396, 397 and exercise398, 399 should be considered to optimise body weight
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and body composition. Indeed, muscle mass has been reported to be the main
determinant of survival over BMI alone in dialysis patients.15, 143, 351, 356

Despite patients being referred to the clinic earlier or at higher levels of GFR by the
nephrologists over time, the prevalence of malnutrition remained stable and high at
41.4% in the second period. Malnutrition at initiation of dialysis is an independent
predictor of mortality, morbidity and hospitalisation,13,

14, 156, 317, 346, 348

and the same

applies to non-dialysis CKD patients well before dialysis is required.98 In our cohort,
approximately 20.0% of patients were rated as malnourished and overweight (SGA B
and C + BMI ≥26 kg/m2); such observation at the initiation of dialysis has been shown
to associate with high mortality risk compared to other patients. 317 Early structured
nutrition intervention to malnourished patients, with or without presence of
overweight/obesity, should be implemented before dialysis starts.363 A recent
observational study revealed pre-dialysis dietitian care for more than 12 months
independently associated with higher s-albumin and lower total cholesterol levels at the
start of dialysis; and lower 1-year mortality after initiation of dialysis.400 In view of the
complex nutrition requirements of ESKD patients, early nutrition intervention is
recommended.

A Canadian study reported that timely referral of patients at CKD stage 4 to the
multidisciplinary renal management clinic (RMC) resulted in significant non-progression
or improved renal function, leading to delayed initiation of dialysis compared to those
referred late in stage 5.264 Similar advantages of multidisciplinary pre-dialysis programs
were also reported elsewhere.262, 263, 265, 267 The major outcome of our clinic was that
enrolling patients in the clinic at an earlier stage of CKD or higher GFR may provide a
window of opportunity to improve outcomes. The structure of our clinic was different
from the Canadian and other studies as a nephrologist or medical officer made the
referral but did not attend the clinic. Secondly, our clinic was almost a “one-off”
assessment by various health professionals, with further intervention arranged for
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patients if required. Due to limited staffing resources, the nature of the clinic and limited
post-clinic intervention, it was uncertain if comparable outcomes were achieved.
Further study is needed to examine the outcomes of our patients. Our study raised the
issue of growing demand on nutrition intervention due to an increase in patient
numbers and a higher prevalence of nutritional abnormalities. There were other
substantial needs for nutrition interventions not examined in this study, such as
hypertension, poorly-controlled diabetes, hyperkalaemia and hyperphosphataemia, etc.
This was compounded by the fact that our patients were more advanced in age and
thus required additional attention for age-related nutritional health issues, such as
sarcopenia, chewing and swallowing problems and food provision. Furthermore,
attendance at this pre-dialysis clinic was not mandatory for all ESKD patients in our
unit, and the results cannot be generalised to those who did not attend the clinic.
Undoubtedly, a substantial number of patients waiting to start dialysis or planning to be
maintained on the conservative pathway were at severe nutritional risk similar to
reports in the literature.239, 401

From our understanding, this study was the first to examine the relationship between
nutritional status and future choice of ESKD management including, conservative
management or no-RRT. The proportion of patients who chose to start a home dialysis
(HD or PD) program remained steady over time, similar to the ANZDATA report 5 on
new dialysis patients. However, the rate of preferring PD significantly increased (39.2%
vs. 52.9%, 2=7.9, P =0.01) and was accompanied by a decline in home HD (21.0% vs.
9.5%, 2 =12.8, P <0.0001) over time. This may have been because automated PD
(APD) became more readily available to patients over the last few years. APD is a
machine-operated PD, which is simpler to perform compared to the traditional
manually-operated continuous ambulatory PD (CAPD); it costs less and reportedly
improves quality of life of patients with ESKD. Our result aligns with the trend of more
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patients starting APD than CAPD, as previously reported for the period of 1999 and
2008.5, 402

It is not surprising that those patients who preferred conservative management were
more advanced in age, had lower levels of GFR and higher prevalence of malnutrition.
The general understanding is that in elderly patients there is no significant survival
advantage in starting dialysis compared with staying in conservative care, especially in
those with multiple co-morbidities.16,

403, 404

Since malnutrition is one of the major

determinants of survival in this population,401 nutrition intervention should be provided
to improve the outcomes of these patients. For patients who planned future dialysis,
those who preferred hospital dialysis were older and had higher prevalence of CAD,
DM and malnutrition, all of which require more intense nutrition intervention. Studies
are needed to explore if prevention or intervention of malnutrition plays a role to move
these patients to home dialysis programs, and/or to delay the start of dialysis, as both
strategies would help reduce health care costs.

The strength of this study was the long study period, with a reasonable sample size
that allowed meaningful comparison of the change in characteristics of these patients
over time. The major limitations were the retrospective nature of the study with missing
data and lack of measure of inflammation, e.g., C reactive protein (CRP), which is
closely linked to nutritional status. In spite of these limitations, the current study
provides invaluable baseline information of a cohort of patients who enrolled in a predialysis clinic over a 10-year period.

5.6

Conclusions

The number of patients enrolled in our multidisciplinary clinic doubled in the second 5year period over the 10-year observation. The leading cause of ESKD remained
diabetic nephropathy, with an increase in prevalence overtime. Prevalence of obesity
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and diabetes increased significantly, mirroring the obesity and diabetes epidemics in
the general population; malnutrition rate remained constant but with an increase in total
number reflecting larger numbers enrolled in the clinic in the second period.
Demographic and nutritional parameters were found to be closely related to the
patients’ choice of future treatment options, especially in patients who preferred a
conservative pathway followed by hospital dialysis, those patients being more
advanced in age with a higher prevalence of malnutrition. Therefore, nutrition
intervention should be considered in pre-dialysis groups, including elderly patients who
have chosen conservative or hospital-dependent dialysis.

Implications for clinical practice:

The number of patients with nutrition abnormalities requiring nutrition intervention has
grown exponentially, supporting the need of structured nutrition care process by
dietitian including assessment and intervention in the pre-dialysis CKD stages.
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Chapter 6 Thesis Conclusions

Nutrition abnormalities are common in patients with CKD and are associated with poor
clinical outcomes and QOL. During the course of decline of renal function these
nutritional problems emerge and change in nature and magnitude through to dialysis
and transplantation. The findings presented in this thesis focused on the examination of
nutritional abnormalities in ESKD or CKD stages 4 to 5 before, and at the start of
dialysis. The studies revealed the prevalence and prognostic significance of these
nutritional abnormalities, which are independently associated with mortality risks. One
of the major strengths of this thesis was the naturalistic study design so that all patients
of the defined treatment or program were included in the observation; in contrast to the
majority of the published data there was therefore no experimental selection bias.
These are representative data of ESKD patients of a typical Australian renal unit
setting, which was seldom examined previously. Moreover, the major strength of this
thesis has been the continuous research for better practice through a series of clinical,
practice-based and epidemiological studies.
The primary research question of the thesis was: “Is nutrition management good
enough only when it starts at or near dialysis initiation?” and how can we do better to
improve work practice and patient outcomes.

6.1

Summary of findings

The first part of the thesis began with the examination of demographic, clinical and
nutritional characteristics of patients at commencement of dialysis, and a number of
parameters were found to be independently associated with high mortality risks. The
preliminary analysis two years after the initial data collection indicated an unfavourable
outcome of malnourished patients; therefore a pre-dialysis assessment clinic was
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established to provide education pre-dialysis. The nutritional characteristics of this
clinic were examined. A summary of the findings is listed below:

1. A high prevalence of nutritional abnormalities presented at the initiation of dialysis
was observed and associated with high mortality risk over the 10-year observation
period. Older age (>65 years), presence of PVD, reduced s-albumin and
malnutrition (SGA score B and C) independently predicted mortality over the 10-year
study period (P <0.0001, P <0.0001, P =0.01 and P =0.02 respectively).
Furthermore, in contrast to the current understanding of the “obesity paradox”,
overweight/obese was not found to be protective to mortality risk. In fact, when
combined with malnutrition, it was associated with the highest mortality risk
compared to other combinations of BMI < or >26 kg/m2 and SGA categories. In
addition, GFR levels at which dialysis started did not associate with mortality,
indicating that with sound clinical practice and judgement, including nutrition, dialysis
can be started at lower levels of GFR.
2. High prevalence of nutritional abnormalities was observed in the initial assessment
of patients who attended the pre-dialysis clinic. The mean GFR of this cohort was
17.0±6.3 mL/min/1.73m2; prevalence of malnutrition and overweight/obesity was
40.5% and 62.4% respectively. The dietary intake of protein and energy positively
correlated with GFR; in other words, as renal function declined, dietary intake
decreased. Furthermore, the prevalence of malnutrition, muscle wasting measured
by MAMC and presence of symptoms increased as GFR decreased. Self-imposed
restrictive diet and poor eating habits also contributed to abnormal nutrition in this
cohort.
3. Self-rated appetite scores were found useful in ranking energy and protein intakes
but subjective reporting of a good appetite was likely to associate with adequate
protein intake, not energy intake.
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4. Over the 10-year period from April 2002 to March 2012, patients were enrolled in the
pre-dialysis assessment clinic at an earlier point in the second 5-year period. GFR
was 16.7±6.7 vs. 22.1±9.1 mL/min/1.73m2 (P <0.0001) in the first and second
periods respectively. Despite earlier referral, malnutrition rate scored by SGA
remained high at 39.7% vs. 42.0% (P =0.62). In addition, the total number of
patients who attended the clinic doubled, reflecting the need for additional service
provision to treat malnutrition.
5. There was a significant increase in the prevalence of obesity and diabetes over the
10-year study period, which mirrored epidemics in the general population.
6. Patients who preferred a conservative (or no dialysis) pathway or hospital-based
dialysis were more advanced in age and had a higher prevalence of
co-morbidities and nutrition abnormalities, including malnutrition.

6.2

Summary of findings to address research question and hypothesis

The global research question of this thesis was “Is nutrition management good enough
only when it starts at or near dialysis initiation?” and the aim was to examine the
relationships between nutritional factors and clinical outcomes in people with ESKD.

Hypothesis 1: nutritional abnormalities at the initiation of dialysis would be associated
with high mortality risk.

Addressing Hypothesis1 (chapter 3): The results support the hypothesis that nutritional
abnormalities presented at the initiation of dialysis are associated with high mortality
risk over a 10-year observation period.

There were a number of additional significant findings. a) In contrast to the current
understanding of the “obesity paradox”, overweight/obese was not found to be
protective to mortality risk. In fact, when combined with malnutrition, it was associated
with the highest mortality risk compared to other combinations of BMI < or >26 kg/m 2
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and SGA categories. b) GFR levels at which dialysis started did not associate with
mortality, indicating that with sound clinical practice and judgement, dialysis can be
started at lower levels of GFR.

Hypothesis 2: abnormal nutrition would be prevalent in advanced CKD before dialysis
was required.
Addressing Hypothesis 2 (Chapter 4): High prevalence of nutritional abnormalities was
observed in the initial assessment of patients who attended the pre-dialysis clinic. This
supports hypothesis 2.
The mean GFR of this cohort was 17.0±6.0 mL/min/1.73m2; and prevalence of
malnutrition and overweight/obesity was 40.5% and 62.5% respectively. The dietary
intake of protein and energy positively correlated with GFR; in the other words, as renal
function declined, dietary intake decreased. Furthermore, the prevalence of
malnutrition, muscle wasting measured by mid-arm muscle circumference and
presence of symptoms increased as GFR decreased. Self- imposed restrictive diet and
poor eating habits also contributed to abnormal nutrition.
Hypothesis 3: the subjective rating of a good appetite using the ADAT appetite score238,
299

would be useful in reflecting adequate intakes of protein and energy.

Addressing Hypothesis 3 (Chapter4): The results of this study did not entirely support
hypothesis 3. The results indicated self-reported appetite scores were useful in ranking
energy and protein intakes, but subjective reporting of a good appetite was only likely
to associate with adequate protein intake, not energy intake.

Hypothesis 4: as the clinic became more established over the 10-year study period,
patients with ESKD would be referred to the clinic earlier (or at higher levels of GFR)
for management. Hopefully, less malnourished patients would be presented to the
clinic in the second half of the study period.
169

Addressing Hypothesis 4 (Chapter 5): Initially the results support hypothesis 4: over the
10-year observation, patients were enrolled at the clinic at an earlier point in the
second five-year period, with GFR being 13.2±4.5 vs 17.1±5.5 mL/min/1.73m2 (P
<0.0001) respectively. However, despite the earlier referral, malnutrition rate scored by
SGA remained high at 39.7% vs 42.0% (P =0.62). Therefore, overall the results refute
hypothesis 4. In addition, the total number of patients who attended the clinic doubled,
reflecting the need for additional service provision to treat malnutrition.
Hypothesis 5: in view of the obesity epidemic, there would be a higher prevalence of
overweight and obese patients between the first and second half of the study period.
Addressing Hypothesis 5 (Chapter 5): The results support hypothesis 5: there was a
significant increase in the prevalence of obesity and diabetes over the 10-year study
period, which mirrored the obesity and diabetes epidemic in the general population.
Hypothesis 6: nutritional status would be associated with the future choice of RRT

Addressing Hypothesis 5 (Chapter 5): The results support hypothesis 6: Patients who
preferred a conservative (or no dialysis) pathway or hospital-based dialysis were more
advanced in age and had a higher prevalence of co-morbidities and nutrition
abnormalities, including malnutrition.
To answer the global research question of this thesis “Is nutrition management good
enough only when it starts at or near dialysis initiation?, the answer is NO. To improve
health outcomes of patients with ESKD, structured nutrition management should be
implemented well before dialysis is required and even before the pre-dialysis stage.

6.3

Strengths and limitations

The naturalistic approach of these retrospective studies allowed the data of all patients
to be included for analysis.

From our experience with nutrition research, not all
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patients were willing to consent to participate in studies, especially the older and frail
patients. The sample sizes were powerful enough for analysis to answer the research
questions that were proposed. The other major strength of our studies was the
extended observation period that allowed the long-term effects of nutritional factors on
mortality to be examined. Most importantly, this thesis built upon the research in
practice framework to translate research evidence to aim for practice improvement. It
involved a series of clinical science, practice-related research, epidemiological study
that have led to a change of work place culture and practice, such as establishment of
a pre-dialysis clinic and earlier referral to the clinic over time, which were subjected to
continuous evaluation and improvement.

The major limitation, like all retrospective studies, is that we could only draw
associations between the study factors and outcomes, but could not surmise causal
relationships. Similar to the shortcomings of epidemiological studies, we may have
missed important confounding factors that could affect the results. For example, we
could not examine inflammation in our analyses, as the commonly-used inflammatory
marker CRP was not routinely measured in our cohort of patients. Despite this
limitation, we were able to collect a wide range of nutritional data typically measured in
nutritional assessment as recommended by the clinical practice guidelines.205, 216 These
measures included anthropometry (weight, height, BMI, weight history, TSF and
MAMC), biochemistry (s-albumin), clinical signs and symptoms (appetite, nausea and
taste change/aversion), dietary intake using the structured diet history method with
sufficient details for computer analysis, and the global assessment score – SGA.
Although the results of these studies could not infer any causality, this information may
help complement the limitations of RCT275,

405

for clinicians to deduce good clinical

practice in the absence of high level evidence, or to formulate a further intervention
study. The prevalence data was useful to help plan service provision.
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In addition, there are many unique features of our studies; to our knowledge, at the
planning stage of our studies the following aspects had never, or seldom, been studied
by other researchers.

In Study I, we only included patients who had started dialysis after a gradual decline of
renal function. Therefore we excluded factors that may affect the nutritional state other
than chronic uraemia, e.g., AKI and ex-transplantation. We also examined the
combination of malnutrition and overweight/obesity factors, and showed the detrimental
effects of such a combination. Furthermore, if patients were maintained as clinically
sound, including optimal nutritional status with limited symptoms (as part of the SGA
score), we found there is no need to consider early initiation of dialysis, which imposes
tremendous heath, social and economic burden. Approximately $50,000 to $80,000 per
year is required to maintain a patient on dialysis, depending on treatment modality and
setting.4 However, data was excluded from analysis for 50% of the total participants
who started dialysis because of other reasons, such as AKI; many of whom still
required long-term dialysis. The relationship between the baseline nutritional factors
and outcome of these patients could be very different and a separate analysis is
required.

The comprehensive cross-sectional analysis of nutritional status and dietary intake
encompassed by Study II of the study was seldom performed in the literature. We not
only considered the typical energy and protein intake, but also included other
micronutrients and consumption of core foods, such as fruit and vegetables. The
relationships between intake, appetite and symptoms have seldom been explored
before. For clinical importance, we found self-rated appetite did not equate to adequate
intake, especially energy intake; therefore structured dietary intake assessment by a
dietitian should be an essential part of nutrition care in patients with ESKD. However,
these results were generated by analysis of a referred population of patients with CKD

172

stages 4 to 5, and therefore cannot be generalised to patients who were not referred to
the clinic at other CKD stages.

6.4

Latest evidence since the initial literature review

The latest evidence in the literature was included in the discussion sections of each
chapter. At the time of submission of this thesis, to the best of the PhD candidate’s
knowledge the research findings summarised in Section 6.1 of this thesis were
considered to be novel, and there is no major contradiction to the current
understanding in the field of renal nutrition. Therefore, the current findings support the
direction of future research proposed in Section 6.6.

6.5

Conclusions

In conclusion, nutritional factors, along with Older age (>65 years) and comorbidities, independently predict mortality. Nutrition abnormalities emerge well before
dialysis is required; therefore an early continuum of structured nutritional care in
patients with ESKD is recommended.
To answer the question “Is nutrition management good enough only when it starts at or
near dialysis initiation?” the answer is NO.

To improve health outcomes of patients with ESKD, structured nutrition management
should be implemented well before dialysis is required and even before the pre-dialysis
stage. However, the efficacy, cost-effectiveness and best model of care are yet to be
determined.

6.6

Implications for clinical practice

The results of these studies revealed poor outcomes associated with nutritional
abnormality in ESKD from pre-dialysis stage or during dialysis. There is growing
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evidence to support the benefit of various nutrition interventions involving a dietitian,257,
363, 397

this includes pre-dialysis intervention on the favourable outcome one year after

dialysis started;400 therefore, timely structured nutrition care involving a dietitian is
strongly recommended. The results of our study and the literature suggest intervention
should start no later than CKD stage 3b, or when GFR falls <45 mL/min/1.73m2 or even
earlier, as recommended by the newly-developed CARI guidelines for CKD stages 1 to
3 (early CKD)83 – of which the PhD candidate is the principal-author. A structured
nutrition care process should be under the framework of medical nutrition therapy
(MNT),221 which includes: a) timely referral to a dietitian; b) nutritional assessment; c)
nutrition intervention and dietary prescription; and d) implementation and monitoring
with defined frequency and duration:

In addition:

1. Judging from the varied combination of nutritional abnormalities, an individualised
treatment plan should be implemented.
2. During clinical and nutritional assessment, a detailed intake assessment should be
performed in addition to the patient’s subjective reporting of appetite.
3. In addition to the traditional clinical and nutritional parameters, patient-centred
outcomes, such as QOL, symptom control and satisfaction, are also important
treatment outcome measures to be assessed longitudinally.

Regular quality assurance activity is important to evaluate the system outcomes.

6.7

Direction of future research

A number of research initiatives are proposed based on the current literature and
findings from the research in this thesis, which represent the knowledge gap to be filled
to improve the outcomes of patients with ESKD.
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1. To examine the logistics and effect of nutrition intervention, especially when
insufficient renal dietitian staffing levels are thought to affect outcomes. This could
be achieved through further analysis of existing data on the pattern of nutrition
intervention from various time points, such as after initial pre-dialysis clinic
attendance and after commencement of dialysis. These data points also serve to
examine the change of nutritional status from the time of pre-dialysis clinic
attendance to time of initiation of dialysis.
2. To plan and conduct RCTs of nutrition intervention in pre-dialysis CKD patients with
targeted criteria and outcome measures, for example:

i.

Integrated nutrition and exercise intervention, as these two factors are closely
linked in the energy and metabolic pathway, especially in the PEW pathway and
lipid metabolism in ESKD. The combined intervention could have escalating
effects.

ii.

Weight reduction through caloric restriction and exercise in overweight and obese
patients. Suggested outcome measures are change in BW, waist circumference
body compositions, blood pressure and possible reduction in antihypertensive
medications used, and parameters of metabolic syndrome, e.g., the homeostatic
model assessment (HOMA) index and fasting serum lipids.

iii.

Nutritional support in malnourished patients, through a combination of dietary
counselling and education regarding diet plans, food fortifications and use of oral
nutrition supplements that suit the need of individual patients. Suggested
outcome measures are: improvement in SGA score (either the 7-point scale
version149 or patient-generated – PG-SGA); QOL using a validated questionnaire
(e.g., SF-36);254,

406

change in anthropometric measures and body composition,

blood nutritional and inflammation markers, e.g., s-albumin and CRP;
improvement in symptoms; dietary intake of energy and protein; and function
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capacity measured using hand-grip strength407 and a physical activity
questionnaire.
iv.

Nutrition intervention in elderly patients on conservative care based on the
current recommendations for nutrition prescription. Outcome measures should
focus on symptom control and QOL measured. Survival analysis could be
performed as a long-term outcome measure.

3. To formulate the “ideal diet” for patients with stage 4 to 5 CKD through dietetic
modelling. This means in addition to the current recommendations for energy,
protein, sodium, potassium, phosphorous and other vitamin and minerals, dietary
patterns should also be considered in view of the known reno- and cardioprotective
properties of fruit, vegetables, oily fish and a Mediterranean-style diet.

4. To design and validate sensitive assessment tools to evaluate the effect of nutrition
intervention. This could be symptom scoring that responds to change of intake and
nutritional status.

5. To perform a cost-benefit analysis of structured nutrition intervention to examine if
the benefits outweigh the implementation costs. Time-saving devices based on
technological innovation – such as patient record and appointment tracking,
communication,

video conferencing

and telecommunication using

personal

computer – should be explored to reduce appointment and travelling time.
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Appendices
Appendix A Renal medication list for dietitians
ANTIHYPERTENSIVES
ACE Inhibitors (increase K)
Captopril
Enalapril
Fosinopril
Lisinopril
Perindopril
Quinapril
Ramipril
Trandolapril

DIURETICS
Loop Diuretics (decrease K)
Frusemide
Bumetanide
Ethacrynic acid
Indapamide

Angiotensin 2 Blockers
(increases K)
Irbesartan
Candesartan
Telmisartan
Eprosartan
Losartan
Beta Blockers
Atenolol
Bisoprolol
Carvedilol
Metoprolol
Pindolol
Propranolol

Potassium Sparing Diuretics
(increase K)
Spironolactone
Amiloride
Triamterene

Calcium Channel Blockers
Amlodipine
Felodipine
Lercanidipine
Nifedipine
Diltiazem
Verapamil
Vasodilators
Prazosin
Hydralazine
Minoxidil
Centrally-acting
Clonidine
Moxonidine
Methyldopa

Thiazides (decrease K)
Hydrochlorothiazide
Chlorthalidone
Bendrofluazide

PHOSPHATE BINDERS
Aluminium (Alutabs)
Calcium (Caltrate, Cal 600,
Calsup, Titralac)
Lanthanum (Fosrenol)
Magnesium combinations
(Mylanta, Gastrogel,
Gastrobrom)
Sevelamer (Renagel)
ERYTHROPOIETIN
Darbepoetin (Aranesp)
Epoetin (Eprex)
Epoetin Beta (NeoRecormon)

DIABETES
Sulphonylureas (hypoglycaemia)
Glimepiride
Glibenclamide
Glipizide
Gliclazide
Biguanides
Metformin (lactic acidosis)

IMMUNOSUPPRESSANTS
Calcineurin Inhibitors
Tacrolimus (hyperglycaemia)
Cyclosporin
MTOR Inhibitors
Sirolimus (hyperlipidaemia)
Everolimus (hyperlipidaemia)
All above may cause electrolyte
disturbances
Mycophenolate
Azathioprine
Prednisolone (decreases K)
VITAMINS & MINERALS
Calcitriol (Vitamin D)
Paricalcitol (Vitamin D analogue)
Cinacalcet (Sensipar) –
Calcimimetic
Folic Acid
Ferrous sulphate
Vitamin B group + C
RENAL MISCELLANEOUS
Bis-Phosphonates
Alendronate
Risedronate
Pamidronate
Sodium Bicarbonate
Allopurinol
Colchicine
LIPID-LOWERING AGENTS
HMG CoA Reductase Inhibitors
Atorvastatin
Fluvastatin
Pravastatin
Rosuvastatin
Simvastatin
Other Agents
Gemfibrozil
Fenofibrate
Ezetimibe

NB: This is not an exhaustive list. Many anti-hypertensive medications come in a combined form
with a diuretic. Compiled by Ms J Tierney, Deputy Director of Pharmacy, The St. George
Hospital, updated 2007.
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Appendix B Preliminary analysis of the pre-dialysis assessment clinic

Proceeding of Australian and New Zealand Society of Nephrology, 40th Annual
Scientific Meeting, poster 146. Nephrology; 9 (Suppl.), A1–A43, 2004.
NUTRITION MANAGEMENT IN PRE-DIALYSIS ASSESSMENT CLINIC – 18
MONTHS EXPERIENCE
M Chan1, M Brown2
1
Department of Nutrition and Dietetics, The St. George Hospital, Sydney, NSW
2
Department of Renal Medicine, The St. George Hospital, Sydney, NSW
Background: One of the nutrition goals in renal medicine is to prevent malnutrition
which predicts morbidity and mortality. Between 8/00 and 6/02, assessment of 97 new
dialysis patients with progressive ESRF indicated a high prevalence of malnutrition
using Subjective Global Assessment (SGA B:C =41%:14%) and 56% of patients had
low serum albumin. Less than 30% of these patients received nutrition intervention in
the pre-dialysis stage. A multidisciplinary pre-dialysis assessment clinic was then
established, in which the dietitian became responsible for the nutrition assessment and
intervention of patients with GFR <25 mL/min based on clinical practice guidelines
(e.g., CARI and K/DOQI) and agreed department protocols.
Methods: Clinical characteristics of these patients and evaluation of the nutrition
component of the pre-dialysis clinic are described.
Results: 77 patients (49M:28F, age 67.0±14 year) attended the clinic between 4/02
and 10/03. Mean GFR was 14.4±5.6 mL/min/1.73m2 (range 4.8–30.0). 54.6% of these
patients were malnourished (SGA B:C =46.8%:7.8%) well before dialysis was required
and 18.2% experienced >5% unplanned weight loss in the previous 6 months.
Computerised nutrition intake analysis indicated suboptimal intake of protein (26.0% of
patients <0.75 g/kg IBW/d – Australian RDI; 13.7% of patients <0.6 g/kg IBW/d) and
energy (72.6% of patients <30–35 kcal/kg IBW/d). 30/51(58.8%) of patients reported a
good appetite but estimated protein and/or energy intake was suboptimal. Factors
identified for suboptimal intake included nausea/taste aversion (53.3%) and selfimposed dietary restrictions (19.7%). Only 39.0% of patients had physician referral for
nutrition intervention. After the initial evaluation at 6 months, ‘blanket referral’ for
nutrition intervention was established. Preliminary data indicated ~91% of recent clinic
patients and >70% of new dialysis patients with progressive ESRF were assessed
and/or received intervention by the dietitian.
Conclusions: Pre-dialysis assessment clinic allows a systematic approach of nutrition
management to patients with advanced renal failure and is sustainable.
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Appendix C Subjective Global Assessment (SGA) tool – 7-point scale
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Appendix D Ethics approval letter for Study I
Ethics approval letter, reference number: 03/115 Chan
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Appendix E

Ethics Approval letter for Study II

Ethics approval letter I, reference number: 03/134 Chan
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Ethics approval letter 2, reference number: LNR/12/STG/104, LNRSSA/12/SGA/105
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Appendix F

Appetite & Diet Assessment Tool (ADAT) 5-point Likert scale

Question: Overall, how would you describe your appetite?
(1) Very good
(2) Good
(3) Fair
(4) Poor
(5) Very poor
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Appendix G Audit checklist
Nutritional assessment
(A) Anthropometry

Demographic
Age

Weight

Gender

weight history

Race

Height

Clinical data

Triceps skinfold

Cause of kidney failure

Mid-Arm circumference

Co-morbidities, presence of:

(B) Biochemistry /blood results

Coronary artery disease

Serum creatinine

Chronic lung disease

Serum albumin

Cerebral vascular disease

(C) Clinical signs and symptoms
Appetite score – appendix F
Presence of nausea
Presence of taste change
(D) Dietary intake assessment

Peripheral vascular disease
Diabetes Mellitus
Smoking habits
Future treatment option
Conservative care

Diet history

Haemodialysis(home/hospital)

Nutrient analyses

Peritoneal dialysis

(E) Exercise and Physical activity

Transplantation

Others
Subjective Global Assessment
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Appendix H Sample structured diet history interview sheet

 Introduce self to the participant
 Read out: The following interview aims to assess your usual intake on a ‘typical day”. Please consider all the questions I ask you carefully
and answer as honestly as possibility, to the best of your ability.
 Sample questions for Breakfast:
- Do you have breakfast? Do you always have breakfast?
- What do you eat for breakfast?
- Do you eat bread?
- How many slices would you have?
- Do you have anything spread on it such as margarine, butter, jam or vegemite? Salted or unsalted? Amount?
- How many times per week would you say you had this for breakfast?
Meal time
Food consumed
Serving size
Frequency
Specific information / Did you finish the
cooking methods
meal?
(including
brand
name, oil used)
Breakfast
Cereal:
Milk/Juice:
Extra (yoghurt, fruit, sugar):

Bread/toast/buns/rolls:
Spread (margarine, butter. Jam, honey,
vegemite, others), salted or unsalted
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Meal time

Food consumed

Breakfast
continued

Extras (cheese, tomato, ham):

Serving size

Frequency

Specific information /
cooking methods
(including brand
name, oil used)

Did you finish the
meal?

Hot food (eggs, bacon, sausages, baked
beans, pancakes):

Condiments(i.e. maple syrup, tomato
sauce, salt, pepper)

Drinks (tea, coffee, juice, other):

Added to drinks (milk, sugar, lemon):

Do you eat these foods everyday? If not,
what do you usually eat on other days and
how often?
Weekend variation:
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